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Organic osmolytes are methylamines, polyols, or amino acids that are essential 
for cell volume regulation. Some have other important biochemical roles. For 
example, N,N,N-trimethylglycine (betaine) is an osmolyte that also acts as a methyl 
group donor in one-carbon metabolism. Previous methods for the analysis of betaine 
and its metabolite N,N-dimethylglycine (DMG) used derivatization and high 
performance liquid chromatography with ultra violet detection (HPLC-UV). They 
required a long sample run time, and often lacked specificity. Liquid chromatography 
- tandem mass spectrometry (LC-MS/MS) methods were developed with the aim of 
improving the analysis of betaine and other osmolytes. The objective was to measure 
the osmolytes: betaine; glycerophosphorylcholine (GPC); taurine; myo-inositol; 
sorbitol; and trimethylamine-N-oxide (TMAO), as well as N,N-dimethylglycine 
(DMG), choline, sarcosine, and carnitines. The use of LC-MS/MS improved the 
analysis of many osmolytes (and related metabolites) compared to previous HPLC-
UV methods, and the number of osmolytes that could be analyzed was increased. The 
analysis of polyols was challenging and no suitable method was found for the analysis 
of sorbitol; however, amide columns were effective at separating inositol isomers. To 
demonstrate applications for these methods, samples from overweight people with 
type 2 diabetes were analyzed to improve knowledge about how osmolytes interact 
with other metabolites, and their potential use as risk markers in disease. Betaine, 
DMG, and choline concentrations had low intra-individual variation in the plasma and 
urine. However, GPC, taurine, and TMAO were more variable. Most subjects with 
diabetes who were taking bezafibrate had extremely elevated urine betaine. A 
previously unknown metabolite, N,N-dimethylglycine-N-oxide (DMGO), was 
identified in plasma and urine. DMGO significantly correlated (p < 0.05) with DMG, 
betaine, and choline, suggesting that it is derived from the oxidation of DMG. The 
discovery of DMGO in human samples suggests that a re-evaluation of the widely 
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1.1.  Thesis overview 
Mass spectrometry is a rapidly evolving technology that can be used to improve 
the analysis of many metabolites in order to provide more information about their role 
in health and disease. Previous methods for the measurement of betaine and its 
metabolite, N,N-dimethylglycine, involved the use of derivatization followed by high 
performance liquid chromatography (HPLC) with UV (or fluorescence) detection.
1
 
These methods often had low specificity and were prone to interference from other 
components in the samples. The objective of this project was to use mass 
spectrometry based technologies (that were not previously available in our laboratory) 
to develop improved analytical methods for betaine, other osmolytes, and other one-
carbon metabolites. The aim was also to use these new technologies to measure a 
wider range of osmolytes including ones that were difficult to measure by previous 
methods. The analytical methods developed in this project were applied to clinical 
samples in order to investigate the metabolic processes that osmolytes (and related 
metabolites) are involved in, and help to assess their potential for use as risk markers 
in disease. 
Chapter 1 is a review of osmolytes, including: the structure of some important 
mammalian osmolytes; how these osmolytes are accumulated by cells; other 
biochemical roles that these osmolytes play; how osmolyte concentrations are known 
to change in disease; and analytical methods that have been used for the measurement 
of betaine, other osmolytes, and other one-carbon metabolites. The aims and 
hypotheses for the thesis are listed at the end of this chapter. 
Chapter 2 includes the development and validation of liquid chromatography - 
mass spectrometry methods for the measurement of betaine, other methylamine based 
osmolytes and one-carbon metabolites, and taurine in human plasma and urine. 
Results obtained by tandem mass spectrometry (LC-MS/MS) are compared with 
single quadrupole mass spectrometry (LC-MS), and HPLC-UV. 
Chapter 3 describes attempts to use the chemical properties of polyols to 
enhance selectivity and detection with the overall aim of developing a reliable method 
for the measurement of sorbitol and myo-inositol in plasma and urine. 
In Chapter 4, applications for the analytical methods that have been developed 
are demonstrated by measuring osmolytes and related metabolites in clinical samples 
from a population of overweight people with diabetes. Investigations were carried out 
3 
 
on the metabolism and potential use of osmolytes (and related metabolites) as risk 
markers in disease. 
The distribution of osmolytes and related metabolites in different blood 
components (including, whole blood, plasma, red blood cells, and white blood cells) 
was investigated and is discussed in Chapter 5. 
The identification of a previously unknown metabolite, N,N-dimethylglycine-N-
oxide (DMGO) and its potential metabolic significance is described in Chapter 6. 
DMGO was synthesized for use as a standard to enable its identification and 
quantification in plasma and urine samples using LC-MS/MS. 
Finally, in Chapter 7, the aims and hypotheses of the thesis are re-addressed, 
future work is discussed, and the main conclusions of the thesis are stated. 
 
1.2.  Introduction to osmolytes 
Organic osmolytes are essential for cell volume regulation in all taxa of animals, 
plants, and micro-organisms.
2,3
 Osmolytes are abundant in the human body and can 
play other important biochemical roles. For example, N,N,N-trimethylglycine 
(betaine) is a major mammalian osmolyte
3
 that is also involved in one-carbon 
metabolism, acting as a methyl group donor.
4
 These roles are inextricably linked, and 
the metabolic processes controlling the availability of betaine can be regulated in 
response to osmotic stress.
4b, 5
 
When under osmotic stress, cells accumulate osmolytes from the blood plasma. 
While these molecules have no osmotic role in the plasma, the plasma plays an 
important role in osmo-regulation by acting as a pool from which tissues obtain 
osmolytes, particularly in tissues which do not produce them. By increasing the 
intracellular concentrations of osmolytes, cells are able to remain isotonic in more 
saline environments, therefore avoiding large changes in cell volume and 
dehydration.
3
 There are three main classes of organic compounds that are used as 






 Mammals can 
produce osmolytes in vivo when they are required, but there are also many important 
dietary sources. For example: there are high concentrations of betaine in wheat 
products, shellfish, silver beet, beetroot and spinach;
7
 myo-inositol is present in high 
concentrations in citrus fruits and kiwifruit
8






Compatible solutes are compounds that are not harmful to macromolecules 
inside cells. In order to function as an osmolyte, a compound must be a compatible 
solute. Perturbing solutes, such as urea, are harmful to cells and destabilize proteins. 
While not harming cells, some compatible solutes are actually beneficial and are 
called compensatory solutes. Compensatory solutes are compounds which stabilize 
proteins against physiological stress such as freezing and heat, and the presence of 
perturbing solutes.
10
 By protecting the folded structure of proteins, compensatory 
solutes can allow them to function normally under stressful conditions.
11
 Some 




Different mammalian organs use specific combinations of organic osmolytes for 
cell volume regulation. For example, the kidneys use: betaine (Fig. 1.1, (1)); 
glycerophosphorylcholine (GPC) (2); taurine (3); myo-inositol (4); and sorbitol (5).
13
 
Betaine is a highly water soluble zwitterionic compound which contains a quaternary 
ammonium group at one end and a carboxyl group at the other end of the molecule. 
GPC is a zwitterionic quaternary ammonium choline derivative. Taurine is an amino 
acid containing a sulfonate group and is not incorporated into proteins. myo-Inositol 
and sorbitol are polyols with a hydroxyl group attached to each of six carbon atoms. 
myo-Inositol contains a non-aromatic six-membered ring structure, whereas sorbitol 








Although betaine is generally retained by the kidneys, people with diabetes
14
 
and people on fibrate therapy
15
 are known to have increased urinary excretion of 
betaine. As well as being an important osmolyte and compensatory solute, betaine is 
also involved in one-carbon metabolism.
4b
 Betaine is a substrate for the enzyme 
betaine-homocysteine methyltransferase (BHMT), where it acts as a methyl group 
donor, forming N,N-dimethylglycine (DMG), and converting homocysteine to 
methionine (Fig. 1.2).
4b, 16
 DMG can also donate a methyl group resulting in N-
methylglycine (sarcosine), which can be further demethylated to glycine. BHMT 
expression has been shown to be upregulated under hypotonic conditions, and down 
regulated in hypertonic conditions in liver cells, effectively making more betaine 
available when it is required as an osmolyte.
17
 Because the BHMT metabolic pathway 
is affected by the hydration state of cells, the roles of betaine as a methyl donor and an 
osmolyte are linked.
4b, 18
 Betaine is also required for DNA methylation, and may help 
to protect against cancer.
19
 While it is an important dietary nutrient, betaine is also 
synthesized in the body by a two-step oxidation of choline.
4b
 Other choline derivatives 
that play important biological roles include: GPC which is an important osmolyte that 
also acts as a compensatory solute, stabilizing intracellular proteins;
13, 20
 acetylcholine 
which is a neurotransmitter; and phosphatidylcholine which is important for cell 









Fig. 1.2. Metabolic pathway for the metabolism of homocysteine. Abbreviations: 
betaine homocysteine methyltransferase (BHMT); cystathionine-β-synthase (CBS);  
dimethylglycine dehydrogenase (DMGDH); methylenetetrahydofolate reductase 
(MTHFR); tetrahydrofolate (THF). 
 
 
Taurine plays many other important biochemical roles as well as acting as an 
osmolyte in mammals.
22
 For example, taurine is used as a neurotransmitter and 
neuromodulator, and is involved in thermoregulation and appetite suppression.
23
 
Plasma taurine concentrations have been reported to be 58 ± 16 µmol/L in healthy 
people, and taurine is excreted in the urine at a rate of 980 ± 580 µmol/day.
9
 Plasma 
taurine has been reported to be significantly lower in vegans (45 ± 7 µmol/L) due to a 
lower dietary intake.
9
 High levels of taurine are added to energy drinks, greatly 
increasing the intake for people who consume them. While dietary taurine sources are 
important, it can also be synthesized in the liver from the metabolism of cysteine.
24
 
Sorbitol is produced from glucose via aldose reductase when the body is under 
osmotic stress. The polyol osmolytes, sorbitol and myo-inositol, are accumulated in 
the kidney and liver.
2c
 People with diabetes
25
 and people with renal failure
26
 have 
increased urinary excretion of sorbitol and myo-inositol. While being an important 
osmolyte, inositol is also a precursor of phosphatidylinositol which is an important 
component of neural cell membranes.
27
 Tissue levels of myo-inositol are highest in the 
7 
 
brain and kidney at around 5 mmol/L, and plasma levels of myo-inositol have been 
reported in the range 17.5 – 40.7 µmol/L in healthy individuals.
28
 
While carnitine is used as an osmolyte by some bacterial cells,
29
 it is not 
known to play a role as an osmolyte in mammals. Carnitine is however necessary in 
mammals for carrying fatty acids through the mitochondrial membrane for energy 
metabolism.
30
 Other biological osmolytes, such as: dimethylsulfoniopropionate 
(DMSP); homarine; and trimethylamine-N-oxide (TMAO), may be consumed in the 




Although osmolytes are found in all mammalian cells, they have been most 
widely studied in the kidney cells where the osmotic stress can be extreme. High 
concentrations of betaine and other osmolytes are particularly found in the kidney 
cells due to a need to counteract the high salt and urea levels which are found in the 
kidneys.
31
 Mammalian kidneys have higher levels of osmolytes in the medulla than in 
the cortex. myo-Inositol concentrations average 15 mmol/Kg (wet weight), betaine 
and GPC concentrations are around 3 mmol/Kg (wet weight), and sorbitol 
concentrations average 1.4 mmol/Kg (wet weight) in the inner-medulla of the human 
kidney.
32
 The inner-medulla cells uptake betaine, taurine, and myo-inositol using 
specific transporter proteins which are activated by a sodium gradient into the cells.
33
 
For example, the betaine gamma-aminobutyric acid transporter, BGT1, is a widely 
used membrane transporter protein for betaine.
33b, 34
 As well as transporting betaine 
through the cell membrane, BGT1 also transports the neurotransmitter gamma-
aminobutyric acid (GABA).
35
 Hypertonicity increases transcription of the BGT1 
transporter gene.
5
 Betaine and proline have also been shown to be transported by a 
different transporter (SIT1) that is activated by fertilization in early mouse embryos.
36
 
Specific transporters for other mammalian renal osmolytes include: the taurine 
transporter - Na/Cl dependent taurine co-transporter (NCT), and for myo-inositol - the 
sodium/myo-inositol transporter (SMIT).
33
 These transporters are activated by 
increases in sodium and chloride ions. 
The osmolytes, sorbitol and GPC, are not known to have cell wall transporter 
proteins, but the metabolic pathways for their formation or degradation are regulated 
in response to cell volume changes. Small changes in the hydration state of cells 
trigger cellular metabolism and gene expression.
37
 Increased aldose reductase activity 





production has not been shown to be increased under osmotic stress. However, the 
enzyme responsible for converting GPC to choline, GPC-choline phosphodiesterase, 
is inhibited in the presence of high salt or urea in the kidneys.
39
 
Traditional HPLC methods for the measurement of osmolytes involved long 
sample preparation and sample run times, and often lacked specificity. In order to 
better investigate the role of osmolytes in health and disease, there is a need for more 
efficient analytical methods that can measure a greater number of osmolytes in a 
shorter time. The use of evolving technologies such as mass spectrometry or NMR 
spectroscopy is an obvious way to try and achieve this. 
 
1.3.  The measurement of osmolytes and related metabolites 
Osmolytes, such as betaine, myo-inositol, sorbitol, GPC, and TMAO lack a 
significant chromophore (or fluorophore), and typically require pre-column 
derivatization before they can be measured by HPLC methods with ultra-violet (UV) 
or fluorescent detection.
1
 However, osmolytes can potentially be measured more 
efficiently using specialized techniques such as nuclear magnetic resonance 
spectroscopy (NMR),
40
 or mass spectrometry.
41
 Osmolytes have been measured in 
kidneys and other tissues where they are present in high concentrations using HPLC 
with refractive index detection.
6
 However, this technique is not sensitive enough to 
measure concentrations in biological fluids such as blood plasma or urine. Refractive 
index detection also lacks specificity, so separating analytes from other metabolites in 
complex samples, such as urine, is difficult. While evaporative light scattering 
detectors (ELSD) offer better sensitivity than refractive index detectors, they still lack 
the selectivity required to measure metabolites in many complex sample matrices.  
 
HPLC with UV or fluorescence detection following derivatization 
Betaine and other zwitterionic betaine analogues, such as carnitine, 
acetylcarnitine, proline betaine, dimethylsulfoniopropionate (DMSP), and 
trigonelline, were traditionally measured by HPLC following derivatization of the 
carboxyl group with a chromophore or fluorophore to make them suitable for UV or 
fluorescence detection.
1
 The carboxyl groups on zwitterions such as betaine are 
relatively unreactive and therefore require highly reactive derivatizing reagents to 
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react with them. Derivatizing reagents which have been used for this purpose include: 
bromophenacyl bromide;
42
 bromophenacyl trifluoromethanesulfonate (triflate);
1a
 
naphthacyl triflate; and phenanthrenacyl triflate.
43
 The cationic ester derivatives 
formed by derivatizing carboxyls with these reagents can be measured by HPLC with 
UV detection, or fluorescence detection when using phenanthrenacyl triflate.
43a
 HPLC 
stationary phases which have been used to measure these derivatives include normal 
phase silica, alumina, or strong cation exchange (SCX).
1b
 Methods involving 
derivatization are more labour intensive and require long run times to separate 
analytes from the large number of compounds present in biological samples that may 
be derivatized. Attempts to measure derivatives of betaine and betaine analogues by 
capillary electrophoresis have only been partially successful.
1b
 Insufficient sensitivity 
is often a problem with capillary electrophoresis due to the small path length that the 





 showed that TMAO can be derivatized by triflate reagents. 
However, the reaction yield was low, and the limit of detection was high, which is 
likely to be due to the lack of a carboxyl group on the TMAO molecule. Therefore 
this approach is not useful for the measurement of plasma TMAO concentrations. 
Polyols such as sorbitol and myo-inositol have been measured in tissues using 
derivatization of the hydroxyl groups with phenyl isocyanate.
44
 This technique is not 
specific for polyols and many peaks can be expected in the chromatograms of 
biological samples due to the large number of hydroxyl compounds present that can 
potentially be derivatized. 
While derivatization followed by HPLC with UV (or fluorescence) detection 
can be useful for the measurement of many osmolytes and related metabolites, a 
different approach is required to measure the more analytically challenging ones such 
as polyols, TMAO, and choline. Evolving technologies, such as mass spectrometry (or 
NMR), are likely to play an important role in enabling the measurement of osmolytes 
that have been traditionally difficult to measure.  
 
 Liquid chromatography - mass spectrometry 
Liquid chromatography – mass spectrometry techniques are increasingly being 
used in clinical laboratories to measure analytes such as osmolytes and one-carbon 
metabolites in biological samples.
41, 45
 Because mass spectrometry separates and 
10 
 
detects ions, an analyte must be ionizable in order to be detected by the mass 
spectrometer. Small molecules may not fragment to give mass transitions which 
produce adequate sensitivity or selectivity for quantitative analysis. Derivatization can 





Fig. 1.3. Diagram of a triple quadrupole mass spectrometer showing the fragmentation 
of betaine. 
 
Figure 1.3 illustrates how a triple quadrupole mass spectrometer acts as a 
detector in an LC-MS/MS system. Samples are injected into the flow of the mobile 
phase and separated on a chromatographic column using HPLC. The column eluent is 
then sprayed into the ion source of a triple quadrupole mass spectrometer where it is 
ionized using techniques such as: ESI (electrospray ionization); APCI (atmospheric 
pressure chemical ionization); or APPI (atmospheric pressure photoionization). The 
ions are then drawn into the mass spectrometer where they are separated in 
quadrupole 1 (Q1) according to their mass to charge ratio (m/z). The selected ions are 
then fragmented in the collision cell by colliding with N2 gas molecules under a high 
vacuum. The fragment ions are then selected by mass in quadrupole 3 (Q3) and then 
detected by an electron multiplier. In MS/MS mode, the mass transitions from the 
parent ion mass to a fragment ion are measured because only fragment ions that have 
come from the selected parent ion are seen by the detector. This gives three levels of 
11 
 
selectivity, including: separation by chromatography; separation by monitoring the 
mass of the molecular ion; and separation by monitoring the mass transition from 
molecular ion mass to the fragment ion mass (MS/MS).
47
  
While different compounds may have the same (or very similar) mass, it is 
unlikely that they will fragment to give the same fragment ions. There are exceptions, 
for example, many methylamines fragment to give a trimethylamine species. DMG 
and choline both have a molecular ion mass of 104 and give a fragment ion of 58, 
therefore a choline peak is observed in the multiple reaction monitoring (MRM) 
chromatogram of DMG for the mass transition 104 → 58.
41 
Care must be taken in 
these situations to ensure that the compounds are well separated chromatographically. 
Interfering substances in the sample matrix such as salts can affect the ionization 
efficiency.
48
 This may lead to differences in the detector response between the 
standards and the samples, therefore lowering the accuracy and precision of the 
method. While these substances may not show up in the chromatograms, they can still 
negatively affect the method by interfering with the ionization process. Ways to 
overcome ion suppression due to sample matrix effects include: the use of deuterated 
internal standards, improving the chromatography, and pre-column sample clean-up 
such as solid phase extraction (SPE).
48-49
  
When measuring a mixture of compounds by LC-MS/MS it is ideal to separate 
them chromatographically, even though they may have different mass transitions and 
not be present in the same multiple reaction monitoring (MRM) chromatograms. The 
use of buffers in the chromatographic mobile phase is limited to volatile acids, such as 
formic acid, acetic acid, and trifluoroacetic acid, and bases such as ammonium, and 
triethylamine. LC-MS/MS methods for measuring hydrophilic compounds such as 
betaine generally use a binary gradient which starts with a low water and low buffer in 
the mobile phase, and moves to high water and higher buffer concentration in the 
mobile phase as the sample run progresses.
41
 Many LC-MS/MS methods have 
traditionally used reversed phase columns. However, because osmolytes are highly 
hydrophilic they are best separated using normal phase columns, such as silica (often 
referred to as hydrophilic interaction chromatography (HILIC)),
1b,1a,45a
 or strong 
cation exchange (SCX) columns.
1b
  
When setting up methods using LC-MS/MS it is important to find the correct 
compound-specific parameters by carrying out a compound optimization on standard 
solutions for each analyte. This gives the optimal potentials (decoupling potential, 
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collision energy, and collision cell exit potential) required to obtain the highest signal 
intensity for a particular compound. These voltages are used to control the behaviour 
of ions inside the mass spectrometer. Decoupling potential is a voltage applied at the 
orifice plate to help prevent ions from clustering together, collision energy controls 
the degree of fragmentation in the collision cell, and collision cell exit potential 
controls the flow of ions from Q2 to Q3. Method-specific parameters which require 
optimization in LC-MS/MS include the curtain gas flow rate and the ion source 
temperature. Most modern mass spectrometers have a choice of ion source, although 
ESI is the most commonly used. However, an APCI ion source can be installed to 
improve sensitivity for neutral compounds that are difficult to ionize by ESI.
47
 APCI 
applies a corona discharge to ionize the solvent gases which in turn transfers a charge 
to the analytes. Some mass spectrometers are capable of applying both ESI and APCI 
ion sources simultaneously in order to obtain optimum ionization and sensitivity. 
Another ionization technique, atmospheric pressure photo ionization, uses photons to 
ionize analytes in the sample. Both APCI and APPI are used to ionize neutral 
compounds such as free steroids, which are difficult to ionize by ESI due to a lack of 
an easily ionizable functional group.
47
  
Zwitterions such as betaine and carnitine are easily ionized, and under acidic 
conditions the carboxyl group may be protonated so that they are often already present 
as cations when they enter the mass spectrometer. Other osmolytes, such as polyols, 
are not so easily ionized and may require APCI, adduct formation, or pre-column 
derivatization. 
LC-MS/MS has revolutionized screening of new-borns in clinical laboratories, 
and allows for rapid screening of many inborn errors of metabolism, including amino 
acid disorders, organic acid disorders, and fatty acid oxidation disorders.
50
 LC-
MS/MS has many advantages over traditional HPLC-UV methods for the 
measurement of osmolytes. There is usually no need to derivatize the samples 
resulting in faster sample preparation, there are shorter run times, and precision and 
accuracy is generally improved by the use of isotopic internal standards (isotope 
dilution). Isotopic internal standards are chemically identical to their respective 
analytes except that some of the atoms have been replaced with isotopes such as 
deuterium. These internal standards extract and chromatograph almost identically to 
the corresponding analytes, but they have a different mass, and can be monitored 
using a different mass transition. Unfortunately, isotopic internal standards are not 
13 
 
always commercially available, meaning that it may not always be possible to use 
them for every analyte of interest. Isotopically labelled standards can sometimes be 
synthesized in the laboratory if required using deuterated starting materials. As well as 
deuterium, other stable isotopes such as 
13
C are sometimes used in internal standards. 
Deuterated internal standards in mass spectrometry can improve accuracy and 
precision because they have very similar chemical properties to the analytes, therefore 
they partition the same into the extraction solvent, and ionize the same in the mass 
spectrometer. 
Triple quadrupole mass spectrometers are most commonly used for 
quantifying metabolites in clinical laboratories, whereas high mass resolution 
instruments such as time of flight (TOF) instruments are more commonly used in 
academic environments.
51
 Triple quadrupole mass spectrometers are useful in clinical 
laboratories because they offer high sensitivity and selectivity, and they can monitor 
many mass transitions simultaneously. However, the mass resolution of triple 
quadrupole instruments is generally much lower than other instruments such as TOF 
mass spectrometers. Therefore ions which have a mass within 1 or 2 Da of the analyte 
of interest can cause interference. The mass range of triple quadrupole instruments 
typically only detects ions up to 2000 Da. TOF mass spectrometers can measure a 
much greater mass range for (example 20-20,000 Da), and are therefore more suitable 
for detecting proteins and other large molecules. Qtrap instruments are available 
which can act as a traditional triple quadrupole mass spectrometer, but can also trap 
ions in the 3
rd
 quadrupole, allowing for further fragmentation of the fragment ions. 
This can provide more structural information that can be useful for identifying 
unknown compounds. 
A single quadrupole mass spectrometer may be adequate for measuring certain 
metabolites in biological samples. However, single quadrupole mass spectrometers 
are less selective as they do not have a collision cell and can only measure the 
molecular ion by selected ion monitoring (SIM). Compounds with the same (or close) 
mass will show up in the same chromatogram, although this is not necessarily a 
problem if all compounds with the same mass are separated chromatographically.  
In recent years, LC-MS/MS technology has become more affordable, and 
instruments have become increasingly available in clinical laboratories. 
Manufacturers are also constantly designing LC-MS/MS systems that are more 
sensitive, allowing for the measurement of a greater range of metabolites that are 
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present at low concentrations, and may have previously been undetectable. An 
example of this is the measurement of low plasma concentrations of N,N-
dimethylglycine-N-oxide shown in Chapter 6. 
 
Gas chromatography - mass spectrometry 
 Gas chromatography-mass spectrometry (GC-MS) has been used to measure 
polyols including the osmolytes sorbitol and myo-inositol.
52
 In order to be analyzed by 





 The sample run times required to separate polyols in biological 
samples are typically around 40 to 60 minutes.
52b, 53
 Eades et al.
52b
 showed a 
separation of sorbitol, mannitol, myo-inositol, and galactitol in tissues within 40 
minutes after derivatization with butylboronic acid. Lee and Chung
52a
 measured a 
range of polyols including sorbitol and myo-inositol in urine by GC-MS after reaction 
with acetic anhydride. Jansen et al.
54
 used GC methods to measure a range of polyols 
in urine and plasma after formation of trimethylsilyl ethers.  
 
NMR Spectroscopy 





 Methylamines are particularly suited for analysis by 
1
H NMR due to 




  Lee et al.
40
 described a method for measuring a range of 
methylamines including betaine and DMG in urine using 
1
H NMR. However, the 
detection limits were high compared to mass spectrometry methods, typically around 
15 µmol/L, so sensitivity would be limiting for the measurement of many metabolites, 
particularly in samples such as blood plasma where methylamine concentrations are 
often lower. Polyols can be especially difficult to measurement by NMR. The lack of 
identical protons creates low sensitivity, and there is often interference from other 
polyols and sugars in biological samples. However, Bedford et al.
13
 were able to use 
NMR to measure the polyol osmolytes, inositol and sorbitol, in possum kidneys. 
Proton NMR requires minimal treatment of the samples, and has the ability to 
measure many analytes simultaneously. However, there are problems with using 
NMR as a quantitative analytical tool that need to be considered. For example, the 
limits of detection are usually higher than other techniques. Detection limits can be 
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improved by obtaining more transients when collecting the spectra, although this is 
done at the expense of longer sample acquisition times. Using an NMR with a larger 
magnetic strength provides improved sensitivity. However, large NMR systems (over 
500 MHz) are expensive and bulky and the technology is not usually available in 
clinical laboratories. Lower limits of detection can also be achieved by installing a 
cryoprobe on the NMR system. Analyzing aqueous samples such as urine requires the 
use of a water suppression technique to remove the large water signal from the 
spectrum. This adds to the time it takes to run samples. The analysis of blood samples 
by NMR spectroscopy is even more difficult. The concentrations of analytes in blood 
are often lower than in urine, and blood contains large amounts of protein which 
causes interference in the spectrum.  
When using NMR to measure methylamines in aqueous samples, the samples 
need to be acidified in order to separate the betaine methyl group signal from TMAO. 
An internal standard needs to be added to each sample for calibration, and deuterium 
oxide (D2O) also needs to be added as a lock standard.
40
 A suitable internal standard 
must also be added to the samples in order to quantify analytes in the sample. Unlike 
UV absorbance, peak heights in NMR are arbitrary numbers, and no two spectra can 
be directly compared. However, the ratios of the analyte peaks to the internal standard 
are quantitative since the level of the internal standard in each of the samples is 
constant. These ratios are then compared to ratios of standards of known 
concentrations of the analytes to the internal standard, and this is used to calibrate the 
data.
56
 Internal standards must be sufficiently soluble in aqueous samples such as 
urine. Internal standards are usually chosen which produce a 
1
H singlet in a 
convenient place in the spectrum (typically 0-1 ppm) so as not to co-resonate with 
other peaks in the samples. Examples of suitable internal standards for the analysis of 
methylamines in urine by 
1
H NMR include: tetramethylsilyl-2,2,3,3-
tetradeuteropropionic acid (TSP), 4,4-dimethyl-4-silapentane-1-ammonium (DSA), 
acetonitrile, trimethylacetonitrile, or trimethylacetamide (pivalamide). 
Many metabolites have been measured simultaneously by NMR spectroscopy 
in overseas metabolomics studies.
57
 However, there are factors that limit the use of 
NMR as a diagnostic tool in clinical laboratories, or for clinical studies involving the 
measurement of large numbers of samples. For example, NMR instruments are 
expensive to purchase compared to other technologies, and the large magnets make 
them difficult to house in a clinical laboratory setting. The bench-work cost of sample 
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analysis is low for NMR spectroscopy and mass spectrometry methods, however, the 
main costs that need to be considered are the capital cost of the equipment, and the 
running costs, including service contracts to maintain the equipment.  
 
1.4.  The suitability of analytical techniques for measuring osmolytes 
 Consideration should be given to the chemical properties of a particular analyte 
when choosing an analytical method. This gives important clues as to the best way of 
measuring it. For example, if the analyte has a strong native absorbance or 
fluorescence then it might be sufficient to measure it using a simple HPLC method. If 
an analyte has functional groups that can be derivatized with a UV absorbing or 
fluorescent moeity, then pre-column derivatization followed by HPLC might be 
appropriate. If an analyte ionizes and fragments easily, then mass spectrometry may 
be the best way to measure it. If an analyte does not ionize easily and cannot be 
derivatized, but it does have multiple identical protons, then 
1
H NMR may be useful 
for measuring it. Some osmolytes, such as polyols, are challenging to measure by any 
method. 
Taurine is difficult to measure by conventional methods for amino acid analysis, 
such as the ninhydrin reaction. It has been measured by NMR
58
 and by mass  
spectrometry,
59
 but there are problems. It has no methyl groups to produce a large 
singlet signal in the 
1
H NMR spectrum. It is also difficult to measure by mass 
spectrometry, particularly in positive ion mode, because the strongly acidic sulfonic 
acid group is not easily protonated. However, taurine has been successfully measured 
by mass spectrometry in negative ion mode.
59
 A number of reagents have been used to 
derivatize the amine group on taurine for measurement by HPLC with UV or 
fluorescence detection.
60
 However, these derivatizing reagents are not specific and 
derivatize many other amino acids in biological samples, therefore giving a complex 
mixture of peaks to separate chromatographically. 
There are difficult analytical problems associated with the measurement of 
polyols, such as sorbitol and myo-inositol, in biological samples. They only contain 
relatively unreactive hydroxyl functional groups, have a negligible absorbance in the 
visible or UV spectrum, and have complex 
1
H NMR spectra with multiplets of single 
protons causing low sensitivity. Polyol osmolytes also have multiple isomers 
including abundant sugars. Interference from glucose is likely to be particularly 
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problematic for measuring polyols because it has the same mass as inositols, and it is 
present in much higher concentrations (approximately 4 mmol/L) in blood samples 
than sorbitol (< 2 µmol/L)
61
 and myo-inositol (approximately 20 µmol/L).
62
 Polyols 
such as sorbitol and inositols are neutral species which may be difficult to ionize in a 
mass spectrometer due to a lack of readily ionizable functional groups. Potential ways 
to overcome these problems and measure sorbitol and myo-inositol in plasma and 
urine samples are investigated in Chapter 3. 
 
1.5.  Osmolytes in disease 
 Obesity, diabetes, and cardiovascular disease are an increasing problem in the 
New Zealand population. People with the metabolic syndrome are overweight, have 
high blood pressure, high blood lipids, and are at risk of developing type 2 diabetes 
and cardiovascular disease.
63
 Relatively little is known about how changes in 
osmolyte concentrations may contribute to the progression of these health conditions.  
Because concentrations of osmolytes are different in many disease states, it is 
possible that they may be useful risk markers of disease. While risk markers may be 
quantitatively associated with a disease, they are not necessarily causal, and changing 
the concentration of a risk marker by an intervention, such as supplementation, does 
not necessarily change the disease outcomes.
64
 Risk factors are variables that are 
causal and directly affect the probability of a disease occurring.
64
 While risk factors 
and risk markers are typically measured in fasting samples, concentrations can be 
affected by the diet and other factors which may lead to short term variations. It is 
therefore important to investigate the individuality of metabolites in different 





Type 2 diabetes mellitus is a growing concern in the western World and is an 
increasing burden on the New Zealand health system. Maori and Pacific Islanders 
have a disproportionately high incidence of type 2 diabetes, whereas type 1 diabetes is 
more common in European New Zealanders than other ethnic groups.
66
 Risk factors 
for developing type 2 diabetes include poor diet and obesity, smoking, and physical 
inactivity.
67
 Obesity and type 2 diabetes are more common in lower socio-economic 
groups because high sugar foods with low nutritional value are often more affordable 
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than nutritious foods such as fruit and vegetables. Many people with diabetes go on to 
develop further complications such as retinopathy (cataracts), nephropathy (kidney 
disease)
67
 and cardiovascular disease.
68
 Glycemic control in diabetes is monitored by 
measuring glycated haemoglobin A1c (HbA1c), a form of haemoglobin that is bound to 
glucose. HbA1c is a more useful marker of glycemic control than glucose because it is 
less affected by short-term fluctuations in blood sugar levels.
69
 HbA1c is also a marker 
of protein glycation, which is a major cause of health complications in diabetes.  
Because sorbitol (5) is produced from the reduction of glucose, sorbitol 
concentrations are increased in the blood when glucose concentrations are poorly 
controlled in diabetes.
25, 70
 Although sorbitol is useful in that it is used as an osmolyte 
by cells, an increase in sorbitol concentration is problematic for a couple of reasons. 
Firstly, increased circulating sorbitol can displace other osmolytes in the body, which 
may be a significant cause of cell and tissue damage.
25, 71
 Secondly, the conversion of 




Low betaine in blood plasma has been shown to be an important risk marker 
for developing diabetes.
73
 However, lifestyle interventions and the use of the anti-
diabetic drug, metformin increase plasma betaine.
73
 People with diabetes are known to 
excrete more betaine into the urine than the normal population.
14
 The urinary loss of 
methylamine based osmolytes from people with diabetes is likely to be detrimental, 




Concentrations of various osmolytes have been shown to be different in the 
blood and urine of people with diabetes compared to the normal population.
14, 71
 For 
example, the urine excretion of both myo-inositol and chiro-inositol have been 
reported to be greater in people with diabetes (median = 825 µg/day, and 74.0 µg/day 
respectively) compared to normal (88 µg/day and 2.09 µg/day respectively). The urine 
ratio of myo-inositol to chiro-inositol has been reported to be a sensitive marker of 
insulin resistance.
75
 This suggests that inositol measurements may be useful as an 
early marker of diabetes, and may help to identify people who are at risk of 




 have been 
shown to be elevated in the urine of people with diabetes, and urinary myo-inositol 
has been reported to be a marker of glucose intolerance.
76
 Supplementation with myo-
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inositol can be beneficial and has been shown to decrease the risk of developing 
gestational diabetes in pregnant women.
77
 
Taurine levels are lower in the eye lens of people with diabetes, and also 
reduce with age. A deficiency of taurine has been linked with the formation of 
cataracts.
2c, 78
 For example, lenses exposed to high galactose concentrations (30 





One-carbon metabolism and cardiovascular disease 
As well as being a major osmolyte, betaine is also an important source of 
methyl groups in the body. People with acute coronary syndrome have been reported 
to be at greater risk of having a heart attack if they have low plasma betaine.
79
 As has 
been mentioned, betaine donates a methyl group to homocysteine, forming 
methionine and DMG (Fig. 1.2). Homocysteine is damaging to the endothelium, 
leading to atherosclerosis, and has been well established as a risk factor in 
cardiovascular disease.
4b, 80
 DMG is a feedback inhibitor of BHMT which limits the 
effectiveness of betaine therapy in reducing homocysteine levels, so a continual 
supply of betaine is important.
4b
 It is likely that a depletion of betaine reserves 
contributes to the development of cardiovascular disease by reducing the body’s 
ability to remove homocysteine. However, homocysteine can also be lowered by 
folate and vitamin B6 (see Fig.1.2). Whether or not homocysteine is directly causative 
for cardiovascular events is still a major point of discussion in the literature. In 2006, 
the HOPE 2 study
81
 reported that lowering homocysteine with folate, vitamin B6, and 
vitamin B12 does not significantly reduce the risk of death from cardiovascular causes 
in patients with pre-existing cardiovascular disease or diabetes. The Norwegian 
vitamin (NORVIT) study also found that lowering homocysteine with folate, vitamin 
B6, and vitamin B12 did not significantly lower the risk of recurrent cardiovascular 
events in people who have had a myocardial infarction (heart attack).
82
 Neither of 
these studies used betaine as a therapy for lowering homocysteine. Betaine has other 
advantages including its role as an important osmolyte and compensatory solute, as 
well as being a methyl group donor. These studies only investigated the effect of 
lowering homocysteine in people who had known cardiovascular disease or diabetes, 
however, maintaining low homocysteine levels in healthy people may lower the risk 
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of developing cardiovascular disease in the first place. Homocysteine concentrations 
can be kept low by consuming a diet containing important nutrients including: 
betaine; folate; vitamin B6; and vitamin B12.
80
 
 Patients with high blood lipids are often prescribed the lipid lowering drugs, 
fibrates. However, the fibrate drug most commonly prescribed in New Zealand, 
bezafibrate, has been associated with high urinary betaine excretion.
15
 The mechanism 
for the reported loss of betaine from patients taking bezafibrate is not known. It has 
not yet been proven that fibrates actually cause the loss of betaine from the body, and 
it is not known if other osmolytes are affected in the same way. 
Free choline, a precursor in the synthesis of betaine in the body, has been 
shown to be a useful marker for cardiovascular events such as heart attacks.
83
 An 
increase in free choline in the blood is likely to be caused by the release of 
phosphatidylcholine from cell membranes when cell damage occurs. Low plasma 
betaine and high plasma choline have been shown to be significant risk factors for 
cardiovascular disease in people with metabolic syndrome.
84
 Konstantinova et al.
84
 
investigated metabolite concentrations in a large study population with metabolic 
syndrome (>7000 subjects), and found that plasma betaine concentrations inversely 
correlated with components of metabolic syndrome such as non-HDL cholesterol, 
body mass index (BMI) and blood pressure. Whereas plasma choline positively 
correlated with plasma glucose, BMI, and percentage body fat.
84
   
Elevated plasma trimethylamine-N-oxide (TMAO) has also recently been 
reported to be a risk factor for cardiovascular disease.
85
 However, whether or not 
TMAO has a toxic effect in humans and causes cardiovascular disease is still a 
contentious issue. Other chordates (such as fish) beneficially accumulate and use 
TMAO as an osmolyte.
86
 Methylamines such as choline and carnitine are cleaved by 
bacteria in the gut to form trimethylamine (TMA), which is then converted to TMAO 
in the liver.
87
 TMAO also enters the body from the consumption of marine fish, where 
it is accumulated and used as an osmolyte.
86
 
 Taurine depletion has been shown to cause cardiomyopathy in mice,
88
 and a 
deficiency of taurine has also been associated with liver disease, apoptosis, and loss of 
muscle function.
89
  Taurine may also play a role in protecting against cardiovascular 
disease due to its anti-oxidant and anti-inflammatory properties, as well as its role in 
regulating blood pressure.
90
 Dietary taurine can also increase levels of circulating high 
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Osmolytes in other diseases 
 Changes in osmolyte concentrations have been reported to be important in many 
other diseases. For example, people with chronic renal failure have been shown to 
have lower plasma betaine, and excrete higher levels of betaine in the urine.
91
 The 
increased urinary loss of betaine in renal patients may be an important factor in many 
of them going on to develop cardiovascular disease.
92
 





 play important roles in brain chemistry. myo-Inositol supplementation 
has been shown to help treat psychiatric disorders such as anxiety and depression.
94, 93
 
Patients with schizophrenia, bipolar patients, and people who have committed suicide 
have abnormally low concentrations of myo-inositol in the brain.
95
 However, patients 
with Alzheimer’s disease have been shown to have increased concentrations of myo-
inositol and choline in the brain.
96
 It is likely that tissue damage can cause the release 
of free myo-inositol and choline via the degradation of phosphatidylinositol and 
phosphatidylcholine which are present in cell membranes. 
People with trimethylaminuria (fish odour syndrome) have a defect in the liver 
enzyme, flavin-containing monooxygenase 3 (FMO3), which converts TMA into the 
non-odorous TMAO.
97
 Trimethylaminuria sufferers may secrete TMA in the sweat, 
breath and urine, and consequently have a fishy body odour which can be socially 
debilitating.
87a, 97
 Gut bacteria convert quarternary amines such as choline, carnitine, 
and TMAO to TMA.
56
 Therefore, the symptoms of trimethylaminuria can be lessened 
by cutting marine fish (high in TMAO) from their diet, eating less choline rich foods 
(such as eggs), as well as the use of antibiotics to reduce trimethylamine forming 
bacteria in the gut.
56
 The ratio of TMA to TMAO concentration is important for the 
diagnosis of trimethylaminuria. However, the analysis of TMA can be problematic. 
Since plasma TMAO has been reported as a risk factor in cardiovascular disease,
87b
 it 
might also be useful to develop a reliable method to measure the closely related 
metabolite, TMA, in plasma. It is possible that plasma TMA concentrations may also 





1.6.  Research hypotheses 
 The overall aim of this project was to use LC-MS/MS (or NMR spectroscopy) 
to improve the analysis of betaine, other osmolytes, and other one carbon metabolites 
in order to extend knowledge about their role in health and disease, and their potential 
for use as risk markers. Methods were developed using the chemical properties of the 
analytes in combination with mass spectrometry, and were compared with traditional 
HPLC-UV methods. The methods developed in this project were used to measure 
osmolytes and related metabolites in human samples to investigate factors such as: 
their biological variability; how they are affected in disease; and how they interact 




The research hypotheses for this thesis were: 
 
 Hypothesis: Tandem mass spectrometry (LC-MS/MS) can be used to measure 
betaine, other osmolytes, and other one-carbon metabolites in plasma and 
urine with greater efficiency and improved performance than conventional 
HPLC-UV methods. 
 
 Hypothesis: Polyols (including sorbitol and myo-inositol) can be measured in 
plasma and urine using derivatization or complexation with boronic acids or 
transition metals along with techniques such as HPLC, mass spectrometry, or 
NMR spectroscopy. 
 
 Hypothesis: The analytical methods developed in this thesis can be used to 
investigate concentrations of betaine, other osmolytes, and other one-carbon 
metabolites in order to provide new information on their metabolism, and the 










2.  Chapter Two - The Measurement of Methylamines 





2.1.  Introduction 
 A reliable analytical method for the measurement of methylamine based 
osmolytes and related metabolites is essential for their study and monitoring in 
disease. Betaine (Fig. 2.1, 1), choline (6), and trimethylamines-N-oxide (TMAO) (10) 
are useful predictors of health outcomes.
83-84, 98
 The measurement of both TMAO and 
trimethylamine (TMA) is also important for the diagnosis of trimethylaminuria.
56
 It is 
useful to monitor changes in the concentrations of methylamines, particularly 
considering the roles they play in one-carbon metabolism, osmotic control, and 
maintaining protein structure and function.
3
 An efficient and reliable assay for the 
measurement of methylamines was developed here in order to investigate their 
concentrations in at risk groups, such as people with metabolic syndrome and 
diabetes. A better method for the measurement of taurine in plasma and urine was 




This aim of the research described in this chapter was to develop and validate:  
 
 An efficient and reliable LC-MS/MS method that can measure a greater 
number of methylamines that previous HPLC-UV methods, including: betaine, 
N,N-dimethylglycine (DMG), sarcosine, choline, glycerophosphorylcholine 
(GPC), TMAO, creatinine, and carnitines.  
 A mass spectrometry method for measuring both TMA and TMAO using pre-
column derivatization of TMA.  









2.2.  The measurement of betaine, N,N-dimethylglycine, choline, 
glycerophosphorylcholine, sarcosine, trimethylamine-N-oxide, creatinine, and 
carnitines by liquid chromatography - mass spectrometry 
 
Introduction 
HPLC-UV techniques that have traditionally been used to measure betaine, 
carnitine, DMG, and choline required derivatization of the samples, and separation 
from interfering compounds in the sample matrix was often difficult. LC-MS/MS has 
previously been used to measure methylamines in a range of different sample matrices 
without the need for pre-column derivatization.
41, 45
 Tandem mass spectrometry (LC-
MS/MS) has many advantages over traditional HPLC techniques, including: fast and 
simple sample preparation, high selectivity, lower run times, and lower flow rates. 
The use of compound-specific deuterated internal standards in LC-MS/MS also 
allows for more accurate and precise data to be obtained. However, caution needs to 
be taken to ensure that mass spectrometry methods are reliably quantitative over the 
expected biological range. Liquid chromatography - mass spectrometry methods have 
been described for the measurement of betaine and related one-carbon metabolites in 
order to assess their potential as bio-markers of disease.
41, 45a, 99
 In 2002, Koc et al.
99
 
described a single quadrupole liquid chromatograph - mass spectrometer (LC-MS) to 
measure choline and a range of related metabolites, including betaine and GPC in 
tissues and foods. They showed that single quadrupole mass spectrometry produced 
high precision and accuracy and had considerable advantages over previous methods, 
including shorter sample run times, and no need to derivatize the samples, therefore 
allowing considerable savings in labour and reagent usage. As mass spectrometry 
systems became more affordable and advanced, new methods were described using 
more sophisticated tandem mass spectrometers (LC-MS/MS) which can achieve 
greater sensitivity and accuracy.
41, 45
 
The aim was to develop an efficient and reliable tandem liquid 
chromatography mass spectrometry method which can measure the methylamines: 
betaine (Fig. 2.1, 1), GPC (2); choline (6); DMG (7); sarcosine (8); creatinine (9); 
TMAO (10); carnitine (11); acetylcarnitine (12); and propionylcarnitine (13). Results 
using this LC-MS/MS method were compared with established HPLC methods and 






Fig. 2.1. Structures of some biologically important methylamines. Betaine (1), GPC 
(2), choline (6), DMG (7), sarcosine (8), creatinine (9), TMAO (10), carnitine (11), 






Reagents and chemicals 
Carnitine (HCl), acetylcarnitine (HCl), betaine (HCl), N,N-dimethylglycine 
(HCl), choline iodide, glycerophosphorylcholine (cadmium chloride complex), 
sarcosine, and creatinine (anhydrous) were obtained from Sigma (St Louis, MO, 
USA). N,N,N-Trimethyl-D9-glycine (HCl, D9-betaine) and choline-trimethyl-D9 
chloride were obtained from Isotec (Miamisburg, Ohio, USA), D3-creatinine, D9-
trimethylamine-N-oxide, and D3-carnitine were obtained from Cambridge Isotope 
Laboratories (Andover, MA, USA), and N,N-dimethyl-D3-glycine (HCl, D3-DMG) 
was obtained from CDN isotopes (Pointe-Claire, Quebec, Canada). Ammonium 
formate and formic acid were purchased from Sigma-Aldrich (St Louis, MO, USA). 
HPLC grade acetonitrile was obtained from Mallinckrodt (Paris, KY, USA), and 
methanol was obtained from Merck (Darmstadt, Germany). 
 
Sample preparation 
Plasma, urine, or standard (50 µL) was added to 1.0 mL of extraction solvent 
which contained 90% acetonitrile and 10% methanol with 5.0 µmol/L of each of the 
deuterated internal standards added (D9-betaine, D9-choline, N,N-dimethyl-D3-
glycine, D3-creatinine, D3-carnitine, and D9-TMAO). Samples were vortexed for 5 
minutes and centrifuged at 13000 × g for 5 minutes, then transferred to HPLC vials 
and capped for analysis.  
 
Chromatography 
 A number of normal phase (HILIC) columns were investigated for the 
separation of methylamines in biological samples, including: silica (Kinetix HILIC 
100 × 2.1 mm, 2.6 µm, Phenomenex, CA, USA), silica hydride (Cogent Silica C 100 
× 2.1 mm, 4 µm, Microsolv Technologies, NJ, USA), silica hydride with carbon 
(Cogent diamond hydride 100 × 2.1 mm, 4 µm, Microsolv Technologies), a strong 
cation exchange (Epic SCX 12.5 × 3 mm, 3 µm, ES Industries, NJ, USA), and an 
XBridge Amide column (100 × 2.1 mm, 3.5 µm, Waters). A mixed aqueous standard 
(containing 100 µmol/L of each of betaine, choline, DMG, sarcosine, TMAO, 
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creatinine, carnitine, acetylcarnitine, and propionylcarnitine) was injected onto each 
column and their selectivities were compared. All columns were operated with the 
same conditions as described in the next section. 
 
LC-MS/MS 
HPLC was performed on a Shimadzu Prominence (Kyoto, Japan) system. The 
flow rate was 0.3 mL/min. The injection volume was 10 µL. For the validation 
studies, a Cogent 100 mm × 2.1 mm, 4 µm diamond hydride silica column (Microsolv 
Technologies, NJ, USA) was used with a silica guard column, and the oven 
temperature was 40ºC. The gradient used for the analysis is described in Table 2.1. 
Line A contained 10 mmol/L ammonium formate and 10 mmol/L formic acid in 50% 
distilled water and 50% acetonitrile. Line B contained 10 mmol/L ammonium 
formate, 10 mmol/L formic acid, 73% acetonitrile and 27% water. 
 
Table 2.1. Gradient used with Diamond Hydride column.  
Time 
(min) %A %B 
0.0 0 100 
6.0 100 0 
6.1 0 100 
8.0 0 100 
 
Samples were detected using an MDS Sciex API 4000 (Applied Biosystems, 
VIC, Australia) tandem mass spectrometer with an electrospray ionization (ESI) 
probe. Methylamines were measured in positive ion mode using tandem mass 
spectrometry with multiple reaction monitoring (MRM). Mass transitions used for 
MRM are shown in Table 2.2. The dwell time was 150 ms for all compounds. 
Instrument dependent parameters were investigated using betaine as a model 
compound for the method. Ion source temperature was 350ºC, source gas (nitrogen) 1 
was set to 40 L/min and source gas 2 was set to 45 L/min. The collision gas was also 
nitrogen which was produced in a nitrogen generator. In order to find the optimum 
parameters for each compound, a compound optimization was performed by infusing 
2 µmol/L standards of each analyte in mobile phase into the mass spectrometer using 
a syringe pump at a flow rate of 10 μL/min. The optimum compound-specific MS/MS 
mass transitions and potentials are shown in Table 2.2 for each analyte. There were at 
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least four fragments produced in the collision chamber for most of the analytes. 
However, the mass transition which produced the greatest signal was usually chosen 
for quantitation. The structure of the parent ions and the MS/MS fragment ions used 
for detection are shown in Fig. 2.2. The HPLC system and mass spectrometer were 
controlled using Analyst software (Applied Biosystems). Data was calibrated using 
peak area ratios of external standards to internal standards as compared to peak area 
ratios in the samples to the internal standards. The internal standards used for each 
compound are shown in Table 2.2.  
 
 
Table 2.2.  Mass transitions and potentials used to measure methylamines by LC-
MS/MS. 
Analyte Mass transition DP CE CXP Internal standard 
Betaine 118.2 → 59.0 56.0 27.0 4.0 D9-Betaine 
Choline 104.1 → 60.2 16.0 25.0 4.0 D9-Choline 
Dimethylglycine 104.1 → 58.1 51.0 21.0 4.0 D3-Dimethylglycine 
Sarcosine   90.1 → 44.0 6.0 21.0 6.0 D3-Dimethylglycine 
Creatinine 114.1 → 44.0 6.0 29.0 4.0 D3-creatinine 
Acetylcarnitine 204.3 →  85.2 81.0 31.0 8.0 D3-carnitine 
Propionoylcarnitine 218.2 → 85.0 51.0 29.0 4.0 D3-carnitine 
Carnitine 162.1 → 85.0 71.0 31.0 16.0 D3-carnitine 
Trimethylamine-N-oxide 76.1 → 58.1 16.0 27.0 10.0 D9-TMAO 
Glycerophosphorylcholine 258.2 → 104.0 66.0 23.0 8.0 D9-Betaine 
      
      Internal standard Mass transition DP CE CXP 
 D9-Betaine 127.2 → 68.0 61.0 27.0 4.0 
 D9-Choline 113.2 → 69.0 61.0 27.0 2.0 
 D3-Creatinine 117.2 → 47.1 51.0 33.0 4.0 
 D3-Dimethylglycine 107.2 →  61.0 46.0 29.0 4.0 
 D3-Carnitine 165.2 → 85.0 61.0 29.0 6.0 
 D9-Trimethylamine-N-oxide 85.2 → 66.0 91.0 29.0 2.0 
      
 
      Abbreviations: Declustering potential (DP), collision energy (CE), and collision cell exit potential 






Fig. 2.2. Mass transitions used for MRM detection of methylamines by LC-MS/MS. 
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Single quadrupole LC-MS 
 A method for the measurement of methylamines was also developed using an 
Agilent 6120 single quadrupole mass spectrometer with an ESI source connected to 
an Agilent 1200 Series HPLC system (Agilent, VIC, Australia). Methylamines were 
measured by monitoring the parent mass in positive ion mode [M+H]
+
. Mass 
spectrometric parameters (energies and temperatures) were optimised using flow 
injection analyses (Table 2.3). It was expected that single quadrupole mass 
spectrometry (LC-MS) and triple quadrupole mass spectrometry (LC-MS/MS) would 
produce similar results for these low molecular weight methylamine compounds. The 
LC-MS method was validated by comparison with the LC-MS/MS method.  
 
Table 2.3.  Optimized parameters for analytes detected on the Agilent 6120 single 
quadrupole mass spectrometer. 
 
MSD 6120 


















TMAO  76   85 7 35 
Choline 104   90 7 35 
DMG 104   90 7 35 
Creatinine 114 110 7 35 
Carnitine 162   85 7 35 
Acetylcarnitine 204 100 7 35 
     
 Drying gas 
temperature °C 
Capillary 







TMAO 275 1500 
Choline 275 1500 
DMG 275 1500 
Creatinine 275 1500 
Carnitine 275 1500 
Acetylcarnitine 275 1500 
 
Note: Taurine and inositol were measured in negative ion mode. Inositol was detected with an APCI 








 Validation studies were carried out on pooled EDTA plasma, and urine samples. 
Samples were stored at -80 ºC before analyses. 
 
Precision and accuracy 
 Six batches of four replicates were run to investigate the precision of the assay 
for betaine, DMG, choline, carnitine, acetylcarnitine, propionylcarnitine, TMAO, and 
creatinine in a plasma sample containing high and low levels of methylamines. The 




Plasma samples were analyzed for betaine, DMG, carnitine, acetylcarnitine, and 
creatinine using the LC-MS/MS method developed here, and the results were 
compared with those obtained using established HPLC-UV methods using Passing-
Bablok regression analysis carried out with Acomed Statistik V3.
100
  
Betaine, DMG, carnitine and acetylcarnitine were measured by HPLC-UV using 
the method described by Storer et al.
1b
 For betaine, DMG, carnitine, and 
acetylcarnitine 22 plasma samples were derivatized with 2-naphthacyl triflate. The 
samples were separated on a Phenosphere SCX (250 × 4.6, 5 µm) column 
(Phenomenex) and measured by UV detection at 249 nm. 
Creatinine was measured by HPLC-UV without derivatization. Fifty µL of 
sample was extracted into 1.0 mL of 80%:20% acetonitrile and methanol. Samples 
were then vortexed, and centrifuged at 13,000 × g for 5 minutes. Creatinine was 
separated using a Sachtopore titania 150 × 3 mm, 3 m column (Sachtleben Chemie, 
Duisburg, Germany). The mobile phase contained 50 mmol/L H2SO4, 8% water, and 
92% acetonitrile. The flow rate was 0.8 mL/min and the injection volume was 50 μL. 
The oven temperature was set to 40 ºC and detection was by UV at 214 nm. The run 
time was 15 minutes. 
Methylamine results from 48 plasma samples obtained by tandem quadrupole 
mass spectrometry (LC-MS/MS) were compared with single quadrupole mass 





 The LC-MS/MS instrument used was an AB Sciex API4000, and the LC-MS 
single quadrupole instrument was an Agilent 6120.  
To compare the method performance for methylamine concentrations obtained 
by the different methods, a plasma sample and the same plasma with 50 µmol/L of 
added betaine, DMG, choline, sarcosine, TMAO, GPC, carnitine, acetylcarnitine, and 
creatinine were analyzed by LC-MS, LC-MS/MS, and HPLC-UV. Precision was 
evaluated by calculating the coefficient of variation over 10 replicates. Accuracy was 
evaluated as the recovery of analytes added to plasma 
 A urine sample and the sample urine with 100 µmol/L of betaine, DMG, 
choline, sarcosine, TMAO, GPC, carnitine, and acetylcarnitine were measured by LC-
MS, LC-MS/MS, and HPLC. Precision was evaluated for the different methods by 
calculating the coefficient of variation over 10 replicates. Accuracy was evaluated as 
the recovery of analytes added to urine. 
 
Linearity 
 To investigate the linearity of the method aqueous standards containing 50, 100, 
250, 500, 1000, 1500, 2000 µmol/L of betaine, DMG, choline, carnitine, 
acetylcarnitine, TMAO, and glycerophosphorylcholine were measured by LC-MS/MS 
and calibration curves were generated.  
To investigate the linear range in plasma for DMG, choline, GPC, 
acetylcarnitine, and propionoylcarnitine, concentrations ranging from 0 to 50 µmol/L 
were added to plasma. Concentrations of betaine ranging from 0 to 100 µmol/L were 
added to plasma, and concentrations of TMAO, creatinine, and carnitine ranging from 
0 to 200 µmol/L were added to plasma. 
To investigate the linear range for urine, concentrations ranging from 0 to 50 
µmol/L of choline and GPC were added to urine. Concentrations ranging from 0 to 
500 µmol/L of DMG, carnitine, acetylcarnitine were added to urine. Concentrations of 
betaine ranging from 0 to 1000 µmol/L were added to urine, and concentrations of 
TMAO ranging from 0 to 2000 µmol/L were added to urine. 
Each concentration level was analyzed in triplicate for each analyte in both 






Comparison of LC columns 
 The chromatographic separation of methylamines on different columns are 
shown in Figs. 2.3 and 2.4. Only the silica hydride columns were effective at 
separating choline and DMG chromatographically. The diamond hydride had a 
different selectivity to the Silica C column with choline co-eluting with betaine on the 
diamond hydride column, and choline co-eluting with acetylcarnitine on the Silica C 
column. The main difference between these columns is that the diamond hydride 
column has some carbon on the stationary phase. The Cogent columns both have a 
silica hydride surface on the mobile phase so that no silanol groups are present. The 
silica hydride columns generally gave broader peaks for compounds containing 
hydroxyl groups, such as carnitine and choline. Ammonium formate buffer was 
required in the mobile phase, otherwise much broader peaks were observed. 
While the strong cation exchange (SCX) and Kinetex silica columns are useful 
for separating methylamines, they are not suitable for measuring DMG. The DMG 









Fig. 2.3. Total ion count (TIC) chromatograms of methylamines separated on a 
Cogent diamond hydride column (A), and a Cogent Silica C column (B). 







Fig. 2.4. Total ion count (TIC) chromatograms of methylamines separated on a 
Kinetex HILIC silica column (A), and an ES industries SCX column (B). 







All methylamine analytes were separated by a combination of chromatography 
and their mass transition (Fig. 2.5). Choline produced a minor fragment ion at m/z = 
58 which caused interference in the DMG chromatogram. It is therefore important to 
separate these compounds chromatographically for reliable quantitation. Fortunately, 
the silica hydride columns were effective at separating DMG and choline. The lowest 
sensitivity was observed for sarcosine. 
 Carnitine, acetylcarnitine, and propionoylcarnitine fragmented in the tandem 
mass spectrometer to produce the most intense mass transition signal for the m/z = 85 
fragment ion, which is the butanoic acid ion fragment. Betaine, choline, DMG, and 
TMAO all gave fragment ions of trimethylamine, whereas sarcosine and creatinine 
gave a fragment ion of dimethylamine. Choline and DMG both have a mass at 104 Da 
(although they are not isomers) and produce a fragment ion at 58 Da. Consequently, 
choline appears on the same chromatogram as DMG. 
 When detecting nine analytes as well as internal standards, a maximum dwell 
time of 150 ms was required to obtain 15 data points across the peaks. With a dwell 
time of 200 ms, there were only 4 data points across the peak, which was insufficient 








Fig. 2.5. MRM chromatograms showing separation of some methylamines in plasma 
separated on a Cogent diamond hydride silica column. Abbreviations: N,N-
dimethylglycine (DMG), trimethylamine-N-oxide (TMAO), carnitine (Carn), 
acetylcarnitine (Ac Carn). 
 
 
 Precision and accuracy for the LC-MS/MS method 
 The within batch and between batch CVs were below 8% for most 
methylamines in plasma (Table 2.4), and below 6.6% for all methylamines in urine 
(Table 2.5). The limit of detection ranged from 0.01 to 0.5 µmol/L for methylamines 
in plasma. Sarcosine measured by this method had a high detection limit, and poor 






Table 2.4. Method validation data for plasma methylamines measured by LC-MS/MS. 
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Table 2.5. Method validation data for methylamines in urine measured by LC-
MS/MS. 
Analyte Mean (µmol/L) Within-batch CV Between batch CV Recovery (%) 
Betaine 
    Low 91.6 1.55 1.32 
 High 268 1.63 1.47 88 
     Choline 
    Low 14.1 1.82 1.70 
 High 22 1.42 1.10 80 
     Dimethylglycine 
    Low 43.8 0.84 3.76 
 High 133.4 4.38 3.60 90 
     Carnitine 
    Low 125 1.27 1.23 
 High 200 1.07 2.21 75 
     Acetylcarnitine 
    Low 34.6 1.75 1.90 
 High 129 1.34 2.32 94 
     GPC 
    Low 1.7 2.18 2.13 
 High 12.1 2.67 1.54 104 
     TMAO 
    Low 183 1.9 8.1 





The linear range for the LC-MS/MS method was found to be limited at the 
higher concentrations. The calibration curves show that there was a lower than 
expected signal response at concentrations over 250 µmol/L for most methylamines 
(Fig. 2.6).  
The plasma samples with added levels of all methylamines were linear over 
the expected biological ranges with r
2
 of 0.976 for DMG, and r
2
 above 0.985 for all 
other metabolites in the plasma (Fig. 2.7). The r
2
 values for urine with added 
methylamine concentrations were 0.998 and higher. The linearity in the urine was 
greater than for standards, whereas the urine results were still linear at concentrations 







Fig. 2.6. Calibration curves of aqueous standards showing data with peak area ratios 
to the internal standard peak area. Linear regression lines were calculated using 
concentrations up to 250 µmol/L only. Abbreviations: N,N-dimethylglycine (DMG), 






Fig. 2.7. Linearity of methylamines added to plasma and measured by LC-MS/MS 
(error bars represent standard errors). Abbreviations: N,N-dimethylglycine (DMG), 





Fig. 2.8. Linearity of methylamines added to urine and measured by LC-MS/MS 
(error bars represent standard errors). Abbreviations: N,N-dimethylglycine (DMG), 
trimethylamine-N-oxide (TMAO), glycerophosphorylcholine (GPC). 
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Comparison of LC-MS/MS and HPLC methylamine concentrations 
Comparisons of the LC-MS/MS method with established HPLC methods for 
measuring methylamines in plasma are shown in Fig. 2.9. 
The agreement of LC-MS/MS with HPLC was best for creatinine with r
2
 = 
0.999. Both creatinine and betaine methods were not significantly different with 
Passing-Bablok analysis showing a slope not significantly different to 1, and an 
intercept not significantly different to zero. The LC-MS/MS method for DMG had the 
lowest correlation with the HPLC assay (r
2
 = 0.748). The carnitine results showed a 
significant bias of 7% with results tending to be higher when they were determined by 
LC-MS/MS. This is consistent with some carnitine contamination observed in the 
reagent blanks in the LC-MS/MS method (of approximately 2 µmol/L), which was 
identified as coming from the deuterated carnitine internal standard. D9-Carnitine was 







Fig. 2.9. Methylamines in human plasma comparing the current LC-MS/MS method 










Comparison of tandem mass spectrometry (LC-MS/MS) with single quadrupole mass 
spectrometry (LC-MS) 
The comparison of data obtained by LC-MS and LC-MS/MS show that similar 
results can be obtained by both methods with the slope of the Passing-Bablok analyses 
within 15% of 1 for all analytes (Fig 2.10). Correlations (r
2
) were above 0.8 for 
betaine, DMG, TMAO, and carnitine. However, choline (r
2
 = 0.693) and 
acetylcarnitine (r
2




Fig. 2.10. Single quadrupole mass spectrometry results versus tandem mass 
spectrometry for 6 different analytes in plasma. All units are in mol/L. Regression 





Method performance for methylamine concentrations obtained by LC-MS, LC-
MS/MS, and HPLC-UV 
 Plasma methylamine results for the different methods are shown in Table 2.6. 
The concentrations calculated by the three different methods were similar for all 
methylamines in plasma. Precision and accuracy were similar for the different 
methods with CVs below 3% for all analytes and recoveries 85% and higher. 
 CVs for urine methylamine concentrations were below 3% for LC-MS and LC-
MS/MS methods, and below 5% for HPLC-UV methods. Recoveries were over 88% 
for methylamines measured by all methods. The HPLC-UV method appears to 
considerably over-estimate the concentrations of betaine and acetylcarnitine in these 

























Table 2.6. Method comparison data for some methylamines in plasma. 
 
 
  Betaine         DMG      Choline 
  LCMS LC-MS/MS HPLC LCMS LC-MS/MS HPLC LCMS LC-MS/MS HPLC 
Plasma 
         Mean (mol/L) 30.24 32.75     33.7 2.00 2.78 3.28 36.1 40.6 ND 
SD   0.44 0.50 0.56 0.13 0.19 0.19 0.39   0.48 
 CV%   1.47 1.52 1.65 6.61 6.72 5.86 1.09  1.19 
 Plasma + 50 µmol/L added 
       Mean (mol/L) 75.3 79.7 79.7 48.9 50.8 47.5 82.3 90.3 ND 
SD 0.70 1.16 1.39   0.72   1.27    1.01    0.72   0.45 
 CV% 0.92 1.44 1.74   0.88   2.50    2.14    0.88   0.50 
 Recovery %       90      95       92           94 96 88 92 99   
LOD 0.08 0.44 0.2 0.28 0.5 0.12 0.29 0.11 
 
 
  Carnitine          Acetylcarnitine      Creatinine 
  LCMS LC-MS/MS HPLC LCMS LC-MS/MS HPLC LCMS LC-MS/MS HPLC 
Plasma 
         Mean  (mol/L) 30.03 32.75 27.4 2.28 1.08 0.66 62.4 65.0 65.4 
SD   0.30   0.50 0.79 0.03 0.04 0.29 0.63 1.36 1.15 
CV%   0.99   1.52 2.87 1.17 3.89 43.7 1.01 2.09 1.76 
Plasma + 50 µmol/L added 
       Mean (mol/L) 76.83 83.4 71.3 44.8 49.6 46.4 107.4 109.2 111.4 
SD  0.72 2.06  1.46 0.48 0.85 0.97 1.14 2.20    2.48 
CV%  0.94 2.47  2.05 1.06 1.72 2.10 1.06 2.50    2.22 
Recovery %  94 101 88 85 97 91 90 96 92 
LOD 0.08 0.25 0.24 0.12 0.03 0.24 0.31 0.04 0.32 
Note: Means and standard deviations were calculated on 10 replicates. HPLC data was collected using derivatization with 2-naphthacyl triflate, strong cation exchange chromatography and 





Table 2.7. Method comparison data for some methylamines in urine. 
 
 
   Betaine         DMG     Choline 
  LCMS LC-MS/MS HPLC LCMS LC-MS/MS HPLC LCMS LC-MS/MS HPLC 
Urine 
         Mean (mol/L) 31.1 33.0 63.2 17.98 19.24 22.7 6.42 7.48 ND 
SD 0.30 0.74 6.97 0.565 0.60 3.2 0.08 0.28 
 CV% 0.95 2.23 11.0 3.14 3.11 14.1 1.17 3.72 
 Urine + 100 µmol/L added 
        Mean (mol/L) 122.7 129.5 163.8 114.2 113.1 150.8 101.1 110.4 ND 
SD 0.93 2.07 8.05 1.65 2.47 7.2 0.66 1.17 
 CV% 0.76 1.60 4.9 1.44 2.18 4.8 0.65 1.06 
 Recovery %  92 97 101 96 94 128 95 103   
 
   Carnitine         Acetylcarnitine 
     LCMS LC-MS/MS HPLC LCMS LC-MS/MS HPLC 
   Urine 
         Mean (mol/L)    25.79    28.74    34.4 5.14 6.56 41.0 
   SD 0.29 0.60 0.52 0.22 0.16 6.6 
   CV% 1.12 2.09 1.5 4.28 2.48 16.2 
   Urine + 100 µmol/L added 
        Mean (mol/L) 121.3 126.3 150 94.4 101.1 146 
   SD 0.75 1.57 4.6 1.27 2.38 7.6 
   CV% 0.62 1.24 3.1 1.34 2.35 5.2 
   Recovery %  96 98 116 89 95 105 
   






Sample preparation is important for ensuring that the samples are clean 
enough for injection into an LC-MS/MS system, and good chromatography is 
obtained. The sample preparation as described in Holm et al.
41
 (1:3 
sample:acetonitrile) could leave a high salt content and some protein in the injection 
solvent which can have negative effects on the column and the chromatography. The 
method described here uses a greater dilution of 1:20, i.e. 50 μL of sample in 1000 µL 
of extraction solvent. There is still enough sensitivity to measure most analytes with 
this greater dilution. However, the sensitivity was not sufficient to reliably measure 
sarcosine in plasma, where concentrations are reported to be typically less than 2 
µmol/L.
61b
 Improving the sensitivity for sarcosine may require pre-column 
derivatization, or a more sensitive mass spectrometer. The inflated concentration of 
7.7 µmol/L sarcosine in plasma observed here suggests that there may be interference 
from other compounds such as L-alanine or β-alanine. 
The linear range for the detection of methylamines by mass spectrometry has 
been shown to be limited. It was observed that the calibration curves for many 
methylamines were not linear over 250 µmol/L. Therefore, any results above this 
concentration may require the sample to be diluted at least ten-fold, and re-analyzed 
to be within the linear range. It may be necessary to analyze biological samples at 
different dilutions because some analytes are present in low concentrations when 
others are present in high concentrations, meaning some analytes may be diluted 
below the detection limit. As well as external standards, it is also important to ensure 
that the internal standard concentration is within the linear range of the mass 
spectrometer. The linearity of methylamine added to urine was greater with 
concentrations of many analytes still linear at concentrations over 1000 µmol/L, 
possibly because ion interference from the sample may allow less ions to reach the 
detector. The use of deuterated internal standards helps to correct for this effect. There 
are a number of reasons why the signal drops off at higher concentrations in the mass 
spectrometer leading to a non-linear calibration curve. The detector may become 
over-loaded (saturated with ions), the electrospray droplet surface may become 
saturated with the analytes, or singly charged dimers [2M+H]
+
  may be formed by two 
analyte molecules at higher concentrations.
101
 The linear range can sometimes be 





The accuracy of the method was initially poor for DMG (typically recoveries 
were around 70%) when using D9-betaine as the internal standard. However, 
recoveries improved after obtaining D3-dimethylglycine and using it as the internal 
standard for DMG. There were three peaks observed in the MRM for DMG in plasma, 
as was reported by Holm et al.
41
 DMG and choline both have mass transitions of 104 
→ 58, therefore they need to be well separated chromatographically. While 
unmodified silica and strong cation exchange (SCX) columns did not separate choline 
and DMG, the silica hydride columns were found to have a good selectivity for 
separating then. Kirsch et al.
45a
 showed a different selectivity on a Waters Acquity 
BEH HILIC column, with choline eluting before DMG. For methods that do not 
require the measurement of DMG, silica columns or SCX may perform as well. For 
example, the Kinetex HILIC silica column was found to be useful in an LC-MS/MS 
reference method which just measures creatinine. The Kinetex column is a core-shell 
column which is a technology that reduces peak broadening and gives good resolution 
in a short run time.   
The lack of a commercially available isotopic standard for GPC could be 
problematic. While recoveries of 100% were initially observed using D9-betaine as an 
internal standard, a slight change in the chromatography could allow ion interference 
to occur and affect the accuracy of the results. Koc et al.
99
 synthesized a deuterated 
GPC internal standard from a hydrolysis of 1,2-dipalmitoyl-sn-3-
glycerophosphocholine-[N,N,N-trimethyl-D9]. However, 1,2-dipalmitoyl-sn-3-
glycerophosphocholine-[N,N,N-trimethyl-D9] is not commercially available in 
sufficient quantities for synthesis, so this was not considered to be an affordable or 
practical option. 
The comparison of the present LC-MS/MS method with HPLC techniques 
generally showed good agreement for plasma. Comparison with LC-MS/MS shows 
that DMG concentrations are under-estimated by around 40% when measured by 
HPLC-UV using the Phenosphere SCX column. The lower plasma DMG results 
observed by the HPLC-UV method compared to LC-MS/MS are likely to be caused 
by interference in the HPLC assay. The DMG peak was often co-eluting with an 
interfering peak in the HPLC-UV method. There was high agreement for the HPLC 
creatinine method with LC-MS/MS, with no significant difference in the results 
detected by Passing-Bablok analysis. This shows that HPLC and LC-MS/MS are both 
suitable as reference methods for plasma creatinine. Comparison of data for 
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methylamines measured in urine using the different methods showed that HPLC-UV 
is prone to significant interference with large overestimates of concentrations for 
betaine and acetylcarnitine compared to mass spectrometric detection.  
The tandem mass spectrometry (LC-MS/MS) methylamine results generally 
agreed well with single quadrupole mass spectrometry (LC-MS). However, the 
choline and acetylcarnitine results did not correlate as well (r
2
 < 0.7). This is likely to 
be caused by sample instability after the samples were re-frozen and thawed between 
runs using the different methods. There were some unexpected outliers for many 
compounds, which may be due to sample stability, or it may be caused by interference 
in either the LC-MS, or LC-MS/MS assays. Metabolites such as acetylcarnitine and 
choline
41
 are known to have relatively low stability in plasma samples. Because these 
samples were stored for several months between analyses at -20°C, sample stability is 
likely to be a factor in the poor agreement of the concentrations of some metabolites 
between methods. 
 The LC-MS, LC-MS/MS, and HPLC data were in agreement for plasma 
methylamines (Table 2.6). The precision was generally greater when using mass 
spectrometric detection, particularly in urine. However, the main advantage of mass 
spectrometry compared to HPLC is the improved selectivity. This was apparent in the 
urine where interferences can potentially go unnoticed. Spiked controls may not 
necessarily provide a good estimate of the accuracy of a method due to the presence 
of endogenous co-eluting peaks which are not separated chromatographically. Urine 
betaine results can be considerably higher in the HPLC results compared to LC-MS 
and LC-MS/MS in the urine (Table 2.7). Despite this, the HPLC gave a calculated 
recovery of 101% for betaine. Without a comparison with mass spectrometric data it 
would not be possible to know the degree of interference. The HPLC method often 
has co-eluting peaks which affect the accuracy and precision. However, it is not 
always obvious when there is a peak directly underneath the analyte of interest. The 
higher specificity that mass spectrometry provides is especially useful when 
measuring analytes in urine. Other advantages of mass spectrometry methods include 
relatively fast and efficient sample preparation, high specificity, and the ability to 
measure a range of methylamines with a lower flow rate and a shorter run time than 
traditional HPLC techniques. Problems encountered when measuring methylamines 
by mass spectrometry include ion suppression and non-linearity at higher 
concentrations. If urine methylamine concentrations are above the linear range, it is 
54 
 
necessary to further dilute samples before injection. Non-linearity was found to be 
less of a problem when using single quadrupole mass spectrometry. Tandem mass 
spectrometry has greater selectivity than single quadrupole mass spectrometry. 
However, in some cases, such as DMG and choline, the chromatographic separation 









Trimethylaminuria is a condition where the enzyme (flavin monooxygenase 3, 
FMO3) which converts trimethylamine (TMA) to trimethylamine-N-oxide (TMAO) is 
dysfunctional. Trimethylaminuria sufferers accumulate high levels of TMA in their 
urine and sweat. The incidence of trimethylaminuria is thought to be as high as 1 in 
1000 people. However, it often goes on for many years undiagnosed, when people 
may avoid socialising because of the fishy smelling TMA present in the sweat.
102
 
While there is no cure for trimethylaminuria, the condition can be effectively 
managed by antibiotics, and a diet which avoids foods high in TMAO (i.e. seafood) 
and choline (e.g. eggs).
56, 102
  Diagnosing trimethylaminuria (or fish odour syndrome) 
requires the reliable measurement of trimethylamine and trimethylamine-N-oxide in 
urine. An oxidising ratio < 84% indicates that a patient has trimethylaminuria 
(whereas, the oxidising ratio is defined as: ([TMAO]/([TMAO]+[TMA]) × 100).
56
 





 and by LC-MS/MS.
105
 NMR spectroscopy can lack 
the sensitivity to measure TMA in samples from patients who are not sufficiently 
loaded with TMAO (after being asked to consume a meal of marine fish), meaning 
there is potential for a false negative result to be obtained for trimethylaminuria 
diagnosis.  
While TMAO can be measured directly by LC-MS/MS,
45b
 TMA is more 
problematic. TMA is a small molecule which does not fragment sufficiently for 
MS/MS detection, and a noisy baseline signal provides low sensitivity with selected 
ion monitoring or single quadrupole mass spectrometry. Acetonitrile can form adducts 
with ammonium ions to produce a signal at m/z = 59 which may interfere with the 
TMA signal at m/z = 60. TMA also has a similar mass to acetamide which may be 
produced when acetonitrile in the mobile phase hydrolyzes (Fig. 2.11, 14). The 
hydrolysis of acetonitrile to acetamide is a slow reaction that requires a catalyst under 
normal conditions.
106
 However, even a small concentration of acetamide in the mobile 
phase could help explain the high background signal observed when monitoring the 




     
Fig. 2.11. Hydrolysis of acetonitrile to give the acetamide (14) product with a similar 
mass to TMA. 
 
Derivatization of TMA can be used to overcome the problem of high baseline 
interference when measuring TMA by mass spectrometry. TMA can be converted to a 
quaternary ammonium compound which readily ionizes and produces high sensitivity 
for mass spectrometric detection. 
The aim of this section is to develop a method that can measure both TMA and 
TMAO in urine for diagnosis of trimethylaminuria. However, because TMAO is 
reported to be an important risk marker in cardiovascular disease, it is also an aim to 
see if its precursor TMA can be reliably measured in blood plasma, where the 
concentrations are expected to be low. TMA concentrations have not been well 
studied in plasma, which is likely to be because it is analytically challenging to 


















The aim here is to derivatize TMA with an alkyl halide to form a quaternary 
ammonium compound that can be measured reliably by tandem mass spectrometry 
(LC-MS/MS) or single quadrupole mass spectrometry (LC-MS). Results obtained by 
this method will be compared to those obtained by 
1
H NMR.  
Quaternary amines such as proline betaine have been synthesized by reaction of 
tertiary amines with alkyl halides in the presence of silver oxide.
107
 TMA has 





 and the TMA derivative measured by LC-MS/MS. Here, 
the substitution reaction of TMA with the alternative derivatizing agent 
iodoacetonitrile was investigated. Iodide is a much better leaving group than bromide, 
meaning the reaction proceeds more easily. Iodoacetamide was also considered as a 
possible derivatizing reagent for TMA. However, the derivative formed by the 
reaction of TMA with iodoacetamide forms a quaternary amine compound with a 
mass close to D3-creatinine (117.2 Da), and only one mass unit from the betaine 
molecular ion (118.2 Da). The MS/MS transition from a quaternary amine to a 
trimethylamine species fragment is usually the most intense signal. The species 
formed by the reaction with TMA (Fig. 2.12, 15) and iodoacetonitrile, cyano-N,N,N-
trimethylmethanaminium (16) has not been reported to exist in nature and is therefore 
unlikely to be present in biological samples. Whether silver oxide (or another silver 
salt) is necessary to catalyze the reaction was investigated. 
 
 










Materials and chemicals 
 TMA (HCl) and TMAO (dihydrate) were obtained from Sigma. D9-TMA (HCl) 
was purchased from CDN Isotopes, and D9-TMAO (free base) was purchased from 
Cambridge Isotope Laboratories. Disodium hydrogen phosphate (anhydrous), 
acetonitrile, and methanol were obtained from Merck (Darmstadt, Germany). 
 
Reaction conditions 
 To investigate the optimal reaction conditions, a standard containing 100 
µmol/L TMA and 100 µmol/L TMAO was reacted with iodoacetonitrile. The effect of 
iodoacetonitrile concentration, reaction time, and reaction temperature were 
investigated. The presence of: silver oxide; silver carbonate; or silver sulfate in the 
reaction mixture was also investigated. A control with no silver salt added was used as 
a comparison. Each silver salt was made up with Na2HPO4 (10:90 w/w), and a spatula 
(approximately 300 mg) added to the samples separately. For the samples without a 
silver salt, just Na2HPO4 was added. The samples were analyzed in triplicate. 
A 1 mmol/L aqueous standard containing just TMAO was placed through the 
reaction procedure with various concentrations of iodoacetonitrile to investigate if 
TMAO also reacts with the derivatizing reagent.  
 
Sample preparation 
 Samples and standards were diluted ten-fold in distilled water. An extraction / 
derivatizing solution was made up containing 40 mmol/L iodoacetonitrile (Sigma), 20 
µmol/L D9-TMA, 20 µmol/L D9-TMAO, in 90% acetonitrile and 10% methanol. Fifty 
µL of diluted sample or standard was added to 500 µL of the extraction / derivatizing 
solution, and a spatula of Na2HPO4 (approximately 300 mg) was added as a drying 
agent. The samples were then placed on a shaker for 5 minutes and centrifuged 
(13,000 × g, 3 minutes). Fifty µL of the supernatant was added to 500 µL of 
acetonitrile and 250 µL was transferred to HPLC vials and crimp capped for analysis 
by LC-MS or LC-MS/MS. 
 Aqueous calibration standards were run with each batch containing known 
levels of TMA and TMAO. Standard 1 contained 100 µmol/L TMA and 500 µmol/L 
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TMAO; Standard 2 contained 200 µmol/L TMA and 1000 µmol/L TMAO; Standard 
3 contained 500 µmol/L TMA and 5000 µmol/L TMAO. 
 
LC-MS/MS 
 The chromatography was performed using a 100 × 2.1 mm, 4 µm Cogent 
Diamond Hydride silica column (Microsolv Technologies, NJ, USA). A gradient was 
used with a Shimadzu Prominence binary pump system. Solvent A contained 10 
mmol/L ammonium acetate, 10 mmol/L formic acid and 50% water and 50% 
acetonitrile. Solvent B contained 90% acetonitrile and 10% water. The gradient 
started with 60% solvent A, going to 100% solvent A over 7 minutes, then back to 
starting conditions at 7.1 minutes. Detection was carried out using an AB Sciex 
API4000 tandem mass spectrometer. The mass transitions used for detection are 
shown in Table 2.8.  The data was quantified using peak area ratios of the analytes to 
their respective deuterated internal standards using Analyst (ABSciex) software. 
 
 
Table 2.8. LC-MS/MS mass transitions and potentials used. 
  Mass transition DP (V) CE (V) CXP (V) 
TMA-IACN derivative 99.1 → 58.1 51 35 10 
D9-TMA-IACN derivative 108.1 → 66.1 51 39 4 
TMAO 76.1 → 58.1 16 27 10 
D9-TMAO 85.2 → 66.0 91 29 2 
 
Abbreviations: decoupling potential (DP); collision energy (CE); collision cell exit potential (CXP). 
 
 
Single quadrupole LC-MS 
 An Agilent 1200 Series HPLC system connected to an Agilent 6120 Quadrupole 
mass spectrometer were used for the analysis. A 100 × 2.1 mm, 4 µm Cogent 
Diamond Hydride silica column (Microsolv Technologies, NJ, USA) was used for the 
separation. Solvent A contained 10 mmol/L ammonium acetate, 10 mmol/L formic  
acid and 50% water and 50% acetonitrile. Solvent B contained 90% acetonitrile and 
10% water. A gradient was used starting with 60% solvent A, and going to 100% 
solvent A over 7 minutes. The flow rate was 0.3 mL/min, the injection volume was 10 
µL, and the oven temperature was set to 40ºC. Samples were diverted to waste post-
column for one minute after injection, and the total run time was 8 minutes. The mass 
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to charge m/z values used for selected ion monitoring (SIM) were: TMAO = 76.1, D9-
TMAO = 85.1, TMA(iodoacetonitrile derivative) = 99.1, D9-TMA(iodoacetonitrile derivative) = 108.1. 
The capillary voltage was set to 3500V. The data was quantified using peak area 






 A normal urine sample, and a urine sample with 500 µmol/L TMA and 1000 
µmol/L TMAO added, were analyzed by tandem mass spectrometry LC-MS/MS 
using an AB Sciex API4000. A normal urine sample, and a urine sample with 1000 
µmol/L TMA and 2000 µmol/L TMAO added, were analyzed by single quadrupole 
mass spectrometry ( LC-MS) using an Agilent 6120 mass spectrometer. Six batches 
containing four replicates of the normal urine, and urine with elevated concentrations, 
were analyzed to determine the intra-assay and inter-assay co-efficient of variation 
(CV) for both TMA and TMAO. 
 
Accuracy 
 Recoveries were calculated from TMA and TMAO added to urine samples. The 




 Various concentrations of TMA (50, 125, 250, 500, 750, and 1000 µmol/L) and 
TMAO (100, 250, 500, 1000, 1500, and 2000 µmol/L) were added to urine, the 
samples were measured in triplicate by the current LC-MS/MS method, and the 





 The use of a silver salt decreased the yield of the TMA derivative (Fig. 2.13). 
The yield of the TMA derivative decreased with reaction time whether a silver salt 
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was present or not. However, allowing the samples to react for 5 minutes gave the 
drying agent some time to work, and the standard error of the measurements were 
lower. Addition of silver carbonate produced the lowest yield of derivative after 5 
minutes of reaction.  
The peak area of the TMA iodoacetonitrile derivative was optimized at around 
40 mmol/L iodoacetonitrile (Fig. 2.14A). Increasing the concentration of 
iodoacetonitrile above this improved the yield slightly more, but also increased the 
cross reaction, where TMAO reacts with the derivatizing reagent (Fig. 2.14B). This 
reaction was increased with increasing concentration of iodoacetonitrile with the ratio 
of apparent TMA present in a TMAO standard over 6% at 100 mmol/L of 
iodoacetonitrile. A concentration of 40 mmol/L or less iodoacetonitrile is required to 
ensure that the cross reaction is under 1%.  
 
 
Fig. 2.13. The effect of silver salt and reaction time on the TMA (iodoacetonitrile 






Fig. 2.14. The effect of iodoacetonitrile concentration on the TMA derivative using an 
aqueous standard containing 100 µmol/L TMA (A). The mean of three replicates ± SE 
are shown for each concentration of derivatizing reagent. The ratio of TMA/TMAO 
peak area in a pure aqueous 1 mmol/L TMAO standard over different concentrations 





Multiple reaction monitoring (MRM) chromatograms are shown for the TMA 
iodoacetonitrile derivative and TMAO in Fig. 2.15. The TMA derivative elutes at 




Fig. 2.15. LC-MS/MS chromatograms showing TMA and TMAO after derivatization 
of TMA with iodoacetonitrile. 
 
 
Precision and accuracy 
 The CVs were below 8.3% for TMA and TMAO, except for the lower level of 
TMA where the CV was 16%. The recoveries were over 95% for TMA and TMAO in 










Table 2.9. Method performance for the measurement of TMA and TMAO.  
 
  TMA   TMAO 
  Normal level High level   Normal level High level 
Mean (µmol/L)  8.3 525 
 
183 1147 
Within batch CV% 16.0      2.1 
 
      1.9        5.7 
Between batch CV%  8.2     7.6 
 
      8.1        6.5 




 The linearity of TMA and TMAO added to urine is shown in Fig. 2.16. TMA 
added to urine and measured as the iodoacetonitrile derivative gave high linearity up 
to 1000 µmol/L with r
2
 = 0.999. TMAO also showed high linearity up to 2000 µmol/L 
with an r
2
 of 0.998. The assay was non-linear at higher concentrations, with the 
response in aqueous standards showing significant tailing off at 2000 µmol/L for 






Fig. 2.16. Linearity of the TMA and TMAO added to urine and measured by LC-




Single quadrupole LC-MS 
 
Extracted ion chromatograms (EIC) are shown for the TMA iodoacetonitrile 






Fig. 2.17. A urine sample showing extracted ion chromatograms (EIC) at A, m/z = 76, 
and B, m/z = 99 after derivatization with iodoacetonitrile. 
 
 
Precision and accuracy 
 The CVs were below 7.9% for TMA and 2.9% for TMAO. The recoveries were 
over 91% for TMA and TMAO in urine (Table 2.10). The limit of detection (S/N = 3) 
was 1.3 µmol/L for TMA and 1.0 µmol/L for TMAO.  
 
Table 2.10. Method imprecision and accuracy for the measurement of TMA and TMA 
by single quadrupole LC-MS.  
  TMA   TMAO 
  Normal level High level   Normal level High level 
 
Mean (µmol/L) 17.4 939 
 
197 2109 
Within batch CV% 5.0 1.6 
 
2.8  1.4 
Between batch CV% 3.5 7.8 
 
2.8        1.6 




 The TMA added to urine and measured as the iodoacetonitrile derivative 
showed high linearity up to 1000 µmol/L with r
2
 = 0.999. TMAO also showed high 
linearity up to 2000 µmol/L with an r
2






Fig. 2.18. Linearity of: A, TMA, and B, TMAO added to urine and measured by LC-





 Alkyl halides are useful for the derivatization of tertiary amines such as 
trimethylamine. Iodo-compounds have previously been used to quaternize secondary 







 Here, iodoacetonitrile is used to derivatize TMA for analysis by LC-
MS or LC-MS/MS. The addition of the acetonitrile group to the TMA molecule 
makes it easily fragment in the mass spectrometer and produce good precision, 
accuracy, and linearity for the assay. The observation that the yield of the TMA-
iodoacetonitrile derivative decreased with reaction time suggests that an undesirable 
secondary reaction may be occurring which destroys the derivative. The methylene 
group between the amine nitrogen and the nitrile group may under-go further reaction. 
This appears to be exacerbated by the use of silver salts which produced considerably 
lower derivative yields (see Fig. 2.13). The TMA derivative was least stable in the 
presence of silver carbonate, suggesting that the degradation reaction may be base 
catalysed. After centrifuging the samples and removing the Na2HPO4 and silver salts, 
the TMA derivative was stable, and the assay was quantitative. 
The limit of detection for trimethylamine using tandem mass spectrometry is 
much lower than for NMR methods,
109
 meaning a clinically meaningful result for a 
TMA/TMAO ratio can be achieved for trimethylaminuria, even on a sample from a 
patient that was not well TMAO loaded. The sensitivity is much improved by using 
LC-MS (or LC-MS/MS) compared to NMR. However, the linear range was found to 
be much narrower with tandem mass spectrometry. The single quadrupole mass 
spectrometer had a greater linear range than the tandem mass spectrometer. While it 
may be necessary to dilute samples with concentrations greater than 2 mmol/L TMA 
or TMAO, the advantage of tandem mass spectrometry is the higher specificity 
associated with measuring mass transitions compared to monitoring the parent mass 
(SIM), meaning there is less chance of having interfering peaks from other 
compounds in the chromatograms.  
The observed cross reaction resulting in the formation of the TMA derivative 
from TMAO (likely via O-alkylation mediated deoxygenation) was problematic, but 
could be kept to less than 1% by using a concentration of derivatizing reagent of 40 
mmol/L. This was considered sufficient for the reliable diagnosis of trimethylaminuria 
from the analysis of urine. Urine samples analyzed for the diagnosis 
trimethylaminuria often contain high TMAO levels, unless the patient is homozygous 
positive and contains more TMA than TMAO. To adequately diagnose 






Unfortunately, the unwanted reaction of TMAO with alkyl halides is 
problematic for the measurement of TMA in plasma. Plasma TMA concentrations are 
reported to range from 0.29 to 1.66 µmol/L
110
 and are considerably lower than plasma 
TMAO concentrations, so any interference from TMAO will affect the accuracy of 
the method. Therefore this method was not considered sufficiently reliable to measure 










Derivatization of TMA with alkenes 
 
Introduction 
Tertiary amines such as trimethylamine can undergo reactions with alkenes such 






Fig. 2.19.  Reaction of TMA with acrylic acid (A), reaction of TMA with acrylamide 
(B), and reaction of TMA with acrylonitrile (C). 
 
  
The aim here is to investigate whether these alkenes can react with TMA. It is 
hypothesized that TMAO will not react with these reagents to form the same 
derivative. This may allow for a more reliable method to be developed for the 
measurement of TMA in plasma. 
 
Methods 
A 100 µmol/L aqueous standard of TMA was derivatized with either: acrylic 
acid, acrylamide, acrylonitrile, or methacrylic acid (Sigma). To find the optimum 
concentration of reagent for the reaction, various concentrations of alkene reagent 
were added to acetonitrile, 50 µL of the TMA standard was added, and a spatula 
(approximately 250 mg) of disodium hydrogen phosphate (anhydrous) was added. 
The samples were mixed on a vortex mixer for 5 minutes, then centrifuged (13000 × 
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g, 5 minutes). The effect of concentration of these reagents on peak area was 
investigated. Alternatives to disodium hydrogen phosphate were investigated 
including: no drying agent, sodium dihydrogen phosphate (monohydrate), 
tripotassium orthophosphate, sodium sulfate, sodium carbonate (anhydrous). 
The TMA derivatives were detected using an Agilent 6120 single quadrupole 
mass spectrometer in positive ion mode with electrospray ionization. The acrylic acid 
TMA derivative (propiobetaine) was monitored at m/z = 132.1, the acrylamide 
derivative (trimethylammonium propylamide) was monitored at m/z = 131.1, and the 
acrylonitrile derivative was monitored at m/z = 113.1. The optimized mass 
spectrometer parameters were: fragmentor voltage 100 V, capillary voltage 2000 V, 
drying gas temperature 325°C, drying gas flow rate 9 L/minute, and nebulising 
pressure 25 psig. Chromatography was performed on a Cogent diamond hydride with 
a gradient of 10 minutes going from 50% A to 100% A. Solvent A contained 10 
mmol/L ammonium formate, 10 mmol/L formic acid, and 50 % water and acetonitrile.  
Solvent B contained 10% water and 90% acetonitrile. The flow rate was 0.3 mL/min. 
 
Results and discussion 
 The separation of TMA alkene derivatives on the diamond hydride silica 
column is shown in Fig. 2.20. 
 
 
Fig. 2.20. Ion chromatograms showing the chromatography of the acrylonitrile, 
acrylamide, and acrylic acid derivatives of TMA. Derivatized 100 µmol/L aqueous 






Fig. 2.21.  Effect of concentration of acrylic acid on the TMA peak area measured as 
the acrylic acid derivative (A). Effect of concentration of acrylamide on the TMA 
peak area measured as the acrylamide derivative (B). Effect of acrylonitrile 
concentration on the TMA peak area measured as the acrylonitrile derivative (C). 
 
 
The optimum concentration of acrylic acid, acrylamide, or acrylonitrile was 
approximately 400 mmol/L in the reaction solvent (Fig. 2.21). The response decreased 
at greater concentrations of derivatizing reagent, suggesting that an undesirable 
reaction may be occurring which destroys the derivative. The interference in the mass 
spectrometer from the excess alkenes may be problematic at higher concentrations. 
While, these alkenes have fairly low boiling points, some polymerization is likely to 
be occurring inside the mass spectrometer. Adding disodium hydrogen phosphate 
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produced the largest peak area for the TMA derivatives. Addition of sodium carbonate 
only produced a small TMA derivative peak with acrylamide. In the absence of drying 
agent no product peaks were observed (data not shown). The reaction of 
trimethylamine with alkenes is acid catalyzed. However, the addition of the more 
acidic reagent sodium dihydrogen phosphate produced a lower yield of derivative than 
disodium hydrogen phosphate, possibly by protonating trimethylamine. The sodium 
dihydrogen phosphate used was not anhydrous, so would not be an effective drying 
agent. While the reaction requires the presence of hydrogen ions to proceed, it is 
likely that adding too much acid protonates TMA, whereas the reaction requires the 
uncharged form of trimethylamine. This would explain why the reaction does not 
proceed as well under strong acid conditions. 
There was no TMA peak observed when injecting a pure TMAO standard 
derivatized with acrylic acid or acrylamide, showing that TMAO does not react with 
the alkenes to produce the same derivative as TMA.  
The use of acrylamide is preferable to acrylic acid. While both reagents 
derivatize TMA efficiently, acrylic acid reacts with TMA to produce propiobetaine 
(sometimes referred to as β-alanine betaine),
111
 which is used as an osmolyte in 
plants, and may therefore be present in the diet. Any endogenous propiobetaine in the 
samples will give the appearance that more TMA is present than there actually is, 
potentially leading to a false diagnosis. The lesser known product of acrylamide and 
TMA, trimethylammonium propylamide, has not reported to be found in the diet. 
Acrylamide has been reported as a cancer risk in foods where it is found as a by-
product of cooking.
112
 Acrylamide is not likely to be present in human samples in 
concentrations that would significantly interfere with the TMA reaction, whereas a 
concentration of 400 mmol/L of acrylamide is required for complete reaction with 
TMA. 
After injecting multiple samples containing acrylamide or the other alkenes, the 
signal of the trimethylamine derivative dropped, and the mass spectrometer was found 
to be visibly dirty with contamination across a wide mass range after the injection of 
multiple samples containing acrylamide reagent. It is likely that excess reagent is 
polymerizing and accumulating inside the mass spectrometer, which required the 
source and capillary to be thoroughly cleaned. For this reason, acrylamide and related 




Improved measurement of trimethylamine and trimethylamine-N-oxide in urine by 




 Nuclear Magnetic Resonance (NMR) spectroscopy has been traditionally used 
to measure TMA and TMAO for the diagnosis of trimethylaminuria.
56, 105b
 NMR has 
advantages over other techniques because of simple sample preparation and the ability 
to measure TMA and TMAO simultaneously in a single spectrum. However, the 
measurement of TMA and TMAO in urine has previously been problematic. 
Acidification of the sample is required to separate the methyl resonances of TMAO 
and betaine in the spectrum.
40, 56
 However, acidification of the samples has the side 
effect of protonating TMA which splits the peak into a doublet, therefore increasing 
the detection limit and reducing the sensitivity. Ways to prevent the TMA from 
splitting were investigated. Furthermore, the TMA peak is present on the side of a 
peak from the citric acid quadruplet, which reduces the sensitivity of the TMA assay 
even more.  
Improvements to the analysis of TMA and TMAO by NMR were made, and this 





Reagents and chemicals 
 Trimethylacetamide and deuterium oxide (D2O) were obtained from Sigma. 
Aluminium chloride was purchased from BDH (Poole, England). Hydrochloric acid 
was obtained from Merck.  
 
Sample preparation 
An NMR reagent was made up by adding 500 mmol/l of HCl, 760 mmol/L of 
AlCl3, and 10 mmol/L trimethylacetamide to D2O. This solution was centrifuged and 
stored in the fridge for up to three months. Two hundred µL of the NMR solution was 
added to 600 μL of urine sample or aqueous standard. Samples were then centrifuged 
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(11,000 g) and 700 µL was transferred to 5 mm NMR tubes and capped. Samples 





H NMR spectra were obtained using a Varian INOVA 500 MHz NMR 
spectrometer. Spectra were obtained using the method described in Lee et al. [7]. A 
water suppression technique (PRESAT) was used to remove the large water signal in 
the spectra. Eight transients were collected with a 5 second delay. The 
trimethylacetamide methyl resonance singlet peak was set to 1.0 ppm in each spectra. 
Analyte peaks were integrated and peak area ratios to the internal standard were used 
for quantification. To standardize the peaks, the internal standard was set to 100 
arbitrary units in each spectrum. Aqueous standards containing known concentrations 
of TMA and TMAO were run with each batch to construct calibration curves and 
calibrate the data.  
 
Validation 
 Eight replicates of a urine sample with a high and a low added level of TMA 
and TMAO were run and a CV was calculated to show the precision of the method. 
The low urine sample contained an added level of 50 µmol/L TMA and 250 µmol/L 
TMAO. The high urine sample contained an added level of 500 µmol/L TMA and 
2.000 mmol/L TMAO. The linearity of the method was shown by running three 
replicates of four different levels of TMA and TMAO by NMR. Accuracy of the 









Only aluminium chloride was effective in removing the citrate peaks from the 
spectrum and stopping the TMA methyl resonance from splitting. The use of 
aluminium chloride hexahydrate did not achieve this. The citrate peaks were still 
present and TMA methyl resonance was still split when aluminium chloride 
hexahydrate was used. The reagents, aluminium potassium sulfate, and aluminium 
ammonium sulfate were also tried in the method, however they were not sufficiently 
soluble to make up the desired concentration.  
 
NMR spectroscopy 
Adding aluminium chloride to the urine samples before NMR analysis stopped 
the TMA peak from splitting, and a singlet peak was observed for TMA rather than a 
doublet (Fig. 2.22). The citric acid peaks were removed from the spectrum after 
aluminium was added to the sample (Fig. 2.22B). TMA was observed at 2.89 ppm, 
and TMAO was observed at 3.54 ppm when the trimethylacetamide internal standard 
was set to 1.18 ppm and TSP (trimethylsilyl-2,2,3,3-tetradeuteropropionic acid) was 





Fig. 2.22. NMR spectra of a urine sample without AlCl3 added (A), and with AlCl3 









 The coefficient of variation (CV) for TMAO was 4.7% for a urine concentration 
of 0.760 mmol/L, and the CV was 1.7% at a higher concentration of 2.50 mmol/L in 
urine. The coefficient of variation for TMA in urine was 8.1% at a concentration of 85 
µmol/L. The coefficient of variation for TMA in urine was 4.0% at a concentration of 
532 µmol/L in urine.  
 The limit of detection for TMA was 16 µmol/L using aluminium chloride, and 




 The recovery of TMA added to urine was 97%. The recovery of TMAO added 
to urine was 96%. 
 
Linearity 
 The linearity of the method was indicated by an r
2
 value of 0.994 for TMA and 
an r
2





Fig. 2.23. Linearity of TMA and TMAO added to urine and measured by NMR 





An improved method for the measurement of TMA and TMAO by NMR 
spectroscopy is described here. NMR spectroscopy is useful for measuring a range of 
metabolites simultaneously. However, it has the disadvantage that the sensitivity is 
intrinsically low compared to other techniques such as mass spectrometry. Improved 
sensitivity may be achieved by increasing the number of transients collected when 
obtaining the NMR spectrum. However, this makes the acquisition times very long, 
and the gain is only small. In order to be able to quantify TMA in a urine sample, it is 
important that the sample is collected after a TMAO load. Usually the patient is asked 
to eat a meal of marine fish, which is high in TMAO, before sample collection.
56
  
It has been documented that there is a need to acidify the samples to separate 
the methyl resonances of TMAO and betaine.
40
 However, acidifying the sample has 
the side effect of protonating TMA and splitting the TMA peak into a doublet. By 
adding aluminium ions which coordinate with TMA and make TMA appear as a 
singlet rather than a doublet in the spectra of acidified samples, the peak height is 
increased and the sensitivity is improved. 
Citric acid is known to complex with metal ions. For example, Sambano et al.
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used lithium ions to complex citric acid and showed that citric acid can be removed 
from an NMR spectrum by adding lithium chloride. The addition of aluminium ions 
to the sample has two benefits. Firstly, it prevents TMA from protonating at low pH 
and causing peak splitting, and secondly, it complexes with citrate and removes this 
interference from the samples. The citrate 
1
H NMR signal interferes with the TMA 
resonance in the spectrum. When the citrate complexes with aluminium ions, it 
precipitates out of solution and is removed by centrifugation of the sample prior to 
analysis by NMR spectroscopy. The two methylene groups in citric acid are not 
equivalent and produce an AB quartet system. These peaks may vary in position 
depending on the field strength of the NMR spectrometer. However, they were found 
interfere significantly when measuring TMA on a 500 MHz NMR system. 
The use of an appropriate internal standard is also important for achieving 
reproducible results. Trimethylacetamide (pivalamide) is a non-volatile solid that has 
nine identical protons, as do the analytes TMA and TMAO. Trimethylsilyl-2,2,3,3-
tetradeuteropropionic acid (TSP) has traditionally been used to as an internal standard 
to measure water soluble compounds by NMR spectroscopy.
114
 However, more 
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inconsistent results can be obtained when using TSP as the internal standard, which is 
probably due to a lower solubility of TSP in acidified samples, and the TSP free acid 
may tend to come out of solution when the ionic strength is high. Lee et al.
40
 used 
acetonitrile as the internal standard which is volatile, difficult to pipette accurately, 
and has only one methyl group. Acetonitrile also has a resonance at 2.0 ppm which is 
in a region where there is more matrix interference than trimethylacetamide which 
resonates at 1.0 ppm. 
In summary, improvements to the NMR assay for TMA and TMAO have been 
made by adding aluminium chloride to the sample to overcome the problem of the 
TMA peak splitting when samples are acidified. This improved NMR method was 
used in the following sections to compare results obtained using LC-MS and LC-
MS/MS. However, the lower detection limits mean that NMR spectroscopy may be 
less useful compared to mass spectrometry methods for the measurement of TMA and 
TMAO in urine and the diagnosis of trimethylaminuria.  
 
 
Comparison of liquid chromatography – mass spectrometry methods and NMR for 




 Urine samples (n = 26) were analyzed by 
1
H NMR for TMA and TMAO using a 
Varian INOVA 500 MHz instrument. The samples were re-analyzed using the current 
LC-MS method, and by LC-MS/MS (using an ABSciex API4000) and the results 







Method comparison – NMR versus LC-MS/MS 
Results obtained by tandem mass spectrometry TMA results were in 
agreement with the NMR spectroscopy method (r
2
 = 0.997) (Fig. 2.24). Passing-
Bablok analysis showed that the 95% confidence interval for the slope for TMA 
results was 0.859 to 1.016.  
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The results for TMAO were significantly higher by LC-MS/MS than NMR 
(the 95% confidence interval for the slope was 0.700 to 0.996). The LC-MS/MS 
results were particularly under estimated at concentrations over 10 mmol/L, high-
lighting the need to further dilute these samples by at least ten fold. This is likely to be 




Fig. 2.24.  NMR vs LC-MS/MS data for TMA and TMAO. Passing-Bablok regression 




Method comparison – NMR versus LCMS 
The single quadrupole mass spectrometry TMA results were in agreement 
with NMR results (r
2
 = 0.988). The slope of the Passing-Bablok regression for TMA 
of 1.146 indicates that the LCMS results are significantly higher than the NMR results 
as the 95% confidence interval for the slope (1.011 to 1.28) did not include 1 (Fig. 
2.25).  
TMAO showed agreement between the methods with a slope of 0.953 and an 
r
2
 of 0.980. Bablok passing analysis showed that TMAO results obtained by the NMR 
and mass spectrometric methods are not significantly different, as the 95% confidence 
intervals for the slope (0.853 to 1.009) included 1, and the 95% confidence intervals 






Fig. 2.25. TMA and TMAO concentrations calculated by LC-MS compared to NMR. 
Passing-Bablok regression lines are shown. 
 
 
LC-MS and LC-MS/MS have both been shown to be useful for the 
measurement of TMA and TMAO for the diagnosis of trimethylaminuria. There was 
generally good agreement between the mass spectrometric methods and NMR 
spectroscopy. Mass spectrometry methods provide increased sensitivity compared to 
NMR. However, care needs to be taken to ensure samples are within the linear range 
of the spectrometer. The higher agreement of TMAO concentrations between LC-MS 
and NMR, compared to LC-MS/MS and NMR, probably reflects the greater linear 


















2.4.  The measurement of taurine in plasma and urine 
 
Introduction 
Because the sulfonic acid group of taurine is strongly acidic, taurine cannot 
easily be protonated to make it cationic. Therefore, taurine cannot be measured at the 
same time as the methylamines and requires the development of a separate LC-
MS/MS method using negative ion mode. 
 
Methods 
Reagents and chemicals 
Taurine was purchased from Sigma. 2-Aminoethane-D4-sulfonic acid 




Fifty µL of aqueous standard, plasma, or urine sample was extracted into 1.0 
mL of extraction solvent containing 80% acetonitrile, 20% methanol, and 10 µmol/L 
D4-taurine (internal standard). Samples were vortexed and centrifuged at 13,000 × g 
for 5 minutes. 
 
LC-MS/MS 
A Waters (Ireland) XBridge 2.1 × 100 mm, 3.5 µm amide column was used to 
separate taurine with an isocratic mobile phase containing 15% water and 85% 
acetonitrile. A flow rate of 0.3 mL/min was used, with an injection volume of 10 µL, 
an oven temperature of 40ºC, and a run time of 6 minutes. Samples were analyzed 
using an ABSciex API4000 tandem mass spectrometer with an electrospray ion (ESI) 
source connected to a Shimadzu Prominence HPLC system. Taurine was detected in 
negative ion mode using the mass transition 124 → 80. The internal standard for the 
deuterated internal standard was 128 → 80. The decoupling potential was -55 V, the 
collision energy was -30 V, and the collision cell exit potential was -13 V.  
Taurine can be also measured using single quadrupole mass spectrometry by 
monitoring the 124 ion for taurine, and the 128 ion for the D4-taurine in negative ion 





Six batches of four replicates were analyzed to investigate the precision of the 
assay for taurine plasma and urine samples containing a high and normal level. The 
within batch and between batch CVs were calculated for each compound. The linear 
range of the aqueous standards was investigated by measuring aqueous taurine 
standards up to 2 mmol/L. Linearity was also investigated by adding taurine 
concentrations up to 400 µmol/L to plasma, and 1000 µmol/L to urine. Each 
concentration level was analyzed in triplicate for taurine. 
 
Results and discussion 
The Waters XBridge amide column provided sufficient retention of taurine (Fig. 
2.26) separating it from interfering peaks in the MRM chromatograms in the urine and 






Fig. 2.26. MRM chromatograms showing: A). Taurine standard (100 µmol/L) shown 
with the internal standard. B). A urine sample and the same sample with 100 µmol/L 
taurine added.  
 
The recovery of taurine was 81% when 100 µmol/L was added to plasma. 
However, other concentrations added to plasma had >89% recoveries (see Fig 2.28A). 




The recovery of 200 µmol/L taurine added to urine was 83%. The within batch 
CV was below 2.0%, and the between batch CV was below 1.2%. The limit of 
detection for taurine was 0.06 µmol/L (S/N =3). 
 
Table 2.11. Method performance data for the measurement of taurine in plasma and 
urine. 





Low plasma           29.6 1.7 2.9 
 High plasma 110.9 1.2 2.7 81% 
     





Low urine 147 1.12 1.97 





 The method was not linear for aqueous standards above 250 µmol/L (Fig. 2.27). 
The linear range was sufficient in plasma up to 400 µmol/L with an r
2
 of 0.999 (Fig. 
2.28A). The linearity of taurine in urine appeared to be sufficient up to 1000 µmol/L 
with an r
2
 of 0.998 (Fig. 2.28B). However, the lower urine concentrations (0 to 250 
µmol/L) had a different slope, suggesting that concentrations above 250 µmol/L 
should be diluted. 
 
 
Fig. 2.27. Calibration curve of aqueous taurine standards showing data with peak area 
ratios to the internal standard peak area. The regression line was calculated using 






Fig. 2.28. Linearity of taurine added to plasma (A), and urine (B). Means ± standard 






Taurine can be measured by LC-MS/MS in negative ion mode in plasma and 
urine, although care needs to be taken to make sure the assay is operating in linear 
range of the instrument. The linear range was particularly limited in the aqueous 
calibration standards. An amide column provided sufficient retention of taurine to 













2.5.  Chapter summary 
 Methods for the analysis of betaine, DMG, choline, TMAO, carnitine, 
acetylcarnitine, and taurine have been developed and validated so that they can be 
reliably measured in plasma and urine. The concentrations of these analytes in clinical 
samples were measured in Chapter 4 in order to investigate their metabolism in health 
and disease. 
 Similar results can be obtained using tandem mass spectrometry (LC-MS/MS) 
or single quadrupole mass spectrometry (LC-MS) for most methylamines. However, 
HPLC techniques that require derivatization and UV detection can produce greatly 
different results, which is likely to be a consequence of interfering compounds present 
in the samples. Mass spectrometry offers superior specificity compared to HPLC with 
UV (or fluorescence detection) following derivatization. The improved efficiency of 
mass spectrometry based methods compared to HPLC-UV methods allows for a 
greater number of samples to be analyzed in a shorter time, making mass 
spectrometry more suitable for epidemiological studies.  
Separation on an amide column followed by LC-MS/MS in negative ion mode 
has been shown to be a useful technique analysis of taurine in plasma and urine. 
 Lee et al.
40
 validated an NMR method for the analysis of methylamines using a 
500 MHz NMR spectrometer, and reported that the limit of detection for these 
analytes in urine ranged from 15 to 25 µmol/L. While there may be enough sensitivity 
to measure some methylamines in urine, it is unlikely that this instrument would have 
sufficient sensitivity to detect most methylamines in plasma, even if the problem of 
interference from the blood proteins was resolved. While more sensitive NMR 
systems exist, they require dedicated facilities, and they are cost prohibitive for use as 




































3.1.  Introduction 
The polyol osmolytes, sorbitol and myo-inositol, are particularly difficult to 
measure in complex biological samples. In this Chapter, the problems with measuring 
polyols are discussed, and potential ways to overcome these problems are described. 
Polyols are neutral compounds with no chromophores or reactive functional 
groups (other than multiple hydroxyls) that can easily be derivatized. Polyols do not 
possess an aldehyde group, unlike closely related sugars. Sorbitol and myo-inositol 
have multiple isomers, many of which only differ in the orientation of the hydroxyl 
groups. They have complex splitting patterns on proton NMR that are difficult to 
distinguish from sugars (such as glucose) that are often present in much higher 
concentrations in biological samples. 
Interference from isomers of sorbitol and myo-inositol are likely to be 
problematic. For example, mannitol (Fig. 3.1, 17) and galactitol (18) are structurally 
similar isomers of sorbitol (5) that produce ions of the same mass and are expected to 
also have similar fragmentation patterns. They only differ in the arrangement of the 
hydroxyl groups on the molecule. Mannitol is not produced by mammals, but is used 
as an osmolyte by plants and fungi, and can be added to foods as a sweetener, so may 






Fig. 3.1. Structure of isomers, sorbitol (5), mannitol (17), and galactitol (18). 
 
There are nine different stereo-isomers of inositol of which myo-inositol is just 
one. The inositols have multiple roles in nature. myo-Inositol is an important 
mammalian osmolyte.
71





 The only inositol isomers that are likely to be present in human samples in 
detectable concentrations are myo-inositol (Fig. 3.2, 4), scyllo-inositol (19), and chiro-
inositol (20). chiro-Inositol may play a metabolic role in mammals and has been 
associated with insulin resistance.
75b, 116b
 chiro-Inositol is found in the diet, but can 
also be synthesized in vivo from myo-inositol.
116b
 scyllo-Inositol is present in humans 
from dietary sources such as seafood
117
 and citrus fruits.
8
 myo-Inositol is present in 
many foods and can also be synthesized in the body from glucose.
116b
 myo-Inositol is 
also found in mammals as phosphates (such as phytic acid), and phosphatidylinositol, 
which is used in cell membranes.
116b
 Glucose, fructose, and mannose all have a 
molecular mass of 180.2 g/mol, and are also isomers of the inositols. Therefore, care 
needs to be taken to avoid interference from these sugars when using mass 
spectrometry. Glucose is present in mammalian blood in much higher concentrations 




Fig. 3.2. Structure of myo-inositol (4), scyllo-inositol (19), and chiro-inositol (20). 
 
There are different strategies which can be employed to detect polyols. They 
can be measured directly using refractive index detection, or by using mass 
spectrometry with an APCI ion source. They can also be measured by mass 
spectrometry using adducts of ions such as halides.
118
 Alternatively, the hydroxyl 
groups of polyols can be derivatized using highly reactive reagents that contain a 
chromophore to aid detection.
44, 119
 Polyols can also form complexes with transition 
metals,
120
 or boronic acids.
121
 Previous methods for measuring sorbitol and inositol 





 and HPLC with refractive index detection
6








Some of the GC methods described for polyols have been able to separate sorbitol 
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from its isomers. However, they involve intensive sample preparation that includes 
drying down the samples and pre-column derivatization, and they typically have long 
run times of around 40 minutes per sample.
52b
 Enzymatic assays used to measure 
sorbitol using sorbitol dehydrogenase are non-specific, polyols other than sorbitol are 
substrates for this enzyme, and these methods have been shown to significantly over-
estimate the results.
52c
 HPLC with refractive index detection is not sensitive or 
selective enough to measure polyols in complex biological samples such as plasma or 
urine. HPLC methods using derivatizing reagents such as phenylisocyanate and p-
nitrobenzoate are not selective for cis-diol polyols, and multiple peaks are likely to be 
present in the chromatograms for each of the many compounds in biological samples 
which contain hydroxyl groups. Polyols and sugars have been measured directly by 
LC-MS/MS
125
 or as chloride adducts in negative mode
118b
 and cesium adducts in 
positive mode.
126
 A method has been described using the direct measurement of 
plasma and urine myo-inositol in negative ion mode by LC-MS/MS.
127
 However, a 
large lead column with a long run time of 55 minutes was required to separate myo-
inositol from other isomers and the peaks were very broad.
127
 The sulfonated resin 
columns in the lead or calcium form, that have traditionally been used to separate 
polyols, are not very compatible with mass spectrometry. They are only available in 
wide-bore format and require long run times and a solvent splitter after the column to 
reduce the flow into the mass spectrometer. This in turn reduces the sensitivity of the 
assay and reduces sample throughput. These columns are also restricted to using 
mainly water in the mobile phase and will only tolerate a small organic solvent 
content. 
Polyols such as sorbitol and myo-inositol form complexes with boronates to 
produce anionic species which can be detected by mass spectrometry in the negative 
ion mode.
122, 128
 Boronates are known to complex with cis-diols. These interactions 
are potentially useful to improve both the separation and detection of polyols. The 
hydroxyl groups on the polyol isomers have different orientations. Complexation with 
boronates may enhance these structural differences, and improve the ability to 
separate them chromatographically. Boronate cis-diol complexes are volatile cyclic 
species that should be easily ionizable.  
Boric acid can also complex with polyols. Ackloo et al.
129
 showed that adding 
ethanediol in the mobile phase avoids leaving boric acid residue in the mass 
spectrometer. The ethanediol boric acid complex is volatile, whereas ammonium 
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borate by itself leaves a white residue on drying. The polyol osmolytes, sorbitol and 
myo-inositol, may compete with the ethanediol on the column. And an ion containing 
both sorbitol and ethanediol bound to a boric acid has been reported.
129
  
The interaction of polyols with various chemicals was investigated with the 
aim of improving the extraction, chromatography, and detection of polyol osmolytes. 
Mass spectrometry techniques, as well as interactions of polyols with boronic acids, 
transition metals, and derivatizing reagents were investigated. The objective was to 
develop and validate methods so that they can be used to reliably measure sorbitol and 
myo-inositol in plasma and urine. 
 
3.2.  Extraction of polyols 
The samples were initially extracted into acetonitrile (90%) and methanol 
(10%). However, polyols have a low solubility in organic solvents such as methanol 
and acetonitrile, and the extraction efficiency was low. 
 
 
Fig. 3.3. Run number versus peak area for the D6-myo-inositol internal standard 
measured as the iodide adduct by LC-MS/MS.  
 
The inositol signal was variable throughout the run, as seen by a plot of the D6-


































after the fifth injection. There were regular spikes where the signal increased for a 
couple of injections, then dropped off again. The samples where the signal for the 
internal standard was higher correspond to the aqueous standards. This suggested that 
ion suppression in the urine samples may be a problem. While the internal standard 
adjusted calibration corrects for this variation in signal, the sensitivity of the method 
was affected. The main issue with the variation in signal is the difference in detection 
limit between the aqueous standards and the urine samples. Adding urea to the 
standards did not change the peak area significantly, which suggests that urea was not 
an interfering substance in the urine. However, adding sodium chloride to a standard 
reduced the signal significantly. Removing the cations from urine (Fig. 3.4) and 
plasma (Fig. 3.5) by adding Dowex 50 cation exchange resin before extraction 
appeared to improve the sensitivity. However, it was noted that there was high 
pressure in the column after injecting the samples, particularly the plasma. It was also 
noted that the protein was not precipitated in the extraction solvent after Dowex 50 
was added to the sample, possibly due to acidifying it. It was then questioned whether 
the difference in response between the standards and the samples is actually a 
solubility problem instead of an ion suppression problem. Inositols are highly 
hydrophilic compounds which are not very soluble in organic solvents. It is therefore 
possible that the inositols were going out of solution with the precipitate during 
sample extraction and centrifugation. To attempt to solve this problem, the protein in 
the samples was precipitated with trichloroacetic acid before adding the sample to the 





Fig. 3.4. A urine sample (A), the same urine sample with Dowex 50 resin added 
before extraction (B). The XBridge column was used here. The mobile phase for this 







Fig. 3.5.  A plasma sample (A), and the same plasma sample with Dowex 50 resin 
added before extraction (B). 
 
 
Another approach to improve the extraction efficiency was to pipette the 
samples into an extraction solution where the inositols were more soluble. To 
investigate the solubility of inositol in different solvents and solvent mixtures, three 
replicates of a plasma or urine sample (50 µL) were extracted into 1.0 mL of each of 
the following solvents: acetonitrile (A); 10% methanol / 90% acetonitrile (B); acetone 
(C); or 25% dimethylsulfoxide (DMSO) / 75% acetone (D). Samples were measured 
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directly in negative ion mode by LC-MS with an APCI source after separation on an 
amide column (see Section 3.3). Inositols were found to have a high solubility in 
dimethylsulfoxide (DMSO). Figure 3.6 shows the highest extraction efficiency was 
achieved in a mixture of 25% DMSO and 75% acetone. Extraction of samples into 
25% DMSO / 75% acetone gave approximately 70% recovery of myo-inositol in 
plasma samples compared to the aqueous standards, as determined by the D6-myo-
inositol internal standard peak area. The extraction efficiency of inositols in 
acetonitrile and acetone was low. However, addition of 10% methanol to acetonitrile 
improved the extraction of inositols, particularly in the urine. Addition of DMSO to 
acetone greatly improved the extraction efficiency of inositols in both plasma and 
urine. 
 
Fig. 3.6. Extraction efficiencies of inositols in plasma and urine using different 
extraction solvents: acetonitrile (A); 10% methanol / 90% acetonitrile (B); acetone 




3.3.  Chromatography of polyols 
 
Introduction 
In order to reliably quantify sorbitol and myo-inositol, it is important to 
chromatographically separate the structural isomers. Columns that have previously 
been used to separate polyols are mainly sugar columns with large volumes that are 
not ideal for mass spectrometry. They are typically wide bore columns that require 
high flow rates, and a high water content in the mobile phase. They require long run 
times and produce wide peaks. These columns contain beads of sulfonated resin 
which requires regular regeneration with ions such as lead or calcium in order to 
work. Normal phase columns such as silica, amino, diol, or amide have also been 
reported for the separation of some polyols and sugars.
130
 How some of these columns 
separate sorbitol and myo-inositol was investigated here. 
 
Methods 
A range of different columns were investigated for the separation of the polyols 
of interest, including: silica (Kinetex HILIC core-shell silica 2.6 µm, 2.1 × 100 mm, 
Phenomenex), amide (Waters XBridge 3.5 µm, 2.1 × 100 mm or Waters Acquity 
UPLC 1.7 µm, 2.1 × 100 mm), titania (Sachtopore, 3 µm, 2.1 × 150 mm), amino 
(Phenosphere 3 µm, 150 × 4.6 mm, Phenomenex; Shodex Asahipak 5µm, 250 × 4.6 
mm, Phenomenex), and an ion exclusion column (100 × 7.8 mm, Fast Carbohydrate, 
Pb column, Biorad). In order to optimize the chromatography, a Jasco refractive index 
detector was used to detect polyol standards eluted through the various columns. 
During these investigations, the refractive index detector flow cell cracked and the 
instrument was uneconomical to repair. Further work developing the chromatography 
of polyols was carried out using mass spectrometric detection with either an AB Sciex 




Results and discussion  








Fig. 3.7. Chromatogram showing separation of polyols on a BioRad fast carbohydrate 
lead ion exclusion column. This separation was carried out by injecting a 2.5 mmol/L 
mixed standard of glucose, mannitol, myo-inositol, and sorbitol with a flow rate of 0.6 




The BioRad lead ion exclusion 150 × 7.8 mm, 10 µm column produced a 
separation of mannitol and sorbitol within 20 minutes (Fig. 3.7), although the peaks 
were broader than on other columns. Galactitol and sorbitol were co-eluting on the 
lead column (Fig. 3.8). Ion exclusion columns (containing sulfonated resin in metal 
ion forms) have been used extensively for the measurement of carbohydrates because 
they are known to be effective at separating polyol isomers. A lead column has been 
shown to effectively separate isomers of inositol.
127
 Lead columns give a better 
separation of sorbitol and mannitol than calcium columns. How these columns 
separate these isomers is not well understood. However, it is likely to be a result of 
the hydroxyl groups on the polyols interacting with the metal ions on the column. As 
sorbitol is retained longer, it is likely to form a stronger chelate with lead ions than 
mannitol. There are limitations with the use of ion exclusion columns, as well as the 
fact that they produce broad peaks. They are generally large with an internal diameter 
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of 7.8 mm, and do not come in smaller sizes for mass spectrometry. However, a flow 
splitter can be used after the column to reduce the flow into the mass spectrometer. 
According to the manufacturer, these columns must also be operated with water as the 
mobile phase with no more than 10% organic solvent added. Aqueous samples should 
be injected when using the ion exclusion columns, meaning that a simple solvent 
extraction is not appropriate. Alternative sample clean-ups are required, such as 
protein precipitation using trichloroacetic acid (TCA), or drying down the sample 
after a solvent extraction and reconstituting it in water. The manufacturers also 
recommend that they are operated at high temperatures, typically 60-80ºC.  
 
 
Fig. 3.8. Chromatogram showing separation of isomers mannitol, galactitol, and 
sorbitol on a BioRad fast carbohydrate lead ion exclusion column. This separation 
was carried out by injecting a 3.3 mmol/L mixed standard of mannitol, galactitol, and 
sorbitol with a flow rate of 0.6 mL/min. The column was operated at 80ºC, and 
polyols were detected using refractive index detection. 
 
 
 As well as investigating the chromatography using refractive index detection, 
the lead ion exclusion column was also used with mass spectrometric detection with 
both Q1 and MS/MS monitoring in negative ion mode (Fig. 3.9). The mobile phase 
was 100% distilled water. The flow rate was 0.6 mL/min and a flow splitter was used 
after the column to reduce the flow into the mass spectrometer to 0.3 mL/min. The 
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injection volume was 50 µL and the oven temperature was 60ºC. A high background 
noise was observed which is likely to be caused by the bleeding of lead ions from the 
column into the mass spectrometer leading to ion interference in the chromatograms. 
The 100 µmol/L polyol standards were barely detectable using both monitoring of the 
parent ion (Q1) and tandem mass spectrometry (MS/MS) when using the BioRad lead 
column. Using this column with mass spectrometry was therefore lacking the 




Fig. 3.9. Ion chromatograms of a mixture of 100 µmol/L aqueous standard of sorbitol, 
myo-inositol, glucose, mannitol, and galactitol separated on a BioRad 100 × 7.8 mm 
lead ion exclusion column. A = Q1 at 181 Da (blue), and 179 (red) in negative ion 
mode. B = MS/MS mass transitions 181 → 59 (blue), and 179 → 89 (red). Detection 





Silica, amino, and metal oxide columns 
Silica was effective at separating sorbitol, myo-inositol, and glucose. However, 
sorbitol, galactitol, and mannitol were not separated (Fig. 3.10). The silica based 
amino columns also gave no significant separation of sorbitol and mannitol.  
The amino columns produced a noisy baseline signal in the mass spectrometer, 
suggesting that the bleeding of amino groups was causing ion interference in the 
baseline. The Asahipak amino column provided a slight separation of sorbitol and 
mannitol, and produced less ion interference in the mass spectrometer than the 
Phenosphere amino column. 
Metal oxide stationary phases were unsuccessful at separating polyols. No 
peaks were observed using titania, zirconia, and alumina stationary phases, suggesting 
that the polyols were retained for a long time on these columns. Elution with high 




Fig. 3.10. Q1 Selected ion monitoring (SIM) chromatograms collected in negative ion 
mode at 179 Da and 181 Da. The sample contained 100 µmol/L sorbitol, 100 µmol/L 
myo-inositol, 500 µmol/L mannitol, and 1 mM glucose. Separation was performed on 







The amide columns provided the best separation of myo-inositol, chiro-inositol, 
and scyllo-inositol (see Figs. 3.11 and 3.12). The Waters X-bridge amide column 
separated myo-inositol from its isomers (Fig. 3.11) with only myo-inositol and scyllo-
inositol co-eluting. However, it did not separate sorbitol, mannitol, or galactitol from 
each other. These hexitols all eluted in the same region as glucose. 
 
 
Fig. 3.11. LC-MS/MS chromatograms of iodide adducts collected in negative ion 
mode on a Waters XBridge 3.5 µm, 2.1 × 100 mm amide column. The mass transition 
307 → 127 was used for monitoring myo-inositol and isomers. The sample contained 
500 µmol/L of: myo-inositol, scyllo-inositol, chiro-inositol, glucose, mannose, and 







Fig. 3.12. Separation of a 100 µmol/L mixed standard of polyols on a 1.7 µm, 2.1 × 
100 mm Waters Acquity UPLC amide column. Chromatograms of inositols (A), and 
hexitols (B) are shown. The mobile phase contained 15% water, 85% acetonitrile, and 
10 mmol/L diiodomethane. Detection was achieved using tandem mass spectrometry 
of the iodide adducts. 
 
 
Baseline separation of myo-inositol and scyllo-inositol was achieved on a waters 
1.7 µm particle size (UPLC) amide column (Fig. 3.12A). The Acquity UPLC amide 
column with 1.7 µm particle size improved the separation of myo-inositol and scyllo-
inositol compared to the 3.5 µm column, with nearly complete separation observed 
between the peaks. The UPLC column also produced a slight separation of the 
sorbitol isomers, although not sufficient for reliable quantitation of sorbitol (Fig. 
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3.12B). While there are nine possible inositol isomers, only myo-inositol, chiro-
inositol and scyllo-inositol are likely to be present in humans in significant 
concentrations.
127
 The sugars with the same mass as myo-inositol, glucose, mannose, 
and fructose all eluted earlier than the inositols on the amide column (before 5 
minutes). The double peaks that are observed for the sugars: fructose, glucose, and 
mannose are caused by the separation of the two anomeric forms of the sugar 
molecules (i.e. the ring and open chain form) on the amide column. A single peak can 
be obtained on amide stationary phases for sugars such as glucose by operating at 
higher column temperatures (up to 90ºC),
131
 which speeds up the equilibrium between 
the two forms. However, this is not necessary when just measuring the inositols which 
do not form anomers. 
 
 
Summary of the chromatography of polyols 
 The lead ion exclusion column provided the best separation of the hexitol 
isomers, sorbitol, mannitol, and galactitol. However these columns are not suitable for 
mass spectrometry. They have a large volume, give broad peaks, and bleed ions into 
the mass spectrometer, increasing the background noise and causing poor sensitivity. 
Silica provided some separation of polyols, but amide columns provided greater 
separation with inositols being well separated on a small particle size (UPLC) amide 
column. The good separation of inositols observed on the amide columns is likely to 
be due to hydrogen bonding between the amide and the hydroxyl groups on the 
polyols. It is not clear why amide groups separated the inositols better than the 
hexitols. Unfortunately, no commercially available (mass spectrometry compatible) 










3.4.  Detection of polyols 
 




 Polyols such as sorbitol and myo-inositol can shed a proton to form [M-H]
-
 ions 
which can be detected in negative ion mode. This provides a simple way of measuring 
these polyols, either directly as the parent ions, or by fragmenting them and 
monitoring the mass transitions (MRMs). However, because most polyols tend to 
fragment most strongly by losing a water molecule, the monitoring of MRM 
transitions is unlikely to help separate myo-inositol from glucose, or other sugar 
isomers. The separation of polyols from interfering substances such as glucose is 





Reagents and chemicals 
 Sorbitol, myo-inositol, galactitol (dulcitol), and mannitol were purchased from 
Sigma (MO, USA). D-Glucose was obtained from BDH (Pool, England). scyllo-
Inositol was purchased from TCI (Tokyo, Japan), and chiro-inositol was purchased 




 Detection was investigated operating the mass spectrometer in both Q1 mode 
(selected ion monitoring of the molecular ion), and in MS/MS mode (tandem mass 
spectrometry). 
An aqueous standard containing 100 µmol/L sorbitol and 100 µmol/L myo-
inositol, 1 mM glucose 500 µmol/L mannitol was made up. The aqueous standard was 
diluted 1:5 with acetonitrile, then injected on to a Kinetix HILIC 100 mm × 2.1 mm, 3 
µm column (Phenomenex). The mobile phase contained 80% acetonitrile and 20% 
water, and was delivered in isocratic mode. The injection volume was 10 µL, the flow 
rate was 0.3 mL/min, and the oven temperature was 40ºC. To measure sorbitol and 
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myo-inositol using the parent ion mass, the mass spectrometer was programmed to 
monitor the signal at 179 Da and 181 Da in negative ion mode. To optimize the 
compound-specific parameters for polyols by MS/MS, 5 µmol/L standards of sorbitol 
and myo-inositol were infused into the API4000 (Applied Biosystems) mass 
spectrometer using a syringe pump at 10 µL/min, and compound optimizations were 
performed for MS/MS in negative ion mode.  
 
Results and discussion 
 
Q1 ions 
 There was good separation on the Kinetex HILIC column of myo-inositol and 
glucose (Fig. 3.13). However, sorbitol and mannitol were not separated using this 
chromatography system. The sensitivity was likely to be sufficient for some 
applications by monitoring in Q1 ion mode. The background noise was high when 
detecting ions in Q1 mode on the API4000 tandem mass spectrometer. However, the 
Agilent 6120 single quadrupole mass spectrometer operated with an atmospheric 
pressure chemical ionization (APCI) source was later found to produce increased 
sensitivity compared to the tandem mass spectrometer operated in single quadrupole 
(Q1) mode.  
 
 
Fig. 3.13. Q1 Selected ion monitoring (SIM) chromatograms collected in negative ion 
mode at 179 Da and 181 Da. The sample contained 100 µmol/L sorbitol, 100 µmol/L 




 Using the mass transition 179 → 86.8 for myo-inositol, there was no significant 
glucose peak observed in the chromatogram (Fig. 3.14). The limit of detection for the 
inositol using MRM was 25 µmol/L. The 181 → 59 transition appeared to give better 
sensitivity for sorbitol. However, it was not possible to calculate a limit of detection 
for sorbitol as it was co-eluting with mannitol on the Kinetex HILIC column. It is 
likely that the ionization efficiency of the uncharged polyols would be improved by 
operating the mass spectrometer with an APCI source. The voltages from the 
compound optimizations are shown in Table 3.1. The source parameters were, ion 
source temperature = 350ºC, source gas 1 = 40 L/min, source gas 2 = 45 L/min. 
 
 
Table 3.1. Compound optimization data for fragmentation of polyols. 
Sorbitol     
MS/MS DP (V) CE (V) CXP (V) Intensity 
181.1 →  59.0 -65.0 -36.0 -3.0 32478 
181.1 →  70.8 -65.0 -32.0 -3.0 28058 
181.1 →  89.0 -65.0 -20.0 -5.0 14387 
181.1 → 101.0 -65.0 -20.0 -25.0 9993 
181.1 →  55.0 -65.0 -30.0 -7.0 6327 
     
Inositol      
MS/MS DP (V) CE (V) CXP (V) Intensity 
179.0 → 86.8 -65.0 -20.0 -13.0 25845 
179.0 → 59.0 -65.0 -38.0 -7.0 10152 
179.0 → 70.8 -65.0 -30.0 -1.0 6352 
179.0 → 85.1 -65.0 -20.0 -13.0 5202 







Fig. 3.14. LC-MS/MS multiple reaction monitoring (MRM) chromatograms collected 
in negative ion mode. Mass transitions were 181 → 59 for sorbitol monitoring, and 
179 → 86.8 for myo-inositol monitoring. The sample contained 100 µmol/L sorbitol, 








 Sorbitol is known to form adducts with halides such as chloride, iodide, or 
fluoride.
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 These adducts can be fragmented in the collision cell of a tandem mass 
spectrometer to remove the halide. The choice of halide is important. Fluoride is 
known to cause strong ion interference, and chlorine and bromine have the 
disadvantage that there is more than one main isotope, which complicates the method, 
and reduces the sensitivity. Chorine has an abundance of 76% 
35
Cl and 24% 
37
Cl, and 
bromine has 50% 
79
Br and 50% 
81
Br. The iodide adduct was chosen for quantitation 
because it has only one abundant isotope at 126.9 Da. A high abundance of different 
isotopes splits the mass signal and reduces the sensitivity at any particular mass. 
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Sorbitol and glucose have previously been measured as iodide adducts by adding 








 The mobile phase contained 85% acetonitrile and 15% water, and the stationary 
phase was a Kinetex HILIC (Phenomenex, 2.1 × 10 mm, 2.6 µm) column. Tandem 
mass spectrometry was carried out on an API4000 instrument (AB Sciex). The 
MS/MS conditions were determined by infusing a 5 µmol/L standard of sorbitol and 
myo-inositol in the mobile phase containing iodine into the mass spectrometer and 
performing a compound optimization.  
 Iodine (BDH) and diiodomethane (Sigma) were investigated as mobile phase 
additives for forming iodide adducts. Different concentrations (1, 5, 10, 20 mmol/L) 
of diiodomethane were tested in the mobile phase to investigate the optimum 
sensitivity.  
 
Results and Discussion 
 
 The sensitivity for myo-inositol was improved by measuring the adduct mass 
transition 307 → 127 compared to MS/MS of the free polyol (Fig. 3.15). Iodide 
readily dissociates from the polyol with low collision energy, allowing for an intense 
ion transition signal for quantitation. The optimum concentration of diiodomethane in 
the mobile phase was 10 mmol/L. Increasing the diiodomethane concentration in the 
mobile phase did not increase the peak sizes. While iodine (I2) readily formed iodide 
adducts with polyols, it appeared to build up in the mass spectrometer, gradually 
reducing the sensitivity. For both the sorbitol and inositol iodide adducts, the 
transition from the adduct to the iodide ion was the most intense mass transition 
(Table 3.2). Sorbitol may form a stronger adduct with iodide than inositol, since it is 







Table 3.2 Compound optimization data for fragmentation of iodide adducts of polyols. 
Sorbitol     
MS/MS DP (V) CE (V) CXP (V) Intensity 
309.1 → 126.80 -30.0 -22.0 -5.0 7792000 
309.1 → 125.07 -30.0 -130.0 -35.0 44000 
309.1 → 97.16 -30.0 -42.0 -3.0 22000 
309.1 → 79.65 -30.0 -106.0 -1.0 21000 
309.1 → 96.57 -30.0 -40.0 -5.0 19000 
     
myo-Inositol      
MS/MS DP (V) CE (V) CXP (V) Intensity 
307.1 → 126.70 -30.0 -14.0 -7.0 143017 
307.1 → 199.40 -30.0 -28.0 -3.0 992 
307.1 → 125.48 -30.0 -130.0 -35.0 725 
307.1 → 96.47 -30.0 -38.0 -7.0 417 





Fig. 3.15. LC-MS/MS chromatograms of iodide adducts separated on a Kinetix silica 
column. Mass transitions were monitored in negative ion mode at 309 → 127 for 
sorbitol monitoring, and 307 → 127 for myo-inositol. The sample contained 100 





 Detection of polyols as iodide adducts using a single quadrupole mass spectrometer 
 
Introduction 
Because a mass transition consisting of a halide ion disassociating from a polyol 
molecule is trivial, tandem mass spectrometry offers little advantage in the way of 
specificity. Therefore single quadrupole mass spectrometry can be expected to as 
effective as tandem mass spectrometry in this situation.  
 
Methods 
Samples and standards (50 µL) were extracted into an extraction solvent 
containing 75% acetone and 25% dimethylsulfoxide (DMSO). Flow injection 
analyses (FIA) were performed to optimize the source parameters for the iodide 
adduct of sorbitol and myo-inositol in the Agilent 6120 single quadrupole mass 
spectrometer using negative ion mode with an electrospray ion source. Two µL of a 
50 µmol/L standard of sorbitol was injected repeatedly while altering the fragmentor 
voltage, capillary voltage, source gas temperature and source gas flow rate. No 
column was attached, and the mobile phase contained 15% water, 10 mmol/L 
diiodomethane, and 85% acetonitrile. While altering the other parameters had little 
effect on the intensity, the fragmentor voltage was found to have a strong effect on the 
yield of the iodide adduct (Fig. 3.16). At fragmentor values over 50 V, there was a 
lower yield of the iodide adduct, and at fragmentor values over 100 V, there was more 
free sorbitol present in the mass spectrometer than the iodide adduct. The sensitivity 
was approximately four times lower for myo-inositol than for sorbitol. A relatively 
low fragmentor value is required to avoid the dissociation of the iodide from the 
polyols in the source. The optimal capillary voltage was 4000 V, the optimal drying 










Fig. 3.16. Flow injection analysis (FIA) experiment for sorbitol in the single 
quadrupole mass spectrometer (Agilent 6120), varying the fragmentor voltage. A is 
the FIA for free sorbitol in negative ion mode, and B is the sorbitol iodide adduct in 












Results and discussion 
 
 






Fig. 3.17. Urine with added levels of myo-inositol (green), and scyllo-inositol 
(brown). Samples were extracted in 75% acetone and 25% DMSO, and measured by 
single quadrupole mass spectrometry after separation on an amide column. 
 
 
Recoveries of myo-inositol and scyllo-inositol added to urine were 100% and 
95% respectively (Fig. 3.17). chiro-Inositol was most problematic with smaller than 
expected peaks and low recoveries in urine. This is likely to be caused by the presence 
of ion interference in the urine chromatograms where the chiro-inositol elutes, as the 
other inositols were not affected in this way. 
To test for ion interference, 50 µmol/L of myo-inositol was added to the mobile 
phase and a reagent blank, plasma and urine samples were injected. A negative peak 
was observed in the chromatograms. This interfering substance was found to come 
from the DMSO in the extraction solvent. Therefore, a cleaner grade of DMSO (ACS, 
99.9%) was purchased. Recoveries of chiro-inositol were found to be over 90% after 
this grade of DMSO was further purified by elution through silica (50-200 mesh). 
chiro-inositol 
y = 0.9017x - 2.9699 
R² = 0.9989 
scyllo-inositol 
y = 0.9561x + 101.72 
R² = 0.9976 
myo-inositol 
y = 0.9407x + 45.316 
































Concentration added (µmol/L) 
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The recoveries depend on the efficiency of the extraction, even though the use 
of internal standards can help to account for this. Polyols have a low solubility in most 
organic solvents. However, they are quite soluble in DMSO, especially the inositols. 
By using DMSO in the extraction solvent, there was no need for a two-step extraction 
by precipitating the proteins with TCA before extracting the samples into organic 
solvent. The samples need to be in an injection solvent containing high organic 














Comparison of APCI and ESI with and without formation of iodide adducts 
 
Introduction 
 Methods for the detection of polyols are compared here. The aim was to 
determine whether detecting polyols as iodide adducts provides better sensitivity than 
direct detection. Two ion sources, atmospheric pressure chemical ionization (APCI) 






Fifty microlitres of sample was added to an extraction solvent containing 75% 
acetone, 25% DMSO. The samples were vortexed for 20 seconds, then centrifuged 






Detection of polyols was compared using ESI and APCI with and without 
diiodomethane in the mobile phase. 
Inositols were separated using an Agilent 1200 Series HPLC system and 
detected using an Agilent 6120 single quadrupole mass spectrometer with either an 
electrospray ion source for detecting inositols as the iodide adducts, or an APCI 
source for direct detection. An isocratic system was used with a mobile phase 
containing 85% acetonitrile, 15% water. When measuring the iodide adducts, 10 
mmol/L of diiodomethane was added to the mobile phase. The flow rate was 0.3 
mL/min, the injection volume was 10 µL, and the oven temperature was 40ºC. The 
run time was 20 min, although the samples were diverted to waste post-column for 2 
minutes after injection. The chromatographic separation was performed on a Waters 
Acquity BEH amide 2.1 × 100 mm, 1.7 µm UPLC column (Ireland). Mass 
spectrometer parameters were optimized by flow injection analysis with no column.  
Inositols were monitored directly using selected ion monitoring (SIM) in 
negative ion mode at m/z = 179 for inositols, sorbitol was monitored at m/z =  181. 
When measuring the iodide adducts with electrospray ionization, inositols were 
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detected in negative ion mode at m/z = 307, sorbitol was monitored at m/z = 309, and 
glycerol was monitored at m/z = 219. The fragmentor was set to 50 V, the capillary 
voltage was 4000 V, the drying gas flow rate was 6 L/min, and the source gas 
temperature was 275°C. 
For direct detection with APCI, the fragmentor voltage was set to 90 V, the 
capillary voltage was set to 3000 V, the corona current was set to 6 µA, nebulizing 
pressure was 60 psi, the drying gas was 9 L/min, the drying gas temperature was 
175ºC, and the vaporizing temperature was 300ºC. 
 
Results and discussion 
The best sensitivity was observed when detecting polyols directly using APCI 
without diidomethane in the mobile phase (Table 3.3, Fig. 3.18). If no APCI source is 
available, then it is preferable to measure polyols as iodide adducts using ESI. The 
peak heights were greater using direct detection with ESI, however, the noise was also 
greater than was observed when detecting them as the iodide adducts with 
diiodomethane in the mobile phase.  
 
 
Table 3.3. Comparison of sorbitol and myo-inositol measured in negative ion mode by 
APCI and ESI with direct detection, and detection as the iodide adducts.  
 
    chiro-Inositol myo-Inositol scyllo-Inositol Sorbitol 
APCI Peak height 371 441 280 1401 
 
LOD mol/L           2.4  1.4            3.2     0.4 
  
    
APCI Peak height nd nd nd nd 
(iodide adduct) LOD mol/L     
  
    
ESI Peak height 312 320 215 1078 
 
LOD mol/L           7.8  7.5   11    1.7 
  
    
ESI  Peak height 296 199 186 486 
(iodide adduct) LOD mol/L   2.0  3.0  3.2   1.2 
 
Note: Data was collected by injecting a 100 µmol/L aqueous standard. LOD was calculated as 






Fig. 3.18.  Polyols detected directly using an APCI source (A). Polyols detected 
directly with an electrospray source (B). Polyols detected as iodide adducts with 
diiodomethane in the mobile phase using an ESI source (C). All data was collected by 




Complexes using polyols as ligands 
 




Polyol cis-diols bind to boric acid under alkaline conditions to form cyclic 
borate esters. It was expected that the predominant ion present when there is an excess 
of ethanediol and boric acid in solution will be the polyol-boric acid-ethanediol 
complex (Figs. 3.19B and 3.20B). The ethanediol complexes are formed when the 
polyols are injected into the LC-MS/MS spectrometer and interact with boric acid and 
ethanediol in the mobile phase. As ethanediol binds relatively weakly with boric acid, 
the polyol cis-diols should compete for binding with boric acid. The reason for adding 
ethanediol to the mobile phase is that the complex it forms with boric acid is volatile, 
whereas boric acid is not volatile and will deposit inside the mass spectrometer.  
Ackloo et al.
129
 showed that the predominant ion was boric acid bound to two sorbitol 
molecules in the presence of excess boric acid (Figs. 3.19C and 3.20C). Sorbitol and 
myo-inositol form complexes with boronic acids or transition metal ions which can 
potentially be used to separate the polyols from chemically similar isomers. 
 
 
Fig. 3.19.  Structures of sorbitol and complexes with boric acid and ethanediol in 
negative ion mode. A.) Sorbitol ion, B.) sorbitol-boric acid-ethanediol complex, C.) 






Fig. 3.20.  Structures of myo-inositol and complexes with boric acid and ethanediol in 
negative ion mode. A.) myo-inositol negative ion, B.) inositol-boronate-ethanediol 





Reagents and chemicals 
 Ammonium tetraborate, sorbitol and myo-inositol were obtained from Sigma (St 
Louis, MO, USA). Ethanediol was obtained from BDH (Poole, England). Ammonium 
tetraborate was found to leave a residue on drying. However, when ethanediol was 
added to the solution it was volatile and no residue was left on drying, making the 
solution suitable for mass spectrometry. 
 
Chromatography  
 To separate the polyol complexes, a reversed phase alumina column (Alusphere, 
RP Select, 150 × 4 mm, 4 µm, Merck, Germany), and a reversed phase titania 
(Sachtopore, 150 × 4 mm, 3 µm) column were investigated. A gradient system was 
used going from A to B over 8 minutes. Mobile phase A contained 10 mmol/L 
ammonium tetraborate, 100 mmol/L ethanediol, and 80% water and 20% methanol. 
Mobile phase B was 100% methanol. Standards were injected with no column 
attached and good sensitivity was observed for the inositol complex ion, but not as 





One hundred micromolar standards of myo-inositol and sorbitol were made up 
in 10 mmol/L ammonium tetraborate and 100 mmol/L ethanediol in 50% water and 
50% methanol. These solutions were infused into the mass spectrometer and a Q1 
scan was performed on the standard solutions in negative ion mode. To determine the 
fragmentation pattern, MS/MS was performed on the parent ions corresponding to the 
complex with one mole of boric acid and one mole of ethanediol. Compound 
optimizations were performed on the parent ions of each polyol, and the mass 
spectrometer MS/MS parameters are shown in Table 3.4. 
 
Table 3.4. Compound optimization. Negative ion mode. 
 
Sorbitol ion with boric acid and ethanediol mass of 251.1 
 
MS/MS DP (V) CE (V)   CXP (V) Intensity 
251.1 →   86.9 -40 -36 -13 257000 
251.1 → 162.9 -40 -22 -1 128000 
251.1 → 100.9 -40 -30 -15 119000 
251.1 → 84.92 -40 -30 -13 88000 
     
Inositol ion with boric acid and ethanediol mass of 249.1 
 
MS/MS DP (V) CE (V)     CXP (V) Intensity 
249.1 → 186.8 -75 -26 -9 103000 
249.1 →   86.9 -75 -42 -13 52000 
249.1 → 124.9 -75 -30 -9 41000 
249.1 → 160.9 -75 -26 -1 37000 
 
DP =  decoupling potential, CE = collision energy, CXP = collision cell exit potential. Data collected 
using API4000 LC-MS/MS. 
 
 
Results and discussion 
 
Chromatography 
 The boric acid complexes did not bind well to the amide column and eluted 
considerably earlier than the uncomplexed polyols. In the single quad mass 
spectrometer, the polyol-borate to polyol-borate-ethanediol complex ratio was 2:1, 
which reduces the sensitivity. The uncomplexed sorbitol ion was approximately 1% of 
the intensity of the polyol-boronate ion. The high pH of the mobile phase also restricts 
the use of silica based columns. Chromatographic columns containing particles of 
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titania, alumina, or zirconia are stable at high pH (> pH 7) and therefore potentially 
more useful for separating polyol-borate complexes. However, no peaks were 
observed when using these columns. 
 
Mass spectrometry 
 A Q1 ion scan of infused solutions showed that the expected ions were present. 
With an excess of ethanediol, the main ion formed was boric acid bound to one polyol 
molecule and one ethanediol molecule as seen in Fig. 3.19B and Fig. 3.20B. A 
complex containing boric acid bound to two molecules of sorbitol or inositol was not 
observed. There was however some of the free polyols observed in negative ion mode 
in the Q1 scan with ions at 181.2 Da for sorbitol and 179.0 for inositol which 
corresponds to the mass of these polyols minus a hydrogen ion. There was also a large 
signal at 131 Da which corresponds to boric acid bound to two molecules of 
ethanediol. 
 The MS/MS fragmentation of sorbitol and inositol formed an ion with a mass of 
87 Da (Fig. 3.21)  which was reported by Ackloo et al.
129
 This gives confidence that 
the mass spectrometer is fragmenting the correct ions for the sorbitol and inositol 
complexes. The ion fragment at 101 was observed for sorbitol but not inositol. Ackloo 
et al
129
 showed that mannitol forms a stronger complex with borate than sorbitol with 
a significant peak observed for the uncomplexed polyol 181 Da in the mass spectrum 









Complexes of polyols with boronic acids 
Boronic acids, such as methylboronic acid and phenylboronic acid, are also 
known to form complexes with cis-diols (Fig. 3.22) which may also be useful for 
measuring polyols by mass spectrometry. The reaction of boronic acids with cis-diols 
is reversible and dependent on the pH and the solvent. Boronate esters are more stable 
at higher pH (>10) where the boronate ions are present in higher concentrations.
121, 132
  
There are various ways in which boronic acids can potentially aid the 
separation and detection of polyols. For example, some boronic acids fluoresce more 
when bound to carbohydrates.
133
 The functional groups attached to boronic acids may 
also interact with stationary phases to help with separations. Some ways in which 





Fig. 3.22. Boronate complexes with sorbitol and inositol. A.) Inositol with 
methylboronic acid, B.) inositol with phenylboronic acid, C.) sorbitol with 





Polyol complexes with phenylboronic acid 
 
Introduction 
 The phenyl group on phenylboronic acid may be useful for the separation of 
polyols. The theory is that the aromatic group may bind (by π interactions) with the 
graphite particles of a column such as Hypercarb (Thermo), and therefore provide a 





A Thermo Hypercarb 100 × 3 mm, 5 µm column (Phenomenex) was used with 
5 mmol/L ammonia and 10 mmol/L phenylboronic acid in the mobile phase. Various 
gradients were tried, including: 50% H2O and 50% acetonitrile going to 10% water 
and 90% acetonitrile over 8 minutes; and 90% water and 10% acetonitrile going to 
10% water and 90% acetonitrile over 8 minutes. Other columns that were tried (that 
are stable at high pH) include a Merck 150 × 4 mm, 4 m Aluspher RP Select, and an 
Asahipak ODS 250 × 4 mm, 5m column. These columns were used with a flow 
splitter post column as the required flow rate was too great for the mass spectrometer. 
The mass transitions with the greatest intensities were used for the sorbitol and 
inositol phenylboronic acid complexes. These were 285 → 267 for sorbitol and 283 
→ 265 for inositol (Table 3.5). These mass transitions both have a mass difference of 


















Table 3.5. Compound optimization data for phenylboronic acid complexes of sorbitol 
and inositol. 
 
Sorbitol - phenylboronic acid complex, mass = 285.07 
MS/MS DP CE CXP Intensity 
285.1 → 267.1 -30 -12 -1 11753 
285.1 → 225.1 -30 -18 -13 6273 
285.1 → 121.1 -30 -28 -9 6055 
285.1 → 118.9 -30 -26 -21 1298 
285.1 → 43.0 -30 -56 -5 1727 
Inositol - phenylboronic acid complex, mass = 283.24     
MS/MS DP CE  CXP Intensity 
283.2 → 264.9 -70 -14 -7 10000 
283.2 → 42.7 -70 -82 -1 6000 
283.2 → 43.4 -70 -58 -5 6000 
283.2 → 120.7 -70 -24 -5 6000 
283.2 → 85.0 -70 -40 -3 5000 
 
DP =  decoupling potential, CE = collision energy, CXP = collision cell exit potential. 
Data collected using API4000 LC-MS/MS. 
 
 
Results and discussion 
 The peaks were not well separated on the Hypercarb column. Changing the 
gradient only made a small difference, and when higher water contents were used in 
the initial gradient step the sorbitol peak was split. The Aluspher and Asahipak 
reversed phase columns did not separate the phenylboronic acid complexes either. 
Sorbitol, mannitol, and galactitol all eluted early and were co-eluting. The baseline 
noise was high with phenylboronic acid in the mobile phase. 
 The mass transitions corresponding to the loss of a water molecule in the 
collision cell were the most abundant fragment ions, i.e. sorbitol 285 → 267 and 
inositol 283 → 265. Other mass transitions correspond to the loss of the fragment ion 
corresponding to phenylboronic acid (121 Da) for both polyol complexes. The mass 
transition of 285 → 225 corresponds to the loss of an ethanediol group from sorbitol. 
A comparison of Figs. 3.23 and 3.24 shows that the selectivity changes. 
Sorbitol elutes last when the starting conditions include a higher water content. Two 
peaks were observed for the mass transition 285 → 267 for sorbitol after increasing 
the gradient. Sorbitol can possibly form a complex with phenylboronic acid using one 
of the end chain hydroxyl groups. This alternative sorbitol complex would have the 
same mass and may produce the same fragments in the collision cell. This may 
explain the existence of two peaks in the chromatogram (Fig. 3.24). 
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 The Hypercarb column was investigated for separating polyol-phenylboronic 
acid complexes because it contains graphite particles which are stable at all pH. The 
graphite stationary phase was also expected to help the separation by way of π 
interactions with the benzene ring on the phenylboronate-polyol complex. However, 
this was not found to be the case. With the high background noise, this approach 
would be unlikely to produce the necessary sensitivity to measure polyols, even if a 




Fig. 3.23.  LC-MS/MS chromatograms showing: 1 mmol/L aqueous standards of 
sorbitol (blue) and inositol (red) complexed with phenylboronic acid. Sorbitol 
complex mass transition = 285 → 267, inositol complex mass transition = 283 → 265. 
A Hypercarb column was used, with a mobile phase gradient: starting with 50% water 
going to 10% water over 8 minutes. Detection was carried out on an Applied 
Biosystems API4000 tandem mass spectrometer. 
 
XIC of -MRM (2 pairs): 285.1/267.1 Da ID: Sorbitol from Sample 2 (1mM sorb inos2) of 3sep11pol.wiff (Turbo Spray) Max. 7.4e5 cps.

































Fig. 3.24.  LC-MS/MS chromatograms showing: 1 mmol/L aqueous standards of 
sorbitol (blue) and inositol (red) complexed with phenylboronic acid. Sorbitol 
complex mass transition = 285 → 267, inositol complex mass transition = 283 → 265. 
A Hypercarb column was used here with a gradient starting with 90% water and 
acetonitrile going to 10% water over 8 minutes. Detection was carried out on an 
Applied Biosystems API4000 tandem mass spectrometer. 
 
 
Modification of a stationary phase to enhance the separation of polyols 
 
Introduction 
As cis-diols interact with boronates, a column with a boronate coated surface 
may be useful for the separation of polyols. Boronate affinity columns which are 
useful for separating small molecules such as these polyols are not available 
commercially. The only boronate columns available commercially are designed to 
separate glycoproteins and have a high pore size and particle size. Boronate affinity 
columns can be made by derivatizing the surface of silica with boronic acid groups
134
 
which should provide a useful interaction with cis-diols on the column, therefore 
providing a mode of separation for polyols. It may be possible to modify a silica 
column with boronic acids by pumping a reaction mixture through an unmodified 
silica column to create a column with a boronate functional group attached to the 
silica particles. Boronic acids can be bound to silica using triethoxysilane.
134c
 
However, triethoxysilane is pyrophoric and could not be shipped to New Zealand 
because it is too hazardous, so an alternative synthetic route was investigated.  
XIC of -MRM (2 pairs): 285.1/267.1 Da ID: Sorbitol from Sample 9 (sorbinos1mMx) of 3sep11pol.wiff (Turbo Spray) Max. 3.4e5 cps.

































1.92 6.254.11 5.875.635.224.38 5.144.75 6.32 6.54 6.93 7.273.27
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The aim was to produce a stable HPLC column containing silica particles 
derivatized with boronates so that it can be used to separate polyol isomers such as 
sorbitol, mannitol, and galactitol. 
 
Methods 
 An HPLC column containing unmodified silica (150 × 3 mm, 3 µm, Luna, 
Phenomenex) was modified with m-aminobenzeneboronic acid using an adaptation of 
a synthesis described by Li et al.
135
 (Fig. 3.25). To activate the silica for attachment of 
the boronic acid, 15 mL of γ-chloropropyltrimethoxysilane (Sigma) was added to 150 
mL of toluene. This solution was recycled through the silica column overnight at 
room temperature at a flow rate of 0.3 mL/min. The γ-chloropropylsilane substituted 
silica column was washed with dichloromethane then methanol. A solution was made 
up containing 1 g of m-aminobenzeneboronic acid (Sigma) and 1 mL of 1 M NaOH in 
100 mL of distilled water. This solution was eluted through the column at 80ºC 





Fig. 3.25. A silica column particle derivatized with a boronic acid functional group. 
 
 
Results and discussion 
 The boronate substituted silica column was not successful at separating the 
polyol isomers. With a mobile phase containing 20% water and 80% acetonitrile, no 
peaks were observed (with LC-MS-APCI). When some ethanediol (1 mL/L) was 
added to the mobile phase, a single broad tailing peak was observed for a mixture of 
sorbitol, mannitol, and galactitol. While binding of the polyols to the boronic acid 
would most likely be increased at higher pH, the silica based column would not be 




NMR detection of polyol-methylboronic acid complexes 
 
Introduction 
 The hypothesis is that different polyols bound to methylboronic acid would lead 




 600 µL of 10 mmol/L methylboronic acid in water was added to a 1.5 mL 
microcentrifuge tube. 200 µL of a standard containing: 10 mmol/L sorbitol, mannitol, 
or galactitol, and a water blank were added. 50 µL of 1 mol/L sodium hydroxide was 
added along with 20 µL of acetonitrile and 200 µL of D2O. The mixtures were 
vortexed and transferred to 5 mm NMR tubes. Samples were measured using a Varian 
500 MHz NMR using the PRESAT water suppression technique. 8 scans were 
collected. 
 
Results and discussion 
The methylboronate ion was observed at -0.524 ppm as a singlet (using 
acetonitrile as a reference standard at 1.9 ppm). The methyl group for the polyol 
complexes of methylboronic acid were observed on the side of the methylboronate 
singlet as a major and a minor peak for each ion. The methylboronic acid methyl 
resonances were slightly different when bound to the different hexitol isomers. 
Sorbitol (-0.483 ppm), mannitol (-0.500 ppm), and galactitol (-0.495 ppm). This result 
shows that the methyl group was in a different chemical environment when 
complexed to the different polyols. This could be the basis for a novel detection 
method that can separate these polyols. However, it is unlikely to provide the 
resolution or the sensitivity required for the detection of hexitols and other polyols in 
biological samples. For future work, better resolution may be obtained by collecting 
more scans. The potential interference from other cis-diols such as glucose and the 
effect of pH should also be investigated. Further investigations involving 
methylboronic acid - polyol complexes with NMR detection were not carried out due 




Complexes of polyols with transition metals 
 
Introduction 
 Polyols can form stable complexes with metal ions in the presence of base.
136
 





 Columns that have traditionally been used to separate 
carbohydrates are likely to rely on the complexation of hydroxyl groups with metals 
such as lead or calcium to separate polyols. Those columns contain beads of ion 
exchange resin which are in the lead or calcium form. The transition metals, 
manganese and cobalt, may be useful for measuring polyols in combination with mass 
spectrometry, considering that Mn and Co both have just one abundant isotope.  
 
Methods 
 Samples were prepared by mixing 1 mL of a 10 mmol/L aqueous standard 
containing sorbitol, or galactitol, or mannitol with approximately 3 mL of a 10 
mmol/L aqueous solution of cobalt acetate and 3 mL of an aqueous solution of 20 
mmol/L lithium hydroxide in a test tube. The test tubes were vortexed and any colour 
change was noted. 
 
Results and discussion 
Sorbitol and its isomers galactitol and mannitol all formed an olive green colour 
when mixed with cobalt acetate and lithium hydroxide. However, a sample blank 
containing just water and no polyol remained a pale pink colour. The addition of 
sorbitol and other polyols forms a complex which could potentially be separated on an 
HPLC column and detected using electrochemical detection or mass spectrometry. 
Mannitol binds to cobalt (II) and cobalt (III) in a 1:1 ratio and may be present either as 
a bidentate or tridentate ligand.
136b
  
The polyol metal complexes were not stable enough to measure without having 
metal ions and base present in the mobile phase. Addition of metal ions to the mobile 
phase was problematic when using electrochemical detection. The pressure increased 
gradually in the electrochemical cells when cobalt acetate was pumped through it. 
This approach was not attempted with mass spectrometric detection due to the high 
likelihood of background interference and the risk of contaminating the mass 
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spectrometers with metal ions. Detecting the colour change in the visible spectrum 
when polyols bind to transition metals is unlikely to provide the necessary sensitivity. 
Polyols also appear to bind strongly to metal oxides. Sorbitol and inositols were 
found to bind very strongly to zirconia, titania, and alumina stationary phases with no 
peaks observed within 45 minutes. Attempts to elute the polyols off the metal oxide 
columns by increasing the water content of the mobile phase were not successful.  
 
 
Detection of polyols using derivatization 
 
Derivatization with isocyanates 
 
Introduction 
 The hydroxyl groups of carbohydrates can be derivatized with isocyanates to 
form UV absorbing or fluorescent urethane derivatives (Fig. 3.26).
139
 Since 
isocyanates are readily hydrolyzed by water, the reaction of isocyanates with alcohols 
requires anhydrous conditions.
139
 The reaction also requires the presence of base to 
catalyse the reaction. Previous isocyanate methods have shown that by adding a large 
excess of derivatizing reagent during sample preparation, and heating the samples to 
55ºC, the maximum number of hydroxyl groups are derivatized and only a single peak 
is seen in the chromatograms for each polyol.
44, 123
 Measuring polyols as their 
urethane derivatives is likely to enhance the separation by providing more structural 
differences to the molecules, allowing for better chromatography. Sorbitol and other 
polyols have been detected by UV using pre-column derivatization with 
phenylisocyanate.
44, 123
 There have been no reports of isocyanates used to measure 
polyols in blood plasma or urine. If derivatization with isocyanates is useful in these 
samples, then sensitivity could be improved by the choice of reagent. For example, 1-
naphthyl isocyanate derivatives can be expected to have a higher molar absorbtivity 






Fig. 3.26. Reaction of sorbitol with phenyl isocyanate showing derivatization of the 
maximum possible number of hydroxyl groups. 
 
Methods 
The method of Miwa et al.
44
 was adapted to investigate aqueous standards. 
Fifty µL of 2 mmol/L aqueous polyol standards were dried down under nitrogen. 70 
µL of pyridine and 20 µL of phenylisocyanate were added to the residue, and the 
mixture was reacted in sealed tubes at 55°C for 1 hour. 20 µL of methanol was then 
added to react with the excess isocyanate, and 300 µL of 50% water and 50% 
acetonitrile were added. The excess isocyanate precipitated as a white solid, which 
was centrifuged out at 13,000 × g for 5 minutes. The supernatant was transferred to 
HPLC tubes and capped.  
Attempts to add 20 µL of phenylisocyanate to the sample in pyridine, and 
remove the water (using sodium sulfate) failed to produce any derivative peaks. The 
samples had to be dried down under nitrogen and dry pyridine added for the method 
to work.  
 Fifty µL of derivatized sample was injected onto a Supelco reversed phase 
LC18 (250 × 4.6 mm, 5 µm, Sigma) column using a gradient starting with 30% 
acetonitrile and 70% water, going to 20% water, 40% acetonitrile, and 40% methanol 
over 45 minutes. Detection was carried out using a Shimadzu SPD-20A UV detector 
set to 240 nm. 
 
Results and discussion 
 The method produced polyol urethane derivatives with a high concentration of 
isocyanate present (2:7 isocyanate to pyridine ratio) added to a sample after drying 
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down under nitrogen. Fig. 3.27 shows the separation of phenylisocyanate polyol 
derivatives on the LC18 column. To make the reaction of polyols and isocyanates 
more specific, the cis-diols can be protected using boric acid. Only the hydroxyl 
groups not bound to the boric acid could then react with the isocyanates. This could 
potentially lead to less derivatives being formed for each individual polyol, therefore 
reducing the number of peaks in the chromatogram from each polyol. 








































































Fig. 3.27. Derivatization of polyols with phenylisocyanate showing a mixed standard 
containing 2 mmol/L sorbitol, mannitol, galactitol, myo-inositol, and glucose (red), 
and a blank containing no polyols (blue). 
 
 
 Derivatization with isocyanates generally produces too many poorly resolved 
peaks, often with multiple peaks for one polyol analyte. This approach was therefore 
considered unlikely to be suitable for measuring sorbitol and inositols in biological 





Reaction of polyols with methylisatoic anhydride 
 
Introduction 
 Hydroxyls can react with methylisatoic anhydride (MIA) to form fluorescent 
esters and release carbon dioxide (Fig. 3.28).
141
 When the reaction takes place in the 
presence of boric acid, the cis-diols may be protected, and the number of reactive sites 
that the polyols can be derivatized by MIA may be reduced. By removing the cis-diols 
from derivatization by MIA, the structural differences between the polyols and their 
isomers may be exaggerated, making chromatographic separation more achievable. 
Using methylisatoic anhydride as the derivatizing reagent has advantages over 
isocyanates in that the reaction takes place under mild conditions at room temperature, 
and tolerates the presence of water. Methylisatoic anhydride has been used to measure 
inositol by capillary electrophoresis.
142
 However, there are no reports of its use to 
measure polyols by HPLC. MIA derivatives are reported to fluoresce at excitation 











Fifty microlitres of 10 mmol/L aqueous polyol standard was added to a 1.5 mL 
microcentrifuge tube. To this was added 50 µL of 50 mmol/L triethylamine borate in 
dimethylsulfoxide (DMSO) and the mixture was vortexed briefly. One hundred µL of 
30 mg/mL MIA in acetonitrile was added and the samples were vortexed at room 
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temperature for 10 minutes. 200 µL of distilled water was added to the samples, and 
they were vortex mixed, then centrifuged and transferred to HPLC vials.    
 
HPLC 
 Attempts were made to separate the MIA derivatives using a reversed phase 
column, and on a strong cation exchange SCX column. The SCX column was a 
Phenosphere SCX (Phenomenex, 250 × 4.6 mm, 5 µm). The mobile phase contained 5 
mmol/L triethylamine, 10 mmol/L succinic acid, 5% water and 95% acetonitrile. The 
flow rate was 1 mL/min and the oven temperature was set to 40ºC.  
A reversed phase C30 Develosil (Phenomenex, 250 × 4.6 mm, 5 µm) column 
was used with a gradient going from 20% acetonitrile and 80% water to 30% 
acetonitrile and 70% water over 20 minutes, then to 100% acetonitrile at 35 minutes, 
and back to starting conditions at 40 minutes. The run time was 45 minutes, the flow 
rate was 1 mL/min, and the oven temperature was 40 ºC. The Shimadzu (RF-10AXL) 
fluorescence detector was set to 355 nm for excitation and 440 nm for emission. 
 
Results and discussion 
 The polyol MIA derivatives did not separate well on a strong cation exchange 
(SCX) column (Fig. 3.29). A broad peak was observed for sorbitol when using the 
SCX column which eluted at around 7 minutes. Mannitol and galactitol had slightly 
different retention times but were not well separated. A broad peak corresponding to 
myo-inositol was observed at 10 minutes. Diluting the buffer in the mobile phase did 
not change the retention time of the derivatives, suggesting that cation exchange is not 
the primary mode of separation. The nitrogen bound to the benzene ring on the 
derivative is likely to be only weakly cationic at low pH, therefore resulting in low 











Fig. 3.30. Separation of polyol MIA derivatives on a C30 reversed phase column. 
Chromatograms shown are: a water blank (black); a 10 mM myo-inositol standard 







Fig. 3.31. Separation of polyol MIA derivatives on a C30 reversed phase column. 
Black = blank, dark blue = 10 mM sorbitol, pink = 10 mM mannitol, and light blue = 
galactitol. 
 
 Multiple MIA derivatives were observed on the C30 reversed phase column for 
each polyol: sorbitol, mannitol, galactitol, myo-inositol, and glucose (Figs. 3.30 and 
3.31). Most of the sorbitol peaks were overlapping with mannitol and galactitol or 
only separating slightly. The myo-inositol peaks were better separated from the 
glucose, sorbitol, mannitol, and galactitol peaks. The multiple peaks observed for each 
polyol make separation and quantification difficult, especially when considering the 
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large number of hydroxylated compounds present in biological samples. These 
multiple peaks are likely to be due to a mixture of compounds formed when MIA 
reacts with different hydroxyl groups on the polyols. It was hypothesized that the 
borate added to the sample would complex with the cis-diols before derivatization, 
and therefore reduce the number of hydroxyl sites where derivatization can occur on 
the polyols.  
  Heating the samples during the reaction with MIA to 60ºC did not reduce the 
number of peaks present for each polyol. However, heating the samples did increase 
the size of the peaks in the 27 – 37 minute region corresponding to an increase in the 
formation of the more non-polar derivatives, i.e. products with a higher number of 
hydroxyls on the polyols derivatized by MIA. When no triethylamine borate was 







3.5.  Validation of assays for the measurement of inositols 
 
Validation of a method for the measurement of myo-inositol in urine by LC-MS/MS 




It has been shown that a mass spectrometry compatible amide column 
provides sufficient separation of the three common inositol isomers, myo-inositol, 
scyllo-inositol, and chiro-inositol. All three isomers are found in human urine 
samples. On an amide column, the inositol peaks also separate well from sugars such 
as glucose which have an identical mass. Using an amide column, a useful 
chromatographic separation can be achieved, with myo-inositol sufficiently separated 
from chiro-inositol and scyllo-inositol, as well as from sugars with the same mass 
such as glucose. All three isomers are found in human urine samples. The use of 
diiodomethane in the mobile phase allows for the detection of iodide adducts of the 
inositols with good sensitivity. A method is developed and validated here to measure 
myo-inositol by LC-MS/MS as the iodide adduct following separation on an amide 
column. This approach is a good option for measuring inositols because of the good 
separation of inositol isomers and the low baseline noise. Halide adducts have been 
described for the measurement of polyols by mass spectrometry.
44, 118b, 131
 Iodide 
adducts are preferable to other halides because iodine has only one abundant stable 
isotope and readily forms adducts with polyols. Chloride and bromide adducts are 
problematic because natural chlorine and bromine consist of two abundant isotopes, 
which split the mass signal and reduce sensitivity.  
 
 
Materials and methods 
 
 
Reagents and chemicals 
myo-Inositol, diiodomethane, and Dowex 50 WX8-200 resin were obtained 
from Sigma, chiro-inositol was obtained from Acros Organics (NJ, USA), and scyllo-
inositol was obtained from TCI (Tokyo, Japan). D6-myo-inositol was purchased from 
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CDN Isotopes. Dowex 50 was obtained from Sigma. Acetonitrile (LiChroSolv) was 
obtained from Merck. 
 
Sample preparation 
 An extraction solvent was made up containing 25% dimethylsulfoxide (DMSO) 
and 75% acetone, and 10 µmol/L of both D6-myo-inositol. Fifty microlitres of sample 
or standard was pipetted into 1000 µL of extraction solvent, and vortexed. The 
samples were centrifuged at 13,000 × g  for 5 minutes and transferred to 96 well 
microtitre plates and sealed with aluminium foil. 
 
LC-MS/MS 
The mobile phase contained 85% acetonitrile, 15% distilled water, and 10.0 
mmol/L of diiodomethane. A Waters XBridge (Ireland) amide 100 × 2.1 mm, 3.5 µm 
column was used for the chromatographic separation. The flow rate was 0.3 mL/min, 
the injection volume was 10 µL, and the oven temperature was 50ºC. Samples were 
analyzed using a Shimadzu Prominence HPLC system connected to an API4000 
(ABSciex) triple quad mass spectrometer with an electrospray ionization source. The 
polyols were monitored as the iodide adducts. The mass transition used to monitor 
myo-inositol was 307 → 127 (D6-myo-inositol 313 → 127). The decoupling potential 
was -30 V, the collision energy was -14 V, and the collision cell exit potential was -7 
V. The ion source temperature was 350ºC, the ion spray voltage was 5500 V, the 
source gas 1 was set to 10, source gas 2 was set to 15, the collision gas (nitrogen) was 
delivered at 6 L/min, and the curtain gas was 17 L/min. Polyols were quantified using 
the ratio of peak area to the corresponding internal standard. The data was calibrated 
using aqueous standards of known concentration. 
 
Method validation  
 
Linearity 
 The linear range of the assay was investigated by adding different 






Precision and accuracy 
 Six batches of four urine samples with a low concentration of myo-inositol and a 
high myo-inositol concentration level (urine with 500 µmol/L myo-inositol added) 
samples were analyzed for myo-inositol. Accuracy was evaluated as the concentration 




The maximum peak area for myo-inositol was observed when 10 mmol/L of 




 The method was linear for myo-inositol up to 1000 µmol/L, as shown in Fig. 
3.32, with an r
2









Precision and accuracy 
 Within batch and between batch CVs were below 5.1%. The recovery of myo-
inositol added to urine was 95% (Table 3.6). The limit of detection (S/N = 3) for myo-
inositol was 2.6 µmol/L. 
 
Table 3.6. Precision and accuracy of myo-inositol added to urine 
myo-Inositol Mean Within batch CV% Between batch CV% Recovery 
     
  
Low urine 92.4 5.03 3.18 
 





 Diiodomethane was the preferred reagent for forming iodide adducts in the mass 
spectrometer. Diiodomethane produced low background noise in the mass 
spectrometer, and had minimal effects on the chromatography at a concentration of 10 
mmol/L in the mobile phase. Iodine could be added to the mobile phase as it also had 
no noticeable effects on the chromatography and formed iodide adducts with the 
polyols. However iodine in the mobile phase appeared to build up in the mass 
spectrometer, lowering the sensitivity after a while. The use of an amide column 
provided a useful separation of inositol isomers without the need to use traditional 
sugar columns which are less compatible with mass spectrometry. Amide columns are 
reported by the manufacturers to be more stable than amino columns, which can form 
Schiff bases with sugars. There have been no previous reports of amide stationary 
phases being used to separate inositol isomers. Amide columns are often avoided for 
the separation of sugars because they are known to separate anomers at lower 
temperatures, e.g. two peaks have been observed for glucose. However, polyols such 
as sorbitol and inositol do not form anomers as they are fixed as either open chain 
(sorbitol) or cyclic (inositol) hexitols. The XBridge amide column used here provided 
a separation of myo-inositol from its isomers, chiro-inositol and scyllo-inositol. 
Adding the diiodomethane to the mobile phase means that no post-column mixing is 




 Inositols were found to be more soluble in DMSO than methanol. Therefore, an 
extraction solvent made up of 25% DMSO and 75% acetone proved to be more 
efficient at extracting inositols from plasma. This procedure gives a one-step sample 
preparation which is compatible with either APCI detection or detection of inositols 
as the iodide adducts with electrospray ionization. By having an extraction solvent 
which the inositol analytes are more soluble in gives a better recovery by reducing the 
partition of the analytes into the aqueous layer associated with the protein precipitate. 
Another intermittent problem causing decreased sensitivity was high 
background noise. This appeared to be present in the mobile phase and was 
particularly bad when using water from the distilled water from the Canterbury Health 
Laboratories reversed osmosis system. Using higher quality purified water (from a 
Barnstead, Easypure II ultra-pure water system) in the mobile phase improved the 
sensitivity. However, the mobile phase needed to be prepared fresh for each sample 
run.  
Unfortunately, sorbitol does not easily separate from mannitol and galactitol 
on an amide column. Furthermore, sorbitol could not be quantified as a total hexitol 
(sorbitol + mannitol + galactitol) concentration because of interference from glucose 















Validation of a method for the measurement of inositols in urine and plasma by 





Atmospheric pressure chemical ionization (APCI) is useful for ionizing neutral 
compounds such as inositols.
47
 It is shown here that APCI mass spectrometry gives 
enough sensitivity to measure inositols in human plasma and urine samples without 
the need to form halide adducts. A method is developed and validated using a single 
quadrupole mass spectrometer with APCI detection for the measurement of myo-
inositol in plasma, and myo-inositol, chiro-inositol, and scyllo-inositol in urine. 
 
Materials and methods 
 
 
Reagents and chemicals 
 
myo-Inositol, was obtained from Sigma, chiro-inositol was obtained from 
Acros Organics, and scyllo-inositol was obtained from TCI Chemicals. D6-myo-




One hundred microlitres of sample (or standard) and 25 µL of internal 
standard (500 µmol/L D6-myo-inositol) were added to a 1.5 mL microcentrifuge tube. 
Twenty five µL of 50% (w/v in water) trichloroacetic acid (TCA) was then added and 
the mixture was vortexed for 20 seconds. One hundred microlitres of dichloromethane 
was then added and the mixture vortexed for a further 20 seconds. The samples were 
then centrifuged (13,000 × g, 3 min) and 50 µL of the top layer was transferred to a 
separate tube containing 500 µL of 10% methanol, 90% acetonitrile. The samples 






A Waters Acquity BEH amide 2.1 × 100 mm, 1.7 µm ultra-performance liquid 
chromatography (UPLC) column (Ireland) was used for the chromatographic 
separation. An isocratic system was used because a gradient system did not improve 
the separation of the inositols. The mobile phase contained 85% acetonitrile, 15% 
water. The flow rate was 0.3 mL/min, the injection volume was 10 µL, and the oven 
temperature was 50ºC. The run time was 15 min, although the samples were diverted 
to waste post-column for 2 minutes after injection. Samples were analyzed using an 
Agilent 1200 series HPLC system connected to a 6120 mass spectrometer with an 
APCI ion source. The inositols were monitored using selected ion monitoring (SIM) 
in negative ion mode at m/z 179.2 for inositols, and 185.2 for D6-myo-inositol. The 
capillary voltage was set to 2500 V, the corona current was set to 6 µA, the drying gas 
was 12 L/min, the drying gas temperature was 250ºC, the vaporizing temperature was 
400ºC, and the fragmentor was set to 115 V. Inositols were quantified using the ratio 
of peak area to the peak area of the internal standard (D6-myo-inositol). The data was 




Precision and accuracy 
 To determine the within batch and between batch variation, four batches of six 
replicates of a urine sample with a low concentration, a urine sample with a medium 
level (urine with 100 µmol/L myo-inositol, chiro-inositol, and scyllo-inositol added), 
and urine with a high inositol level (urine with 500 µmol/L myo-inositol, chiro-
inositol, and scyllo-inositol added) were analyzed for myo-inositol, chiro-inositol, and 
scyllo-inositol. Four batches of six replicates of plasma with a low and a high level 
(100 µmol/L added) of myo-inositol were measured to determine the precision and 
accuracy in plasma.  
 
Linearity 
 The linear range of plasma was investigated by adding 25 µmol/L to 125 
µmol/L of myo-inositol to normal pooled plasma. The linear range of the urine assay 
was investigated by adding concentrations (ranging from 10 µmol/L to 1000 µmol/L) 






 myo-Inositol was the only inositol detected in the plasma samples (Fig. 3.33). 
The inositols separated on the amide column. Inositols eluted in the order: myo-
Inositol, scyllo-inositol, chiro-inositol with baseline separation (Fig. 3.34). A gradient 
system did not improve the separation of the inositols. The inositols were retained on 
the column longer than the sugars: glucose, mannose, and fructose, which all eluted 
before 6 minutes. The sugars gave a much lower signal than the inositols, with 
millimolar concentrations of glucose in the plasma giving a relatively small peak. 
There was a small interfering peak co-eluting with chiro-inositol in the urine sample. 
chiro-Inositol and scyllo-inositol were not detected in the plasma where they are 






Fig. 3.33. Extracted ion chromatograms (EIC) at 179 Da, showing: A, a plasma 





Fig. 3.34. EIC chromatograms at 179 Da, showing: A, a urine sample, and B, urine 
with 100 µmol/L chiro-inositol, myo-inositol, and scyllo-inositol added. 
 
 
Precision and accuracy 
 Within batch and between batch CVs were below 8.3% for the measurement of 
myo-inositol in plasma. The recovery of myo-inositol added to plasma was 106% 
(Table 3.7). The imprecision for the inositols was higher at the lower levels where the 
concentrations were closer to the detection limits. The limit of detection (S/N = 3) for 











Table 3.7. Precision and accuracy of inositols in plasma and urine using LCMS with 
APCI detection 
 
  Mean Within batch CV% Between batch CV% Recovery 
Plasma myo-inositol 
    Plasma 28.0 7.4 8.2 
 Plasma + 100 µmol/L added 134 4.7 6.7 106% 
Urine myo-inositol 
    Urine 35.5 12.6 21.5 
 Urine + 100 µmol/L added 124.1 8.5 4.9 89% 
Urine + 500 µmol/L added 511.3 6.1 3.6 95% 
Urine chiro-inositol 
    Urine 9.6 9.3 49.6 
 Urine + 100 µmol/L added 101 7.3 3.7 91% 
Urine + 500 µmol/L added 489 6.0 6.1 96% 
Urine scyllo-inositol 
    Urine 20.9 14.0 37.8 
 Urine + 100 µmol/L added 123 6.9 3.6 102% 




 The regression equation for myo-inositol concentrations added to plasma was     
y = 1.018x + 24.5. Added concentrations of myo-Inositol were linear in plasma with 
an r
2
 of 0.994 (Fig. 3.35). The method was linear in urine up to 1000 µmol/L (as 
shown in Fig. 3.36) with an r
2
 of 0.988 for chiro-inositol, an r
2 
0.992 for myo-inositol, 
and an r
2
 of 0.994 for scyllo-inositol added to urine. The linear regression equation for 
myo-inositol added to urine was y = 0.929x + 36.5, the regression equation for scyllo-
inositol added to urine was y = 0.952x + 37.0, and the regression equation for chiro-
inositol added to urine was y = 0.852x + 28.3. The slopes of the regression equations 
suggested that the recoveries were greater than 90% for myo-inositol and scyllo-
inositol, and the slope suggested the recoveries were around 85% for added 
concentrations of chiro-inositol in urine. The regression lines intercept the y axis at 






Fig. 3.35. myo-Inositol added to plasma, error bars represent standard errors. 
 
                  
 
Fig. 3.36. chiro-Inositol, myo-inositol, and scyllo-inositol added to urine. Error bars 






 Inositols have successfully been measured in plasma and urine samples using 
single quadrupole mass spectrometry with an APCI source with high accuracy and 
precision. The problem caused by the low solubility of inositols in organic solvents 
was successfully avoided by precipitating the proteins before extraction, which 
produced similar peak areas for the samples compared to the aqueous standards. 
However, extraction of the samples into a solution of DMSO and methanol has also 
shown to be effective, and this has the benefit of reducing the number of steps 
involved in the sample preparation. The method was linear (r
2
 = 0.994) for myo-
inositol concentrations added to plasma, and r
2
 = 0.992 for myo-inositol 
concentrations added to urine. However, the between batch imprecision for inositols 
was high for the low urine concentration (CVs > 20%), which is likely to be a 
consequence of the relatively high limits of detection. 
An efficient separation of myo-inositol, scyllo-inositol, and chiro-inositol was 
achieved on a mass spectrometry-compatible amide column. Using a UPLC amide 
column with 1.7 µm particle size improves the resolution so that myo-inositol and 
scyllo-inositol are completely separated. The inositols were also well separated from 
the sugar isomers such as glucose, mannose, and fructose. The sugars appeared to 
ionize less efficiently using APCI compared to the inositols, as the sugar peaks were 
smaller than expected in the samples (see Fig. 3.18). 
Most published methods describing the measurement of polyols and sugars by 
LC-MS use the formation of halide adducts to enhance the sensitivity.
44, 143
 However, 
direct detection of inositols using atmospheric pressure chemical ionization (APCI) 
ionization with selected ion monitoring (SIM) using a single quadrupole mass 
spectrometer was found to give similar detection limits, and similar recoveries for 
myo-inositol and scyllo-inositol. 
 There are few published methods for the measurement of inositols that provide 
information about the performance of the assays. However, it is shown here that myo-
inositol can be reliably measured in human plasma and urine with sufficient precision 
and accuracy to investigate them in conditions such as diabetes. The analysis of chiro-





3.6. Chapter Summary 
 The separation of polyols using traditional sugar columns, such as those 
containing sulfonated resin in the lead form, is not ideal for mass spectrometry. 
However, a mass spectrometry-compatible amide column proved to be effective at 
separating inositol isomers, but did not separate sorbitol from its isomers, mannitol 
and galactitol. The use of iodide adducts to monitor the polyols provides better 
sensitivity than what is observed when directly monitoring the polyols when using 
electrospray ionization. The combination of an amide column and diiodomethane in 
the mobile phase is a useful approach for measuring inositols in biological samples by 
LC-MS. Alternatively, APCI can be used to detect the inositols directly without the 
need to add diiodomethane as a source of halide ions. 
 It was difficult to find appropriate conditions for the use of boronic acids to 
separate and detect polyols using LC-MS/MS. The boronate esters are only stable at 
high pH or in non-aqueous conditions. A suitable chromatography system was not 
found to separate and detect the derivatives. Some boronic acids, such as 8-
quinolineboronic acid, fluoresce only when bound to hydroxyl groups, or fluoresce at 
different wavelengths when bound to hydroxyl groups. However, adding boronic 
acids to the mobile phase creates a high background noise signal in the mass 
spectrometer and was found to be unsuitable for the detection of polyols in biological 
samples. 
 Derivatization of polyols with isocyanates is a possible option, but the sample 
preparation is labour intensive and not suitable for analyzing large numbers of 
samples. Isocyanates only derivatize polyols in the complete absence of water, i.e. the 
samples require drying down under nitrogen before they are derivatized. Attempts to 
dry the extraction solvent with sodium sulfate were not effective, and no polyol peaks 
were observed. The reaction would only work with pyridine as the reaction solvent 
which acts as a weak base and nucleophilic catalyst. Isocyanates also generated 
multiple peaks for some polyols, and the many peaks were not well 
chromatographically separated on a reversed phase column. Methylisatoic anhydride 
has the advantage that it reacts with polyols with a high water content (50%) present 
in the reaction mixture, so drying down the samples is not necessary. However, there 
were many derivatives formed for each polyol and they were difficult to separate by 
HPLC, especially sorbitol and its isomers mannitol and galactitol. These hexitol 
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derivatives also chromatograph in the same region as the glucose derivatives. This 
method is therefore unlikely to be useful for the measurement of sorbitol, especially in 
diabetes samples where high blood glucose is often present. 
 Attempts to use electrochemical detection to measure polyols were 
unsuccessful. Adding electrochemically active reagents such as transition metals or 
ferroceneboronic acid to the mobile phase clogged up the electrochemical cells, 
causing a constant increase in the pressure of the HPLC system. 
The problems with measuring polyols include the low solubility in organic 
solvents, the lack of easily ionizable functional groups and the presence of isomers in 
biological samples which only differ by the orientation of the hydroxyl groups. The 
solubility problem can be overcome by extracting samples into a mixture of DMSO 
and acetone, which gave a greater extraction efficiency than a mixture of methanol 
and acetonitrile. Another option is to precipitate the proteins with TCA prior to 
solvent extraction. 
All attempts to derivatize or form complexes with boronic acids or transition 
metals to aid resolution and enhance detection were unsuccessful due to the formation 
of too many derivatives, poor chromatography, or ion interference. Mass 
spectrometric methods with or without iodide adduct formation were the most useful 
for measuring polyols. Adding diiodomethane to the mobile phase had no significant 
effect on the chromatography. While sorbitol and glucose have a mass difference of 
two, there were still significant interfering glucose peaks co-eluting with the sorbitol 
peak. This may be from the low mass resolution of the spectrometer, and may also be 







considering glucose is present in much higher concentrations in plasma than sorbitol. 
Direct detection of inositols with an APCI source produced similar sensitivity to 
electrospray ionization when detecting inositols as iodide adducts. If APCI is not 
available, then electrospray ionization with diiodomethane in the mobile phase and 












4. Chapter Four - Betaine, Other Osmolytes, and Other 

















4.1.  Introduction 
The work described in previous chapters has shown that liquid 
chromatography – mass spectrometry techniques have improved the analysis of a 
wide range of osmolytes and related metabolites, some of which were particularly 
difficult to measure by older HPLC-UV methods. Osmolyte concentrations can be 
expected to differ in disease due to changes in dietary intake, changes in metabolic 
processes, and changes in urinary excretion. Assays that have been developed for the 
measurement of betaine, other osmolytes, and other one-carbon metabolites were used 
here to analyze clinical study samples in order to improve knowledge about their 
metabolism, and to help show the potential value of these analytes as risk markers in 
disease. How these metabolites correlate with each other, as well as with markers of 
glycemic control and renal function, helps to show what information can be obtained 
by measuring them. The biological variation of osmolytes (and related metabolites) 
was also investigated in order to help evaluate the usefulness of single measurements 
as markers of disease. Other factors that were investigated include the effect of 
different diet treatment, and medications on the concentrations of betaine, other 
osmolytes, and other one-carbon metabolites. While people with type 2 diabetes have 
been shown to have high urinary betaine excretion,
14
 the lipid lowering drug 
bezafibrate has also been associated with increased urinary betaine excretion.
15
 The 
effect of bezafibrate on urine betaine concentrations in people with diabetes was 
investigated to test if these factors are cumulative for elevated urinary betaine 
excretion. A different fibrate drug, fenofibrate, was investigated in healthy subjects 
before and after treatment to determine if it increases urine betaine excretion. This is 
the first study to test whether there may be a causal relationship between fibrates and 













Diabetes is the most common cause of chronic kidney disease and renal 
failure.
144
 Many people with diabetes also go on to develop eye damage, and problems 
with the cardiovascular system.
145
 This is often attributed to the glycation of proteins, 
which is the result of elevated glucose concentrations in the body. A less understood 
pathological process in diabetes is the disruption of osmolytes in the body. The loss of 
osmolytes from the body makes it more difficult to maintain cell volume. This may 
lead to tissue and organ damage, particularly in the kidneys where there is a high 
osmotic gradient. The urinary excretion of the osmolytes, betaine and sorbitol, is 
higher and more variable in people with diabetes.
91
 However, the biological variation 
of these osmolytes in people with diabetes has not previously been reported. It is 
possible that the concentrations of osmolytes in people with type 2 diabetes may be 
useful as risk markers and predictors of secondary complications such as 
cardiovascular disease and renal disease. 
The major osmolytes: betaine, GPC, taurine, and myo-inositol were 
investigated in overweight people with type 2 diabetes. These osmolytes were chosen 
because they have been shown to be the major osmolytes present in tissues such as the 
kidneys and liver
32
 and their concentrations are known to be affected by type 2 
diabetes.
91
 The one-carbon metabolites, choline and DMG, as well as TMAO, 
carnitine, and acetylcarnitine were also measured in the DEWL samples. Sorbitol and 
sarcosine were not measured in these samples because of analytical problems that 







The DEWL study 
 The samples that were analyzed in this study were collected as part of the 
Diabetes and Excess Weight Loss (DEWL) study, which was conducted as a 
collaboration between the University of Otago, and the University of Auckland.
146
 
The DEWL study recruited 419 people with type 2 diabetes who were overweight 
(BMI > 27 Kg/m
2
). They were aged between aged from 30 to 76 years, and were 
recruited from Christchurch, Wellington, and Auckland. Of 419 subjects who were 
recruited, only 294 completed the study which was conducted over a two year period. 
Four samples from each of these 294 patients were collected (after fasting) over the 2 
year period at: baseline (time 0); 6 months; 12 months; and 24 months. This study was 
initially carried out to compare the effects of different dietary advice (high protein or 
high carbohydrate diet) on weight loss as described in Krebs et al.
146
 In the DEWL 
study, no significant differences in outcomes, such as: body fat, blood pressure, lipids, 
renal function, or HbA1c, were observed between the treatments.
146
 There were no 
significant differences in health outcomes for the DEWL study subjects by giving 
dietary advice for a low fat diet containing either a high carbohydrate or a high protein 
intake. However, both treatments showed a small overall weight loss. Fasting glucose, 
HbA1c, renal function parameters (plasma creatinine and estimated glomerular 
filtration rate (eGFR)), body mass index (BMI), cholesterol, triacylglycerides, and 
saturated fatty acids were measured during the DEWL study at each time point. These 
measurements were made by the Department of Nutrition, University of Otago.
146
 A 
spread-sheet recording what diet the DEWL study subjects were on, what medications 
they were taking, age, gender, and biochemistry data was provided by the DEWL 
study researchers. Some health characteristics of the DEWL subjects are shown in 
Table 4.1. The average age in the DEWL study was 59. Many of the participants in 
the DEWL study had poor glycemic control throughout the study with plasma glucose 
levels over 7 mmol/L, and haemoglobin A1C (HbA1c) values over 7% of total 
haemoglobin. While most of the study participants had normal renal function, there 
were some that showed impaired renal function indicated by plasma creatinine levels 
over the normal range (>120 mol/L), and a low estimated glomerular filtration rate 
(eGFR < 80 mL/min for males and < 62 mL/min for females). Renal disease was an 






Table 4.1. Some characteristics of the study population 
       Interquartile range 
  Median 25% 75% 
Plasma Glucose (mmol/L) 7.84 6.54 9.70 
HbA1c (%) 7.73 7.04 8.80 
BMI (kg/m
2
) 34.6 31.3 39.4 
Plasma Creatinine (mol/L) 74.2 64.3 88.2 
eGFR (mL/min/1.73 m
2
) 82.2 69.8 95.8 
Age (years) 59.8 53.2 66.9 
 




The present study on the DEWL samples 
 After the DEWL study was complete, the samples were sent to Canterbury 
Health Laboratories for the purpose of investigating betaine and other osmolyte 
metabolism. Ethical approval was applied for and granted to Dr Krebs (Department of 
Medicine, University of Otago, Wellington) by the Multi-region Ethics Committee to 
investigate betaine metabolism in the DEWL study samples (MEC/06/08/081) without 
the need to obtain further informed consent from the patients. Patient names were not 
known in the present study. Individual subjects were only identified using numerical 
codes which were assigned during the DEWL study. Not all urine samples from the 
DEWL study were available for the analysis of osmolytes as some had been 
previously used up for other measurements. Plasma and urine samples from the 
DEWL study were analyzed using the methods developed in this project for the 
osmolytes: betaine, GPC, taurine and myo-inositol. The methylamines, DMG, choline, 
TMAO, carnitine, and acetylcarnitine were also measured in the samples. 
Concentrations of osmolytes and related methylamines in 64 baseline DEWL 
subjects were compared with subjects from the betaine and body composition (BBC) 
study (n = 62) who had features of metabolic syndrome (they were overweight, had 
high blood lipids, high blood pressure, and no history of diabetes). 
Correlations between osmolytes and related metabolites in the baseline DEWL 
study samples (n = 385 for plasma, and n = 312 for urine) were investigated using the 
Spearman’s rank order test along with other results, including: HbA1c; fasting glucose; 
plasma creatinine; eGFR; and body mass index (BMI) that were collected during the 
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original DEWL study sample analyses.
146
 The changes in osmolyte levels were 
investigated over time, and related to markers of glycemic control and renal function.  
The DEWL study participants were on a range of prescribed medications 
which may affect the concentrations of osmolytes and related metabolites in the body. 
Drugs which the subjects were taking include: diabetic control drugs such as 
metformin and insulin, fibrates, statins, antidepressants, proton pump inhibitors, as 
well as multivitamins. For example, it has been shown that betaine excretion is often 
higher in people who are taking fibrates to lower triglycerides.
15
  Because plasma 
homocysteine was not measured in the original DEWL study, plasma (n = 32) from 
the subjects taking fibrates were analyzed for homocysteine. Plasma from 64 control 
subjects who were not on fibrates, were matched for age ± 3 years and sex, and also 
analyzed for homocysteine. Samples with plasma creatinine > 120 µmol/L were not 
used for controls to exclude renal failure, which is also known to affect betaine 
metabolism.
91
 The concentrations of betaine and other analytes in the fibrate subjects 
were compared with the control subjects using Mann-Whitney rank sum tests carried 
out in SigmPlot (v13, Systat Software Inc, San Jose, CA). 
 Osmolyte and other metabolite concentrations measured in the present study 
could not be related to patient outcomes, such as cardiovascular events or mortality, 
due to ethical restrictions. 
 
Sample analysis 
 Samples were stored at -80ºC prior to analysis. Fifty microlitres of the samples 
were extracted into 800 µL of extraction solvent containing 10% methanol, 90% 
acetonitrile and 10 µmol/L of each of the deuterated internal standards: D9-betaine, 
D3-dimethylglycine, D9-choline, D3-carnitine, D4-taurine, and D9-trimethylamine-N-
oxide. The samples were vortexed, centrifuged (13,000 × g, 3 minutes) and 200 µL 
was transferred into two separate 96 well microtitre plates and sealed with aluminium 
foil. One plate had external standards (50, 100, 250 µmol/L) and controls containing: 
betaine, DMG, TMAO, choline, carnitine, and acetylcarnitine, and the other plate had 
internal standards containing taurine added for sample calibration. A separate method 
was required to measure taurine in the samples because it was measured in negative 
ion mode. All of the methylamines could be measured on the same injection. For the 
plasma runs, pooled plasma was spiked with 50 µmol/L of each of the analytes, and 
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for the urine sample runs, urine was spiked with 100 µmol/L of each of the analytes. 
These samples with and without added concentrations of analytes were used as 
controls and were analyzed in duplicate in every sample run. 
Samples were analyzed by LC-MS/MS using an Applied Biosystems API4000 
tandem mass spectrometer. For separation of the methylamines, a Cogent diamond 
hydride (100 × 2.1 mm, 4. µm) column was used with a gradient going from 40% 
water in acetonitrile to 90% water and 10 mmol/L ammonium formate buffer over 8 
minutes. For the taurine separation, a Waters X-Bridge Amide (100 × 2.1 mm, 3.5 
µm) column was used with an isocratic mobile phase containing 20% distilled water 
and 80% acetonitrile. For both methods the flow rate was 0.3 mL/min, the sample 
injection volume was 10 µL, and the oven temperature was set to 40ºC. The 
methylamines were measured in positive ion mode using multiple reaction monitoring 
(MRM). The MRM mass transitions and mass spectrometer parameters used for these 
methods are given in Section 2.2. Urine samples in which values were over the linear 
range of the assay (250 µmol/L) were diluted ten-fold and re-analyzed. Inositols were 
measured as the iodide adducts using LC-MS/MS as described in Section 3.5. Due to 
time restrictions related to ethics approval, inositols were only measured in a subset of 
the DEWL study samples consisting of 32 subjects who were taking bezafibrate, and 
64 age and gender matched controls. 
 
Method performance 
 To monitor the performance of the method during the sample runs, urine was 
spiked with 100 µmol/L of each analyte, and plasma was spiked with 50 µmol/L of 
each analyte. The high and low controls were prepared with each batch and injected 
throughout each run. Table 4.2 shows the data for the controls that were run in each 
batch of samples. The recoveries in urine ranged from 65-117%. The recoveries in 
plasma ranged from 75-101%. The precision was lowest (with CVs at around 20%) 
for GPC compared to the other analytes because no isotopic standard was available 
for this compound, so D9-betaine was used as the internal standard. The recoveries for 
GPC were also more variable, with 117% recovered in plasma and 75% recovered in 
urine. The precision for GPC was poorer for GPC in this study compared to the 
method validation in Section 2.2, where the data was collected over a shorter time. 
The lower precision and accuracy for GPC observed in the controls during the 
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measurement of the diabetic samples is likely to be a result of instrument drift, and 
changes to the chromatographic column over time leading to a decrease in the 
effectiveness of D9-betaine as the internal standard. The CVs for the urine controls 
were generally higher than expected when compared the method validation data. This 
is likely to be due to instrument drift over the duration of measuring the study 
samples. There were on-going problems with the API4000 mass spectrometer system 
(which were, in part, due to damage from the Christchurch earthquakes). The limit of 
detection was also variable for the analytes in this project due to these instrument 
problems, and the multi-user environment leading to regular contamination of the 
mass spectrometer, and constant changing between methods with different instrument 
parameters. There were also intermittent increases in the baseline noise, especially 
with the betaine MRM signal, that may have been caused by contamination in the 
mobile phase by a compound with a similar mass. The ion source could be cleaned 
with a solution of methanol and water (50/50 v/v) containing 0.1% acetic acid. 







Table 4.2. Method performance data for quality controls measured throughout the 
present study by LC-MS/MS.  
         




       Mean (µmol/L) 19.6 1.5 102.4 11.0 8.4 43.0 0.3 155.4 
SD 1.0 0.2 6.2 2.5 0.5 1.5 0.1 12.8 
CV% 5.2 13.2 6.0 22.8 6.2 3.5 39.0 8.2 
High control 
       Mean (µmol/L) 66.3 47.4 149.2 48.7 56.3 87.3 50.7 196.5 
SD 3.0 2.4 7.8 10.2 3.2 3.4 4.9 15.0 
CV% 4.6 5.1 5.3 20.9 5.7 3.9 9.6 7.7 
         Recovery% 93 92 94 75 96 89 101 82 
 
Urine 
   




       Mean (µmol/L) 163.6 79.5 29.6 3.44 341.7 166.4 44.8 126.8 
SD 11.1 9.2 7.7 0.71 17.7 12.2 8.1 7.8 
CV% 6.8 11.5 26.2 20.7 5.2 7.3 18.1 6.1 
High control 
       Mean (µmol/L) 245.9 168.1 122.3 120.2 406.8 243.4 143.2 212.7 
SD 16.1 11.4 14.7 21.2 21.5 14.2 15.7 12.3 
CV% 6.6 6.8 12.0 17.6 5.3 5.8 11.0 5.8 
         Recovery% 82 89 93 117 65 77 98 86 
 













Concentrations of betaine, N,N-dimethylglycine, choline, 
glycerophosphorylcholine, trimethylamine-N-oxide, carnitine, acetylcarnitine, and 
taurine in overweight subjects with type 2 diabetes 
 
The median values and interquartile ranges for methylamines in the DEWL 
study subjects are shown in Table 4.3. This data was calculated on the baseline 
samples excluding the 32 subjects who were on fibrates. 
 
Table 4.3. Median and interquartile range of the baseline data in the DEWL samples  
 
      Male  
 
        Interquartile range 
           
Female Interquartile range 
 Plasma 
Median   
(mol/L) 
25% 75%      n 
Median           
(mol/L) 
      25% 75% n 
Betaine 32.1 26.2 39.6 158 28.8 23.1 35.0 227 
DMG 2.51 2.09 3.28 158 2.33 1.83 2.88 227 
Choline 10.7 9.3 12.4 158 9.95 8.54 11.5 227 
GPC 1.95 1.34 2.75 158 1.77 1.28 2.34 227 
TMAO 5.9 3.99 10.85 158 5.67 3.92 9.21 227 
Carnitine 46.6 40 53.2 158 43.7 38.2 49.0 227 
Acetylcarnitine 7.19 6.05 9.29 158 7.57 6.5 10.05 227 




              
     Betaine 34.8 18.0 69.1 132 22.9 12.9 57.1 180 
DMG 7.85 5.43 12.39 132 7.42 4.9 11.8 180 
Choline 4.17 2.99 6.2 132 4.18 3.03 7.35 180 
GPC 0.50 0.36 0.72 132 0.61 0.45 0.87 180 
TMAO 66.9 47.3 99.3 132 85.2 46.6 138 180 
Carnitine 14.1 8.06 22.7 132 12.2 7.0 19.5 180 
Acetylcarnitine 4.11 2.32 6.25 132 3.15 1.59 5.55 180 
Taurine 46.1 23.6 82.3 132 20.1 6.8 51.2 180 
 
Abbreviations: N,N-dimethylglycine (DMG); glycerophosphorylcholine (GPC); trimethylamine-N-
oxide (TMAO); creatinine (CRN). 
 
 
Mann-Whitney rank sum tests showed that there are significant differences 
between the genders. Males had significantly higher (p < 0.01) plasma betaine, DMG, 
choline, and carnitine. Males also had significantly higher (p < 0.01) urine betaine and 
urine taurine, and also had significantly lower (p < 0.01) urine GPC. Plasma betaine 





The concentrations of osmolytes and other metabolites in plasma (Table 4.3A) 
are similar to previously reported data on normal populations.
4b,65b,9, 84 
 Lever et al.
91
 
reported that the median plasma betaine in people with diabetes is not significantly 
different to the normal population, which is consistent with the findings of the present 
study. However, the overall median urine betaine level of 25.9 mmol/mol crn in this 
group is considerably higher than that reported in the normal population (median = 
5.9 mmol/mol creatinine (CRN)
65b
). A few individuals in the DEWL study were likely 
to be excreting more than the estimated New Zealand median dietary betaine intake 
(227 mg/day
147
). These individuals may be betaine depleted, and therefore dependent 
on choline oxidation for osmo-regulation and one-carbon metabolism. Elevated urine 
betaine excretion in diabetes has been previously reported.
91,148,14
 No statistically 
significant trends were detected for betaine excretion to increase with time. Possibly 
with a small sample size (116 subjects) a longer time than two years may be required 
to show the pattern of change in betaine concentrations with diabetes. Plasma DMG 
concentrations are consistent with those reported in other populations.
4b
 
Plasma choline concentrations (overall median 10.4 µmol/L) in the overweight 
subjects with diabetes were not elevated compared to other reports.
83
 Cardiovascular 
events such as myocardial infarction have been associated with high plasma choline 
concentrations, though the event itself probably causes an elevation. Plasma choline 
concentrations ≥ 25 µmol/L have been reported to be predictive of major cardiac 
events.
83
 The mean plasma taurine concentration of 53.5 µmol/L observed for the 
DEWL study samples is in good agreement with Laidlaw et al.
9
, who reported a mean 
value of 58 ± 16 µmol/L in normal subjects. There is little data on the osmolyte GPC, 
especially in diabetes, so it is difficult to compare the results with other studies. 
However, the present study shows that the concentrations of GPC in plasma and urine 
of overweight people with diabetes are considerably lower than the other osmolytes, 
betaine and taurine. This may be because GPC is synthesized intra-cellularly in 




The overall mean plasma taurine concentration for the DEWL study samples 
of 61.1 µmol/L is in good agreement with Laidlaw et al.,
9
 who published a mean 
value of 58 ± 16 µmol/L in normal subjects. This suggests that plasma taurine is not 
significantly raised in overweight people with diabetes. There has been very little data 
published on GPC, especially in diabetes, so it is difficult to compare the results with 
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other studies. Pomefret et al.
149
 reported plasma concentrations of GPC (11 ± 1 
µmol/L) to be similar to plasma choline (12 ± 1 µmol/L). However, they did not 
measure GPC by a direct method. The present study shows that the concentrations of 
GPC in plasma (median = 1.95 µmol/L) and urine (median = 0.50 mmol/mol 
creatinine) of overweight people with diabetes are considerably lower than the other 
osmolytes, betaine and taurine. 
The plasma TMAO concentrations were highly variable, and most likely 
affected by the dietary intake of marine foods. The plasma TMAO results were 
slightly higher than what was reported by Tang et al.,
85
 where median plasma TMAO 
was 3.7 µmol/L (interquartile range 2.4 - 6.2). However, the higher and more variable 
TMAO results observed in the DEWL samples may be related to diabetes or simply 
reflect the diet. For example, consuming marine fish will lead to a temporary increase 
in TMAO levels.
45b
 The DEWL study samples were collected while fasting. However 
it is possible that TMAO may still be elevated due to dietary intake. While Tang et 
al.
85
 reported that TMAO is a sensitive marker of cardiovascular disease, any short 
term dietary variations in TMAO could limit its usefulness. 
 Plasma choline concentrations in the overweight subjects with diabetes were 
not generally elevated compared to other studies.
83
 This suggests that these subjects 
may not be at immediate risk of cardiovascular events such as heart attacks which 
have been associated with high plasma choline concentrations.
83
 Plasma choline 
concentrations ≥ 25 µmol/L have been reported to be predictive of major cardiac 
events.
83




Osmolytes and related methylamines in the plasma of overweight subjects who have 
type 2 diabetes compared with overweight subjects who have the metabolic 
syndrome 
 
 The concentrations of plasma metabolites in baseline samples from overweight 
subjects with type 2 diabetes (n = 64) were compared to baseline samples of 
overweight male controls with the metabolic syndrome from the betaine and body 
composition (BBC) study (n = 62) using Mann-Whitney rank sum tests. The DEWL 
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samples used here were the baseline samples from the matched control subjects who 
were not on fibrate therapy (32 males and 32 females). 
 The results are shown in Fig. 4.1 as boxplots. The Mann-Whitney rank sum tests 
showed that myo-inositol (p < 0.001) and GPC (p < 0.001) were significantly lower in 
people with type 2 diabetes. Betaine (p = 0.002) and DMG (p = 0.012) were also 
lower in people with type 2 diabetes. However, taurine (p < 0.001) was significantly 
higher and more variable in the plasma of people with diabetes. Free choline, TMAO, 
carnitine, and acetylcarnitine were not significantly different (p < 0.05) in the two 
groups. Betaine and related metabolites are important risk markers for diabetes. 
Svingen et al.
61b
 reported that low plasma betaine is a strong predictor of developing 
type 2 diabetes in people with no previous history of diabetes. Elevated betaine, 
DMG, and sarcosine in the urine have also been reported to be strong predictors of 
developing type 2 diabetes.
61b
 The diagnostic value of measuring the osmolytes, 
taurine, myo-inositol and GPC as risk markers in diabetes is yet to be determined. 
 The result that myo-inositol is lower in the plasma of people with diabetes 
compared to people without diabetes contradicts Hasegawa et al.,
128
 who reported 
elevated myo-inositol in the plasma of people with diabetes compared to normal 
controls. Ostlund
28
 reported that plasma myo-inositol concentrations were not 
different in people with diabetes (median 24.1 µmol/L) compared to non-diabetics 
(median 24.5 µmol/L). The displacement of other osmolytes from the body by sorbitol 
can occur in diabetes, where sorbitol is found in particularly high concentrations due 
to the reduction of glucose. While plasma betaine has previously been reported to be 
not significantly different in diabetes,
91
 it was found here to be significantly lower in 
the plasma of the DEWL study subjects (overweight people with type 2 diabetes) 
compared to overweight people without diabetes. This may be in part due to the 
presence of 50% females in the group with diabetes, whereas the control subjects with 
the metabolic syndrome were all males. The higher taurine observed in people with 
type 2 diabetes was unexpected. However, higher plasma taurine in diabetes may be 
explained by it being displaced from cells and body tissues by increased circulating 
sorbitol generated by the reduction of glucose. In that case, blood plasma may be a 
poor indicator of what is actually happening in the tissues. Plasma taurine was much 
more variable in people with diabetes than in the control group, showing that 





Fig. 4.1. Boxplots showing plasma osmolyte and methylamine concentrations in the 
DEWL study subjects with diabetes and overweight subjects without diabetes. 
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Osmolytes and related methylamines in the urine of overweight subjects who have 
type 2 diabetes compared with overweight subjects who have the metabolic 
syndrome 
 
 The concentrations of urine metabolites from the DEWL study subjects (n = 64) 
were compared to a group of overweight male non-diabetic controls with the 
metabolic syndrome from the betaine and body composition (BBC) study (n = 62) 
(Fig. 4.2). The DEWL samples used here were the baseline samples from the matched 
control subjects who were not on fibrate therapy (32 males and 32 females). The 
groups were compared using Mann-Whitney rank sum tests on unmodified data. 
Betaine, GPC, myo-inositol, scyllo-inositol, DMG, choline, and TMAO were all 
significantly higher (p < 0.05) in the urine of overweight people with type 2 diabetes 
compared to the non-diabetic controls. TMAO was significantly higher in the urine of 
the subjects with type 2 diabetes (p = 0.009). Carnitine and acetylcarnitine were not 
significantly different (p > 0.05) in the urine of people with diabetes compared to the 
controls. Taurine was also not significantly different in the diabetic urine compared to 
the control group (p = 0.065), but was more variable in people with type 2 diabetes. 
chiro-Inositol was only detected in 12 non-diabetic urine samples. However, the 
concentrations were generally higher in the group with diabetes (median = 2.99 
mmol/mol creatinine compared to median = 1.03 mmol/mol creatinine in the 12 
control group samples). 
Elevated concentrations of betaine, DMG, myo-inositol, chiro-inositol, and 
sorbitol have been previously reported in the urine of people with type 2 diabetes.
71, 28, 
91, 150
 scyllo-Inositol and chiro-inositol are likely to be filtered out by the kidneys 
along with myo-inositol as they are chemically similar compounds, only differing by 
the orientation of the hydroxyl groups. 
With the exception of taurine, the concentrations of most osmolytes (betaine, 
GPC, and myo-inositol) were significantly lower in the plasma and higher in the urine 
of people with diabetes, suggesting that they could be at risk of being depleted of 







Fig. 4.2A. Inositols, taurine, and GPC in the urine of people with type 2 diabetes 





Fig. 4.2B. Boxplots showing urine methylamine concentrations in people with type 2 





The effect of diet on the concentrations of betaine other osmolytes, and other one-
carbon metabolites 
 
The DEWL study participants were given dietary advice prior to the six month 
visit, so an increase in plasma betaine concentrations in the group on high 
carbohydrates was expected at the 6 month time point. However, at 6 months, Mann-
Whitney rank sum tests showed no significant differences in any of the osmolytes and 
related metabolites measured in the present study between the high protein diet and 
the high carbohydrate control diet prescribed in the DEWL study. These results 
support the findings of the DEWL study, where few differences were observed in the 
health outcomes for the subjects on different diets. This could be due to the low 
compliance of the subjects with the dietary advice that they were given over the 
duration of the DEWL study.
146
 It remains inconclusive whether a high protein or 
high carbohydrate diet affects the osmolyte distribution in diabetes. However, 
considering that high carbohydrate diets are likely to contain wheat based products 
such as bread and pasta, which are very high in betaine,
147
 the subjects on high 
carbohydrate diets were expected to show increased betaine levels. High protein diets 
are likely to contain more meat, which is high in taurine.
9
 Because no significant 
differences were observed between the DEWL study diet treatments, study subjects 
on the different prescribed diets were treated as one group for the purposes of 





Variation of betaine, glycerophosphorylcholine, taurine, N,N-dimethylglycine, 
choline,  and trimethylamine-N-oxide in the plasma and urine of overweight people 
with type 2 diabetes over a two-year period 
 
Introduction 
 The biological variation of: betaine; GPC; taurine; DMG; choline; TMAO; 
carnitine; and acetylcarnitine was investigated in the DEWL study samples collected 
over a two year period. The variability of these osmolytes, one-carbon metabolites, 
and other methylamines in people with type 2 diabetes was previously unknown. In 
order to compare with other studies, both the coefficient of reliability and the index of 
individuality were calculated for each metabolite, even though they provide similar 
information. Log-normal reference change values (RCVs) are also calculated to 
determine 95% confidence intervals for the percentage change that can be considered 
significant for repeat measurements. The hypothesis was that osmolyte concentrations 
in plasma and urine change over a two year period as the diabetes progresses and 







Statistical analyses were performed using SigmaPlot (v13.0). A p-value < 0.05 
was considered to be statistically significant. Log-normal RCVs were calculated as 
described by Fraser.
152
 Log-normal RCVs for a positive and negative change were 
calculated using the equation: RCVpos = [exp(1.96 × 2
½
 × σ) – 1] × 100, and RCVneg = 
[exp(-1.96 × 2
½





, and CVt is the total imprecision. A Z-score of 1.96 was used to 
calculate RCVs, corresponding to p = 0.05, or a 95% chance that a change in 
subsequent measurements is significant, and due to something other than normal 
biological variation and analytical imprecision.  
The intra-individual variation over the four time points was determined by 
calculating the coefficient of reliability, which is also known as Cronbach’s α. The 
coefficient of reliability was calculated on urine using log-transformed data. A 
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reliability coefficient close to 1 represents a high degree of intra-individual 
reliability.
153
 The coefficient of reliability was calculated for each compound using 
only subjects where there was a complete set of four time points (baseline, 6 months, 
12 months, and 24 months). There was a complete set of data for 131 subjects for 
urine, and a complete set of 262 subjects for plasma. To enable comparisons with 
previous studies, the index of individuality was also calculated for each analyte, 
whereas a lower number represents higher individuality of the data. The index of 
individuality was calculated as the ratio of within-individual coefficient of variation 





There were no significant differences in urine betaine concentrations observed 
when the four time points were compared by Kruskal-Wallis analysis of variance on 
ranks. However, there was a tendency for urine betaine concentrations to increase 
during the study for approximately 10% of the subjects. 
The coefficients of reliability and indices of individuality are shown in Table 
4.4 for plasma, and Table 4.5 for urine. Because differences were observed between 
males and females in betaine concentration, data are displayed for each gender. 
The results show that there is a high degree of reliability for betaine 
(coefficient of reliability = 0.75) and DMG (coefficient of reliability = 0.79) in the 
plasma. Of all the analytes investigated, betaine (coefficient of reliability = 0.83) and 
DMG (coefficient of reliability = 0.81) concentrations showed the highest degree of 
reliability in the urine. Concentrations for plasma and urine betaine at all time points 
are plotted for the first 50 subjects in Fig. 4.3. 
While betaine showed a high level of individuality in the plasma and urine, the 
other osmolytes were more variable. GPC had a moderate degree of reliability in the 
plasma (coefficient of reliability = 0.42), and urine (coefficient of reliability = 0.59). 
Taurine was much more variable in the plasma (coefficient of reliability = 0.09) than 
in the urine (coefficient of reliability = 0.73). 
Choline concentrations showed a moderate reliability in the plasma 
(coefficient of reliability = 0.67) and in the urine (coefficient of reliability = 0.75). 
TMAO had a low reliability in both the plasma (coefficient of reliability = 0.17), and 
the urine (coefficient of reliability = 0.31). 
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The indices of individuality show similar trends for the metabolites. A smaller 
number for the index of individuality indicates low intra-individual variability (high 
individuality). Plasma taurine had a particularly high index, representing a low 
individuality. GPC and TMAO in the plasma also had high indices of individuality of 
0.84. 
The reference change values (RCVs) were much lower in the plasma than the 
urine for all analytes. A change in plasma betaine concentration of +51% (or -34%) in 
males and +56% (or -36%) in females can be considered significant (p < 0.05). A 
change in plasma DMG concentrations of +64% (-39%) is significant (p < 0.05) for 
both males and females. However, a change in plasma TMAO of +403% (or -80%), 
and a change of plasma taurine of +124% (or -55%) is required to be significant (p = 
0.05) over both genders. Larger log-normal RCV ranges were observed for urine 
metabolite excretions compared to the plasma. For example, urine betaine had a 
positive log-normal RCV of 186 and a negative log-normal RCV value of -65 over 
both genders. TMAO had the highest RCVs in the urine of +480% (or -83%) over 
both genders. 
Carnitine and acetylcarnitine had high test-retest reliability in both the plasma 
and urine. The coefficient of reliability for carnitine in plasma was 0.80 and urine was 
0.46. Carnitine had a log-normal RCV range of 31.5% to -24% in the plasma, and 
272% to -73% in the urine. The reliability coefficient for acetylcarnitine was 0.72 in 
plasma and 0.40 in urine. Acetylcarnitine had a log-normal RCV range of 65.4% to -
39.5% in the plasma, and 332 to -77% in the urine. 
Mann-Whitney rank sum tests showed that there are significant differences 
between the sexes. Males had significantly higher (p < 0.01) plasma betaine, DMG, 
choline, and carnitine. Males also had significantly higher (p < 0.01) urine GB. Males 
had a higher coefficient of reliability for betaine, DMG, and GPC in the plasma 
(Table 4.4) and urine (Table 4.5) than females. The significantly higher plasma 









Fig. 4.3. Betaine in the urine of the first 50 subjects (A). Betaine in the plasma of the 











25%               75% 
Reliability 
coefficient 
CVa %    CVi % Index of 
Individuality 
RCV %  Lognormal 
Positive     Negative 
All subjects (N = 243) 
Betaine 30.3        24.9 36.9 0.75 4.6 11.0 0.38 119.3 -54.4  
DMG 2.34 1.89 2.96 0.79 5.1 12.8 0.22 63.6 -38.9  
Choline 10.4 8.7 12.3 0.67 5.3 10.0 0.48 52.4 -34.4  
GPC 1.54 1.17 2.12 0.42 20.9 9.1 0.25 125.6 -55.7  
Taurine 49.3 41.4 60.5 0.09 7.7 22.0 1.12 123.9 -55.3  
TMAO 6.31 4.09 10.4 0.17 5.7 57.9 0.76 403.0 -80.1  
Carnitine 45.6 39.3 51.5 0.80 3.9 9.9 0.52 31.5 -23.9  
Acetylcarnitine 7.72 6.30 9.91 0.72 9.6 18.3 0.58 65.4 -39.5  
Males (n = 99)           
Betaine 32.1 26.3 40.0 0.77 4.6 10.2 0.42 50.7 -33.6  
DMG 2.50 2.10 3.12 0.83 5.1 12.6 0.22 62.6 -38.5  
Choline 10.9 9.27 12.8 0.67 5.3 9.3 0.49 49.6 -33.1  
GPC 1.52 1.18 2.15 0.48 20.9 6.8 0.28 112.6 -53.0  
Taurine 50.3 42.3 60.9 0.13 7.7 20.5 1.15 115.0 -53.5  
TMAO 6.64 4.04 11.0 0.18 5.7 61.5 0.76 442.5 -81.6  
Carnitine 47.1 40.3 54.0 0.82 3.9 17.0 0.48 30.2 -23.2  
Acetylcarnitine 7.69 6.34 9.57 0.74 9.6 25.7 0.56 63.9 -39.0  
Females (n = 144) 
Betaine 28.9 23.4 35.1 0.72 4.6 11.6 0.34 56.2 -36.0  
DMG 2.20 1.78 2.77 0.76 5.1 12.9 0.21 64.0 -39.0  
Choline 9.92 8.46 11.7 0.67 5.3 10.4 0.42 54.1 -35.1  
GPC 1.55 1.14 2.09 0.30 20.9 10.3 0.23 132.8 -57.0  
Taurine 48.8 40.8 60.4 0.08 7.7 22.9 1.22 129.2 -56.4  
TMAO 6.08 4.14 10.2 0.17 5.7 55.1 0.73 373.3 -78.9  
Carnitine 44.9 38.4 49.8 0.79 3.9                   7.5 0.40 23.1 -18.7  
Acetylcarnitine 7.79 6.29 9.99 0.72 9.6 13.8 0.43 46.3 -31.7  
Median values were calculated from all four time points. Abbreviations: analytical imprecision (CVa); within subject coefficient of variation (CVi); reference change value (RCV); N,N-




Table 4.5. Individuality and test-retest reliability in urine for the DEWL study. 
                        Median 
                   (mmol/mol CRN) 
Interquartile range 
25%               75% 
Reliability 
coefficient 
CVa % CVi % Index of 
Individuality 
RCV % Lognormal 
Positive   Negative 
All subjects (N = 116) 
Betaine 25.9 13.0 52.8 0.83 6.6 32.7 0.38 186.2 -65.1  
DMG 6.75 4.10 9.76 0.81 6.8 25.9 0.29 141.9 -58.7  
Choline 3.63 2.64 5.25 0.75 12.0 23.5 0.26 159.9 -61.5  
GPC 0.56 0.41 0.77 0.59 17.6 15.9 0.22 146.9 -59.5  
Taurine 29.0 10.3 54.9 0.73 5.8 50.6 0.20 328.8 -76.7  
TMAO 70.7 46.3 115 0.31 5.3 65.1 0.33 480.2 -82.8  
Carnitine 12.6 7.2 19.4 0.46 5.8 50.2 0.38 272.0 -73.1  
Acetylcarnitine 3.38 1.88 5.70 0.40 11.0 56.7 0.49 332.0 -76.9  
Males (n = 48)  
   
  
 
   
Betaine 32.4 13.1 66.5 0.91 6.6 32.7 0.40 186.2 -65.1  
DMG 6.92 4.27 9.46 0.89 6.8 19.4 0.38 104.3 -51.0  
Choline 3.51 2.46 4.90 0.72 12.0 21.9 0.30 149.3 -59.9  
GPC 0.49 0.37 0.72 0.83 17.6 2.9 0.06  75.3 -43.0  
Taurine 36.9 19.0 58.1 0.68 5.8 44.3 0.71 271.0 -73.0  
TMAO 65.7 45.8 94.7 0.30 5.3 48.2 0.72 301.6 -75.1  
Carnitine 13.2 7.6 18.6 0.43 5.8 45.9 0.34 236.0 -70.3  
Acetylcarnitine 3.75 2.30 5.77 0.49 11.0 43.3 0.45    257.7 -72.0  
Females (n = 68)  
Betaine 25.4 13.8 53.0 0.78 6.6 24.7 0.28 133.5 -57.2  
DMG 6.99 4.39 10.8 0.79 6.8 19.3 0.19 103.4 -50.8  
Choline 3.94 2.86 5.79 0.78 12.0 14.1 0.15 103.6 -50.9  
GPC 0.62 0.46 0.87 0.52 17.6 11.1 0.14 118.2 -54.2  
Taurine 19.6 6.44 51.5 0.75 5.8 36.2 0.12 205.9 -67.3  
TMAO 86.8 49.4 130.0 0.32 5.3 52.6 0.31 343.8 -77.5  
Carnitine 12.5 7.5 19.8 0.48 5.8 37.8 0.26 175.1 -63.7  
Acetylcarnitine 3.02 1.67 5.39 0.35 11.0 44.3 0.33 223.0 -69.0  
Median values were calculated from all four time points. The coefficients of reliability for the urine results were calculated on log-transformed data. Abbreviations: analytical imprecision 







Two measures are used as guides to test-retest reliability, or individuality. The 
coefficient of reliability ranges from 0 (no consistency on retesting) to 1 (perfect 
concordance on retesting). The index of individuality has an inverse scale, and perfect 
concordance of results within each individual would give an index of individuality of 
0. The upper range is open-ended but in practice a value approaching 1 or greater 
indicates low individuality. When the index of individuality is low, and the coefficient 
of reliability high, reference ranges may be of limited use. More significance is 
attached to changes than to single values, and reference change intervals are used to 
estimate the changes that are likely to be clinically significant. However, it has been 
shown that single values of plasma and urine betaine,
154
 and especially plasma 
DMG,
154-155
 are predictive of secondary cardiovascular events in populations with 
established vascular disease. It is possible that monitoring these markers could show 
trends with time that have additional clinical value. Both statistics, the index of 
individuality and the coefficient of reliability, were calculated in order to compare the 
results with previous studies and other populations. Lever et al.
156
 reported that 
abnormal betaine excretions in a small number of patients (n = 10) attending a lipid 
clinic were highly individual and may persist for many years. The results of the 
present study are consistent with the high coefficient of reliability of 0.73 which was 
reported for urine betaine concentrations by Schartum-Hansen et al.
148
 in a population 
with coronary artery disease; the coefficient in the subgroup with diabetes was similar 
(0.70) despite a much higher median excretion in this group.
148
 The present study 
found an even higher coefficient of reliability of 0.83 for urine betaine (0.91 in the 
males). The main difference in these populations is that the present study investigated 
people with diabetes who were over-weight, whereas Schartum-Hansen et al. 
investigated a larger group of cardiovascular patients that included a significant 
minority with diabetes.
148
 A high reliability of betaine in the plasma and urine was 
also reported by Lever et al.
65b, 157
 in healthy subjects. The coefficients observed for 
people with type 2 diabetes in the present study are generally consistent with those of 
Lever et al.
65b
 who reported coefficients of reliability of 0.43 in the plasma, and 0.78 
in the urine for betaine over an 8 week period. Urinary DMG excretion may have 
slightly lower individuality than betaine, and free choline exhibits lower still. 
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Plasma DMG is much more individual in this population than in a small group 
of healthy young males,
65b
 and these values can be expected to be population 
dependent. Svingen et al.
155
 also reported a high coefficient of reliability (0.93) for 
plasma DMG in people with stable angina. The predictive value of single 
measurements of plasma DMG is not just a reflection of its correlation with 
homocysteine,
155
 and as noted before, it could be expected that changes in plasma 
DMG with time may be a useful additional tool in patient management, and this 
should be investigated. 
The other osmolytes, GPC and taurine were considerably more variable in the 
plasma than betaine. This is possibly related to variations in osmotic control caused 
by fluctuations in their blood sugar levels. 
The results from the present study show that plasma choline has moderately 
high individuality (coefficient of reliability = 0.67), and a change of 52% (or -34%) is 
required to be significant with 95% confidence. This suggests that plasma choline 
may be useful as an indicator of cardiovascular risk in this population. The high intra-
individual variability in plasma taurine (coefficient of reliability = 0.09, positive and 
negative RCVs = 124% and -55% respectively) observed here suggests that a large 
change is required to be regarded as significant beyond the biological and analytical 
variation in this population. However, the urine taurine was much more individual in 
this population (coefficient of reliability = 0.73; index of individuality = 0.23). Plasma 
GPC concentrations had low individuality (coefficient of reliability = 0.42). 
The plasma TMAO concentrations were highly variable in this study group. 
Plasma TMAO has been promoted as a predictive marker of cardiovascular disease.
87b
 
However in the DEWL study group, both plasma concentrations and urinary excretion 
of TMAO are highly variable. TMAO concentrations are especially affected by the 
dietary intake of marine foods. TMAO is an osmolyte in many marine animals, but 
not a mammalian osmolyte, and is often a marker of eating fish. TMAO 
concentrations are also raised in people on high choline diets or taking lecithin, 
betaine, or carnitine supplements.
56
 Elevated plasma concentration TMAO has been 
previously proposed as a marker of renal disease.
158
 The high intra-individual 
variability of TMAO concentrations observed in this population would make it 
difficult to make clinical decisions, at least on the basis of a single measurement. The 
fact that a large change in plasma TMAO (RCV) of 403% (or -80%) is required to be 
95% confident that it is significant (beyond analytical imprecision and biological 
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variability) implies that there may be a low value of a single measurement as a 
diagnostic tool for cardiovascular risk in this population with diabetes.  
A limitation is that most subjects lost weight during the DEWL study,
146
 and 
the dietary changes may be expected to affect the handling of some metabolites. This 
makes the high level of consistencies reported here more remarkable, and we may 
have underestimated the individuality of some of those we studied. However, there 
were no trends for changes with treatment and time found that approach statistical 
significance. 
There are marked differences in the individualities of the osmolytes and one-
carbon metabolites we investigated. The high reliability of betaine plasma and urine 
betaine in this population suggests that betaine concentrations measured at any given 
time provide information about the betaine status of each individual. Although this 
has been shown to have prognostic value, monitoring changes with time may provide 
significantly more information. The high reliability of betaine in plasma and urine 
appears to be more related to its role in one-carbon metabolism, than to its role as an 
osmolyte. Like betaine, the other one-carbon metabolites, choline and DMG, had high 
reliability in the urine and plasma. The other osmolytes, GPC and taurine, were 
considerably more variable than betaine. The high intra-individual variation observed 
for plasma and urine TMAO in this study throws doubt on its value as a disease 






Correlations between betaine, other osmolytes, and other one-carbon metabolites in 
subjects with type 2 diabetes 
 
Methylamines and taurine 
Correlations were identified in the baseline samples from the DEWL study 
using Spearman’s rank order analysis, and the results are summarised in Fig. 4.4. 
Plasma betaine correlated significantly with the following metabolites in the plasma: 
DMG (p < 0.001), choline (p < 0.001), GPC (p = 0.0096), and carnitine (p < 0.001) 
and acetylcarnitine (p < 0.001). While plasma betaine did not correlate significantly 
with taurine in the plasma (p = 0.078), it did correlate with taurine (p = 0.002) in the 
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urine. There was a negative correlation between plasma betaine and total cholesterol 
(p < 0.001). There was a weaker correlation between plasma betaine and creatinine (p 
= 0.035), but not eGFR (p = 0.51). There were no significant correlations observed 
between plasma betaine and plasma glucose or HbA1c. There were strong correlations 
between betaine, DMG, and choline and carnitine and acetylcarnitine in the plasma (p 
< 0.001). Urine betaine correlated strongly with many of the other metabolites 
including DMG, choline, GPC, taurine, carnitine and acetylcarnitine (p < 0.001). 
Urine betaine correlated strongly with HbA1c (r = 0.475, p < 0.001) and plasma 
glucose (r = 0.456, p < 0.001). Betaine fractional clearance (FC) also correlated with 
HbA1c (p = 0.01), and plasma glucose (p < 0.001). Urine DMG and choline also 
showed a significant correlation with HbA1c (p < 0.001) and plasma glucose (p < 
0.001). 
Plasma DMG correlated significantly with markers of renal function (plasma 
creatinine p < 0.001, eGFR p < 0.001). There was also a weak correlation between 
plasma DMG and plasma glucose (p = 0.043). 
Plasma choline also correlated significantly with markers of renal function 
(plasma creatinine p < 0.001, eGFR p < 0.001). Plasma choline also correlated with 
HbA1c (p = 0.007). 
GPC correlated strongly with taurine in the plasma (r = 0.5, p < 0.001) (Fig. 
4.5). GPC did not correlate with betaine, but did correlate with carnitine (p < 0.001) in 
the plasma. Plasma GPC correlated with cholesterol (p = 0.001) and BMI (p = 0.01). 
Urine GPC correlated with HbA1c (p = 0.015) and glucose (p = 0.0017). Urine GPC 
also had a strong negative correlation with plasma creatinine (r = -0.279, p < 0.001) 
and positive correlation with eGFR (r = 0.201, p = < 0.001). These correlations 





Fig. 4.4. Spearman’s rank order correlations for the baseline samples from the DEWL 




Plasma TMAO correlated with acetylcarnitine (p = 0.027), and also correlated 
with plasma creatinine and eGFR (p < 0.001). 
Plasma taurine did not correlate significantly with plasma betaine, but there 
was a weak correlation between taurine and DMG (p = 0.002) and choline (p = 0.005) 
in the plasma. Urine taurine correlated significantly with plasma glucose (p < 0.001). 
However, urine taurine did not correlate significantly with HbA1c (p = 0.054).  
Plasma carnitine correlated with many compounds in the plasma and the urine 
including: acetylcarnitine, taurine, betaine, DMG, choline, and GPC (p < 0.001). 
Plasma carnitine also correlated with plasma creatinine (p = 0.035), and plasma 
glucose (p = 0.003) and HbA1c (p = 0.007). Plasma acetylcarnitine also correlated 
with betaine, DMG, and choline (p < 0.001), and correlated with GFR (p < 0.001). 
Urine carnitine and acetylcarnitine correlated with total cholesterol (p < 0.001). 
 
 









To investigate the concentrations of inositols in diabetes, a subset of the 
DEWL study sample was analyzed for inositols. This subset consisted of the 32 
subjects who were taking bezafibrate, and 64 matched controls. myo-Inositol was 
measured in plasma, and the inositol isomers myo-inositol, chiro-inositol, and 
scyllo-inositol were measured in the urine.  The correlations discussed here are 
from Spearman’s rank order correlation analysis on the control data (Table 4.6). 
Urine myo-inositol correlated strongly with urine betaine (r = 0.70, p < 0.001) (Fig. 
4.6), and its metabolites DMG (r = 0.48, p < 0.001), and choline (r = 0.57, p < 
0.001). Urine myo-inositol also correlated with the osmolyte GPC in the urine (r = 
0.545, p < 0.001), but not with urine taurine (r = 0.23, p = 0.71). Urine myo-
inositol also correlated significantly with markers of glycemic control, plasma 
glucose (r = 0.45, p < 0.001), and HbA1c (r = 0.27, p = 0.03). Urine myo-inositol 
did not correlate significantly with eGFR. Urine myo-inositol correlated with other 
inositols in the urine, i.e., chiro-inositol (r = 0.66, p < 0.001) and urine scyllo-
inositol (r = 0.60, p < 0.001). There were significant correlations between urine 
chiro-inositol, scyllo-inositol, and other metabolites in the urine (including: 
carnitine, acetylcarnitine, TMAO, GPC, choline, betaine, and DMG). The strong 
correlation observed between scyllo-inositol and carnitine (r = 0.48, p < 0.001) and 
acetylcarnitine (r = 0.51, p < 0.001) may suggest that scyllo-inositol plays some 
role in fatty acid metabolism. The three inositol isomers in the urine did not 
correlate significantly with plasma methylamines or plasma taurine. chiro-Inositol 
and scyllo-inositol did not correlate significantly with HbA1c, and only chiro-
inositol weakly correlated with plasma glucose (p = 0.049). 
myo-Inositol was the only inositol detected in the plasma, and had a mean 
value of 18.4 µmol/L and a standard deviation of 5.6 µmol/L. Plasma myo-inositol 
correlated strongly with markers of renal function, plasma creatinine and eGFR, 
but not with markers of glycemic control (Table 4.7). There was also a strong 
correlation between plasma myo-inositol and plasma homocysteine, which is likely 
to be because homocysteine correlates strongly with eGFR, and may be an artefact 
of renal function. Plasma myo-inositol correlated significantly with the plasma 
osmolytes, betaine and taurine, but not with GPC. There were also significant 
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correlations between myo-inositol and DMG, carnitine, and acetylcarnitine (p < 
0.05). 
While myo-inositol correlated strongly with betaine in the diabetic urine, it 
did not correlate significantly with betaine in the small number of healthy subjects 
from the Solvay study (n = 26, p = 0.302). myo-Inositol, which is the only inositol 
isomer known to be a mammalian osmolyte, was the only one to show a strong 
correlation with plasma glucose, showing that people with poor glycemic control 
excrete more myo-inositol in the urine. However, chiro-inositol has been shown to 
be a marker of insulin resistance,
75b
 which may explain its correlation with the 


















HbA1c r = 0.270 r = 0.166 r = -0.008 
 
p = 0.034 p = 0.196 p = 0.952 
Plasma Glucose r = 0.451 r = 0.252 r = 0.110 
 
p < 0.001 p = 0.049 p = 0.393 
Plasma Creatinine r = 0.186 r = -0.022 r = 0.044 
 
p = 0.148 p = 0.865 p = 0.732 
eGFR r = -0.052 r = 0.073 r = -0.066 
 
p = 0.690 p = 0.57 p = 0.609 
BMI r = -0.079 r = 0.0328 r = -0.199 
 
p = 0.561 p = 0.809 p = 0.141 
Cholesterol r = 0.009 r = -0.009 r = 0.175 
 
p = 0.944 p = 0.944 p = 0.173 
Urine Betaine r = 0.705 r = 0.476 r = 0.354 
 
p < 0.001 p < 0.001 p = 0.005 
Urine DMG  r = 0.477 r = 0.382 r = 0.306 
 
p < 0.001 p < 0.001 p = 0.016 
Urine Choline r = 0.567 r = 0.517 r = 0.389 
 
p < 0.001 p < 0.001 r = 0.002 
Urine GPC r = 0.545 r = 0.389 r = 0.410 
 
p < 0.001 p = 0.002 p = 0.001 
Urine TMAO r = 0.192 r = 0.452 r = 0.304 
 
p = 0.135 p < 0.001 p = 0.016 
Urine Carnitine r = 0.315 r = 0.222 r = 0.475 
 
p = 0.013 p = 0.082 p < 0.001 
Urine Ac Carn r = 0.355 r = 0.178 r = 0.507 
 
p = 0.005 p = 0.165 p < 0.001 
Urine Taurine r = 0.231 r = 0.177 r = 0.303 
 
p = 0.071 p = 0.167 p = 0.017 
Urine scyllo-Inositol r = 0.600 r = 0.614 
 
 
p < 0.001 p < 0.001 
 Urine chiro-Inositol r = 0.657 
  
 
p < 0.001 
   
Note: Data from DEWL study subjects, controls used in fibrate study (n = 62). Statistically significant 








Table 4.7. Spearman’s rank order correlations of plasma myo-inositol with other 
metabolites. 
 
  Plasma myo-Inositol 
Plasma Glucose r = 0.042 
 
p = 0.741 
HbA1c r = 0.0196 
 
p = 0.877 
Plasma Creatinine r = 0.374 
 
p = 0.002 
eGFR r = -0.506 
 
p  < 0.001 
Plasma Betaine r = 0.248 
 
p = 0.048 
Plasma Hcy r = 0.505 
 
p < 0.001 
Plasma DMG r = 0.301 
 
p = 0.016 
Plasma Choline r = 0.220 
 
p = 0.081 
Plasma GPC r = 0.119 
 
p = 0.350 
Plasma Taurine r = 0.336 
 
p = 0.007 
Plasma Carnitine r = 0.340 
 
p = 0.006 
Plasma Acetylcarnitine r = 0.339 
  p = 0.007 
 
Note: Data from DEWL study subjects, controls used in fibrate study (n = 62). Statistically significant 
(p < 0.05) correlations are highlighted in bold. Abbreviations: Haemoglobin A1c (HbA1c);  estimated 







Correlations between betaine, other osmolytes and other one-carbon metabolites in 
the urine of healthy individuals 
 Correlations between osmolytes and other metabolites were investigated in the 
urine of healthy subjects and compared to the correlations observed in type 2 diabetes. 
Fig. 4.7 shows correlations of some osmolytes and other metabolites in the urine of 26 
healthy individuals aged 48-60 years from the fenofibrate study (see Section 4.3) at 
baseline (before treatment). 
 
 
Fig. 4.7. Spearman’s rank order correlations for metabolites in the urine of healthy 
subjects showing p-values (A), and r-values (B).  
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 Less significant correlations were observed in the urine of healthy subjects, than 
for people with type 2 diabetes. myo-Inositol did not correlate with scyllo-inositol and 
chiro-inositol in the urine of healthy subjects, unlike in subjects with diabetes where 
the inositols all correlated strongly in the urine. The inositols did not correlate with 
betaine in healthy individuals. This may be partly due to the low sample number of 26 
healthy controls. However, myo-inositol correlated with the other osmolyte, taurine, in 
the healthy individuals. There was a significant correlation between scyllo-inositol 
and choline in the urine of healthy subjects. Plasma was not available for this set of 
healthy study subjects, so correlations in plasma were not investigated. 
 
Osmolytes and glycemic control in type 2 diabetes 
The increased in urinary betaine excretion observed in diabetes has been 
shown not to be a direct result of high glucose levels.
159
 However, the results from the 
DEWL study samples show that the osmolytes GPC, and betaine, and its metabolites 
choline and DMG in the urine, are all somehow related to markers of glycemic control 
(see Fig. 4.4). People with diabetes who have higher HbA1c and plasma glucose 
excrete more of the osmolytes: betaine, taurine, GPC, and myo-inositol in the urine. 
Of the osmolytes investigated, urine betaine correlated the strongest with plasma 
glucose (r = 0.456, p < 0.001) and HbA1c (r = 0.475, p <  0.001) (Fig. 4.8). Urine 
myo-inositol correlated strongly with plasma glucose (p < 0.001), and less strongly 
with HbA1c (p = 0.034). Urine taurine also correlated significantly with plasma 
glucose (p < 0.001), but not with HbA1c (p = 0.054). This suggests that the 
concentrations of myo-inositol and taurine in the urine are affected by the short-time 
sugar concentrations in the body, whereas urine betaine is affected by both the short-
term and long-term sugar concentrations. A correlation between plasma glucose (and 
HbA1c) and betaine excretion has been previously reported in people with diabetes.
14
 
The reason that more betaine and GPC are excreted by the kidneys by people with 
poorer glycemic control may be related to increased sorbitol levels displacing the 
other osmolytes in the kidneys. Alternatively, the betaine transporter proteins may 
become glycated in diabetes which may alter their function leading to a loss of betaine 
from cells and from the kidneys.
91
 It is not clear why the betaine metabolites, DMG 
and choline, in the urine also correlate with plasma glucose and HbA1c. However, it 
appears that the disruption in osmolyte concentrations (or the increase in circulating 
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glucose) affects the betaine / homocysteine pathway because DMG in the urine also 
correlates quite strongly with plasma glucose and HbA1c. DMG is only formed in the 
body from metabolism of betaine by BHMT activity. Betaine is normally 
preferentially retained by the kidneys, so the increased loss which can occur in people 
with diabetes may lead to other health problems. As well as its role in osmo-
regulation, betaine is also involved in reducing homocysteine which is associated with 
cardiovascular disease, and as well as GPC is also used as a counteracting solute to 
maintain protein structure, and therefore betaine (and GPC) depletion may play a 
significant role in tissue and organ degeneration. 
The negative correlation between plasma carnitine and plasma glucose (and 
HbA1c) (p < 0.01) suggests that people with poor glycemic control may tend to have 
less efficient fatty acid metabolism. 
The correlation between plasma choline and HbA1c (p < 0.01) is consistent 
with an increased risk of cardiovascular disease that is associated with diabetes. 
Increased plasma choline is known to be associated with an increased risk of 












Osmolytes and renal function 
 The correlations that have been observed between osmolytes, other osmolytes, 
and other low molecular weight metabolites (such as carnitine and TMAO) in the 
urine are likely to be a consequence of the function of the kidney and its ability to 
filter out low molecular weight metabolites. The filtration of these metabolites is 
likely to vary between person depending on their renal function and glycemic control. 
It is therefore not surprising that so many of these compounds correlate in the urine 
samples. 
There were significant negative correlations between GPC and DMG in the 
urine with plasma creatinine, and there were also significant positive correlations 
between eGFR and urine DMG, GPC, and taurine (see Fig. 4.4). This suggests that 
DMG, GPC, and taurine are less efficiently excreted (or more poorly resorbed) in 
people with poor renal function. However, urine betaine did not significantly correlate 
with plasma creatinine or eGFR. There was a positive correlation between urine 
inositol and plasma creatinine, showing that inositol excretion is increased in people 
with diabetes who have poorer renal function. These results show that people with 
diabetes who have poor renal function tend to excrete less GPC, DMG, and taurine 
and excrete more inositol into the urine. There was no significant correlation between 
urine betaine and markers of renal function (plasma creatinine and eGRF) or renal 
damage (microalbumin). However, plasma DMG correlated with microalbumin (p < 
0.001). Plasma betaine, DMG, choline, TMAO all correlated with plasma creatinine 
to some degree. Plasma DMG, choline, TMAO, and acetylcarnitine all correlated 
negatively with estimated glomerular filtration rate (eGFR). TMAO has previously 
been reported to correlate strongly with plasma creatinine in people with chronic renal 
failure.
158
 eGFR is generally considered to be a better marker of renal function than 
plasma creatinine as it takes into account factors such as the patient’s weight and 
gender. While urine taurine did not correlate with markers of renal function or 
glycemic control, it did correlate with: urine betaine, DMG, choline, and 
acetylcarnitine. The kidneys accumulate GPC in response to high urea as well as 
during osmotic stress.
3
 However, in the present study there was no observed 
correlation with urine GPC and urea. 
Plasma DMG, TMAO, and choline correlated with plasma creatinine and 
negatively correlated with eGFR, showing that these betaine metabolites are 
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accumulated in bodies of people with poorer renal function. The increase in plasma 
choline concentrations observed in people with poor renal function is also suggestive 




Osmolytes, lipid metabolism, and body weight 
 People with raised low density lipoprotein (LDL) cholesterol are reported be at 
greater risk of having a heart attack.
160
 The results of this study show that people with 
high LDL cholesterol tend to have lower betaine in the plasma (p < 0.001), and have 
slightly raised levels of the other osmolytes, GPC (p < 0.01) and taurine (p < 0.05) in 
the plasma. Carnitine (p < 0.001) and acetylcarnitine (p < 0.01) in the urine tends to 
be raised in patients with high LDL cholesterol. Plasma GPC was also negatively 
correlated with total body fat (p < 0.001), showing that the more fat people have, the 
lower the plasma GPC. Plasma triacylglycerides (TAG) was associated with low 
plasma betaine and raised plasma choline and GPC. Saturated fatty acids significantly 
correlated with plasma carnitine, choline, GPC, and TMAO (p < 0.05). 
Betaine supplementation has been associated with weight loss in animals,
4b
 so 
the loss of betaine may also be a contributing factor in obesity in diabetes. However, 
no significant correlation was observed between betaine and weight (or BMI) in the 
present study, which does not indicate that the more obese people are losing more 
betaine in the urine. However the negative correlation between betaine and LDL 
cholesterol is suggestive that low plasma betaine is an important marker of 
cardiovascular risk. The positive correlation between LDL cholesterol and plasma 
GPC and urine carnitine and acetylcarnitine may is likely to reflect the role of these 
metabolites in lipid metabolism.  
 
One carbon metabolism in diabetes 
 The fact that many metabolites correlated in the urine is likely to be an artefact 
of filtration by the kidneys and renal function. However, urine DMG and choline both 
correlated particularly strongly with urine betaine (Fig. 4.9). These metabolites are all 
involved in one-carbon metabolism and the betaine-homocysteine methyl transferase 
(BHMT) pathway. An increase in BHMT activity will cause increased DMG in the 
urine as it can only be formed by this biochemical pathway in the body. The fact that 
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the urine betaine correlates more strongly with the BHMT metabolites than with the 
other osmolytes (taurine and GPC) suggests that the high betaine loss observed in 
diabetes is more complex than a simple displacement of osmolytes caused by 
increased circulating sorbitol concentrations. The betaine metabolites, DMG and 
choline correlated with HbA1c and plasma glucose stronger than the other osmolytes, 
taurine and GPC. It seems possible from these results that a disruption of the BHMT 
pathway may be an important factor in the observed increased urinary loss of betaine, 
which is associated with poor glycemic control in diabetes. 
 
 
Fig. 4.9. Plots showing relationships of betaine with N,N-dimethylglycine (DMG) and 
choline in urine of people with type 2 diabetes. 
 
 
 Plasma homocysteine was not measured during the DEWL study. However, it 
was measured in the fibrate and control samples to compare with the betaine results. 
Correlations of one-carbon (and some other) metabolites with plasma homocysteine in 







Table 4.8. Spearman’s rank order correlations with plasma homocysteine 
  Plasma homocysteine 
Plasma betaine r = 0.140 
 
p = 0.270 
Plasma DMG r = 0.310 
 
p = 0.013 
Plasma choline r = 0.128 
 
p = 0.314 
Plasma carnitine r = 0.346 
 
p = 0.005 
Plasma acetylcarnitine r = 0.263 
 
p = 0.036 
Plasma myo-inositol r = 0.505 
 p < 0.001 
Plasma creatinine             r = 0.300 
             p = 0.016 
Urine betaine r = -0.120 
 
p = 0.344 
Urine DMG r = -0.109 
 
p = 0.389 
Urine choline r = -0.233 
 
p = 0.064 
urine GPC r = -0.263 
 
p = 0.036 
Urine chiro-inositol r = -0.302 
  p = 0.017 
 
Note: Significant correlations (p < 0.05) are shown in bold. Abbreviations: N,N-dimethylglycine 
(DMG), glycerophosphorylcholine (GPC). 
 
 
 Plasma DMG was expected to correlate with plasma homocysteine, because 
DMG is only formed in the body by BHMT activity. The significant correlations of 
homocysteine with carnitine and acetylcarnitine may be related to lipid metabolism. 
Homocysteine also correlated negatively with urine GPC and chiro-inositol, but did 
not significantly correlate with the other inositols in the urine. As has been mentioned, 
the strong correlation between homocysteine and plasma myo-inositol may be partly 
related to kidney function, as they both correlate significantly with plasma creatinine 




The effect of medications on plasma and urine concentrations of betaine, other 
osmolytes, and other one-carbon metabolites 
 
Introduction 
Elevated betaine concentrations have previously been reported in the urine of 
people taking the lipid lowering drug bezafibrate.
15
 However, it was not known if 
other osmolytes such as taurine, GPC, and myo-inositol are also excreted into the 
urine at abnormal concentrations by people taking bezafibrate. The study on the 
effects of bezafibrate has been published in Cardiovascular Drugs and Therapy.
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Differences in the concentrations of betaine, other osmolytes, and other one-carbon 
metabolites were also investigated for subjects who were taking other medications 
such as metformin and insulin. 
 
Methods 
There were 32 DEWL study subjects (16 males and 16 females) on the lipid 
lowering drug bezafibrate. A control group was selected for comparison. The control 
group consisted of a subset of the DEWL study participants (n = 64, 32 males and 32 
females) who were matched for age and gender with the bezafibrate group. Samples 
were analyzed for betaine, DMG, choline, taurine, GPC, and myo-inositol using an 
AB Sciex API4000 tandem mass spectrometer using methods described in Chapters 2 
and 3. myo-Inositol was measured using an Agilent 6120 single quadrupole mass 
spectrometer with an APCI source. The subjects on fibrate therapy were compared to 
the control group using Mann-Whitney rank sum tests. 
 
Results and discussion 
Of the 32 DEWL study subjects who were on the drug bezafibrate, only one 
person had a normal betaine concentration in the urine (18.3 mmol/mol creatinine). 
The rest of the fibrate subjects were above the normal range (> 32.5 mmol/mol 
creatinine
156
). Mann-Whitney rank sum tests showed that the DEWL study subjects 
who were taking bezafibrate (n = 32) had significantly higher betaine (p < 0.001) and 
DMG (p < 0.001) in the urine (Fig. 4.10). The plasma betaine was significantly lower 
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(p < 0.001) in people on fibrates. Plasma homocysteine was significantly higher (p < 
0.001) in people on fibrate therapy. There were no differences in the urine choline 
concentrations between the subjects taking fibrates and the subjects not taking 
fibrates. There was no significant correlation between urinary betaine excretion or 
plasma betaine with homocysteine in the subjects on fibrates or the control group. 
There was a significant correlation (p = 0.01) between plasma DMG and 
homocysteine in the control group. 
There were no significant differences in the plasma or urine between subjects 
taking bezafibrate and not taking bezafibrate for the other osmolytes: taurine, GPC, 
and myo-inositol. scyllo-Inositol and chiro-inositol were not significantly different in 
the urine of fibrate subjects compared to the controls either (Table 4.9). myo-Inositol 
correlated with triacylglycerides (TAG, data not shown) in the subjects on fibrate 
therapy (r = 0.594, p < 0.001), but not in the control group (p = 0.57). 
Mann-Whitney rank sum tests confirmed that urine betaine and urine DMG 
were greater in patients on fibrate therapy (p < 0.001) (Fig. 4.10). Mann-Whitney rank 
sum tests also showed that DEWL subjects taking bezafibrate had significantly lower 
urine acetylcarnitine (p < 0.001), and higher plasma carnitine (p < 0.001) and 
acetylcarnitine (p < 0.001) (Fig. 4.11). Mann-Whitney rank sum tests also showed that 
plasma betaine is significantly lower in people on fibrates (p < 0.001) (Fig. 4.10), and 
that carnitine is significantly higher in the plasma of subjects taking fibrates (p < 
0.001), see Fig. 4.11. Urine TMAO was significantly elevated in the urine of people 






Fig. 4.10. Box plots showing betaine and dimethylglycine (DMG) concentrations in 
the urine and plasma, the fractional clearance of betaine, and plasma homocysteine 
(Hcy) in subjects with type 2 diabetes not taking fibrates and taking bezafibrate. 
 
Subjects who were taking metformin showed significantly elevated urine 
betaine (p < 0.001), DMG (p < 0.001), choline (p < 0.001), and GPC (p < 0.001). 
Subjects on metformin had significantly higher plasma glucose (p = 0.02), and HbA1c 
(p = 0.002). People with type 2 diabetes requiring insulin (isophane) also had 
increased urine betaine (p = 0.034), DMG (p = 0.008), choline (p = 0.006), and GPC 
(p = 0.016). There were no significant differences in the urine concentrations of 
osmolytes in people with type 2 diabetes taking gliclazide, aspirin, or ACE inhibitors. 
Subjects requiring insulin and on metformin had higher betaine, DMG, choline, and 
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GPC concentrations in the urine than subjects who were not on these medications. 
People on metformin and insulin are likely to have increased urinary betaine, DMG, 
and choline excretion because their diabetes is more advanced than people not yet on 
these medications. This is supported by the significantly higher plasma glucose and 
HbA1c in subjects on metformin and isophane, which shows that these patients did 
have poorer glycemic control. Metformin works by inhibiting the production of 
glucose in the liver and is commonly given to people with diabetes. 
The benefits of taking the lipid lowering drug bezafibrate in diabetes have 
been well studied.
162
 However, the negative effect on betaine metabolism has been 
largely over-looked. It has been shown that people taking the fibrate drug bezafibrate 
have high betaine excretion in a population with acute coronary syndrome.
154
 It is not 
known if other fibrates affect betaine metabolism, as the only fibrate available in New 
Zealand until recently was bezafibrate. It is shown here that overweight people with 
type 2 diabetes show the same effect on betaine metabolism when taking bezafibrate. 
However, even without taking fibrates many people with type 2 diabetes excrete 
abnormally high concentrations of betaine in the urine. It has been shown in the 
present study that taking fibrates exacerbates the problem of betaine loss in type 2 
diabetes. Considering that betaine is an important nutrient which protects against 
cardiovascular disease, it may be beneficial for people who have diabetes to be 
supplemented with betaine, especially those who are on fibrates. Betaine 
supplementation in these patients would allow for them to better maintain their tissue 
cell volume and may also improve health outcomes by protecting against a range of 
diseases such as: cardiovascular disease, kidney disease, and cancer.
4b
 The fact that 
other osmolytes do not show the same pattern as betaine in patients on fibrates 
suggests that the effect is likely to involve the disruption of a betaine transporter in 




The observation that free carnitine and acetylcarnitine were increased in the 
plasma and decreased in the urine of patients taking fibrate was novel. This change in 
carnitine metabolism is likely to be a result of the lipid lowering action of fibrates. 
Because carnitine is responsible for the transport of fatty acids, a decrease in 
circulating lipids may lead to more free and acetylcarnitine in the blood. This 
observation is consistent with the findings of Henninger et al.,
163
 where carnitine was 






Fig. 4.11. Box plots showing carnitine and acetylcarnitine concentrations in the urine 





Table 4.9. Urine inositol concentrations in subjects on bezafibrate and controls 
 
                            Controls   Interquartile range    Subjects on fibrates Interquartile range 








myo-Inositol 22.4 7.8 57.3 
 
31.1 18.4 45.5 
scyllo-Inositol 10.4 5.7 13.5 
 
8.3 6.8 12.6 
chiro-Inositol  3.0 1.8 8.1   2.0 1.6  3.9 
 
Note: The controls were age and gender matched DEWL study subjects (overweight people with type 2 





 It was originally hypothesized that subjects who were on a high protein diet or a 
high carbohydrate diet would have different concentrations of betaine, other 
osmolytes, and one-carbon metabolites. However, there were no significant 
differences (p < 0.05) in concentrations of these metabolites observed between the 
two diets the subjects were placed on during the DEWL study. This result may be 
inconclusive due to the reported low compliance of the study subjects with dietary 
advice that they were given.
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The overweight people with type 2 diabetes who were enrolled in the DEWL 
study generally had normal metabolite concentrations in their plasma. However, the 
increased urinary betaine excretion in this group is a concern, especially with over 
half of the subjects having abnormally high betaine in the urine. The betaine loss was 
made even worse when they were taking the drug bezafibrate. This high urinary loss 
of betaine in diabetes could be expected to lead to problems with osmotic control and 
associated tissue damage. myo-Inositol was also elevated in the urine of the DEWL 
study subjects compared to healthy controls. However, urine taurine was not 
significantly elevated in the DEWL study subjects. 
It was not previously known if osmolytes other than betaine are affected by the 
drug bezafibrate. However, it has been shown here that the high urinary betaine 
excretion was not observed for the other osmolytes, and a mechanism other than a 
general disruption to osmotic control is likely to be responsible. The fact that DMG is 
also increased in the urine of people on bezafibrate suggests that there is increased 
BHMT activity occurring, and it is not simply a case of affecting the betaine 
transporters such as BGT1. The increased plasma homocysteine observed in people 
on fibrate therapy is likely to be caused by betaine depletion and the decreased ability 
to convert homocysteine to methionine. There is a need for further research to 
determine the reason for the observed loss of betaine in people who are taking 
bezafibrate. The low intra-individual variability of betaine in the urine suggests that 
the subjects who are losing high levels of betaine continue to do so. It is therefore 
likely to be beneficial to supplement these people with betaine to help prevent the 
onset of further complications, as has been suggested by Lever et al.
164
 
The correlations in the DEWL study samples show that there are a number of 
other factors that affect the concentrations of betaine, other osmolytes, and other one-
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carbon metabolites in people with diabetes, including: lipid metabolism; glycemic 
control; and renal function. For example, the strong correlations between betaine (and 
related metabolites DMG, choline) with glucose and HbA1c show that more betaine is 
excreted by the kidneys in people with poorer glycemic control. The other osmolytes, 
taurine, and GPC, also correlated with markers of glycemic control, although less 
strongly. While plasma myo-inositol didn’t correlate with plasma glucose, urine myo-
inositol did. Plasma myo-Inositol concentrations correlated with markers of renal 
function, and with homocysteine, showing that it is an important risk marker for a 
number of different reasons and is likely to be useful as a diagnostic marker of 
disease. 
 The accelerated loss of betaine is likely to be detrimental for various reasons, 
including: a decrease in osmotic control; choline depletion from cells and cell 
membranes; and elevated homocysteine due to reduced BHMT activity. It would be 
useful to test the hypothesis that people with diabetes who are losing large amounts of 
betaine are more likely to go on to develop other complications (such as, heart 
disease, renal failure, and cataracts). Low plasma betaine is a risk marker for 
developing diabetes.
73
 Unfortunately, ethics approval could not be obtained to relate 
osmolyte concentrations from this project to health outcomes.  
While it is likely that supplementing patients who have diabetes with osmolytes 
such as betaine, taurine, and myo-inositol may be beneficial, it is not known if it 


















4.3.  The effect of fenofibrate treatment on betaine, other osmolytes, and other 
methylamines in the urine of healthy individuals 
 
Introduction 
The lipid lowering drug, bezafibrate, has been associated with elevated betaine 
concentrations in the urine.
15
 However, it is not known if fibrates are causative for 
betaine loss, and it is not known if fibrate drugs other than bezafibrate have the same 
effect on urinary betaine excretion. There has been no previous study where fibrates 
have been given to healthy people and the concentrations of betaine and other 
osmolytes measured before and after treatment. Increased plasma homocysteine has 
been previously reported in patients taking fenofibrate or bezafibrate.
165
 Elevated 
plasma homocysteine and high urinary betaine excretion has been observed in the 
DEWL study subjects taking bezafibrate,
161
 and has also been reported by Lever et 
al.
15
 The fibrate medication, fenofibrate, is investigated here to determine if betaine 
excretion is elevated after administering it to normal healthy individuals. The 
hypothesis was that betaine concentrations significantly increase in the urine of 
healthy subjects after treatment with fenofibrate compared to baseline urine betaine 






 A clinical study was conducted by Solvay Pharmaceuticals (Abbott) at the 
Guy’s Hospital in London. Ethics approval for this study was obtained by Solvay 
Pharmaceuticals.  
 Twenty six healthy individuals (15 males and 11 females) were given a dose of 
145 mg of the lipid lowering drug, Lipanthyl (fenofibrate), for six weeks. Individuals 
were aged between 40 and 65 years, and had normal folate and vitamin B12 levels. 
Subjects fasted for at least 10 hours before sample collection. Urine was collected 
before fenofibrate was given (baseline), then at the end of the study (6 weeks), giving 
a total of 52 samples. The urine samples were shipped to Christchurch, New Zealand, 
as part of a collaboration with Solvay Pharmaceuticals to measure betaine 
concentrations at Canterbury Health Laboratories. Betaine, choline, DMG, TMAO, 
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taurine, myo-inositol, carnitine, and acetylcarnitine were measured in the urine as part 
of the present project. Plasma homocysteine, methionine cysteine, S-adenosyl-
methionine (SAM), and S-adenosyl-homocysteine (SAH) data were provided by 
Solvay Pharmaceuticals. Unfortunately, the plasma samples from the Solvay study 
were not available for the analysis of betaine and related metabolites. 
 
Sample preparation 
 Fifty microlitres of sample was extracted into 1.0 mL of extraction solvent 
containing 90% acetonitrile, 10% methanol, and 10 µmol/L D9-betaine, D9-choline, 
D3-dimethylglycine, D9-carnitine, and D9-trimethylamine-N-oxide. For negative ion 
mode, the extraction solvent contained 10 µmol/L D4-taurine, and D6-myo-inositol. 
Samples were vortexed for 20 seconds and centrifuged at 13,000 × g for 3 minutes, 
then transferred to HPLC vials and capped for analysis.  
 
LC-MS 
 Urine samples were analyzed for methylamines and taurine using an AB Sciex 
API4000 after separation on a Cogent diamond hydride silica column (100 × 2.1 mm, 
4 µm, Microsolv Technologies) as described in Chapter 2. An Agilent 1260 Infinity 
HPLC system connected to an Agilent 6120 single quadrupole mass spectrometer 
with an APCI source was used for inositol analysis as described in Section 3.5.  
 
Statistical analysis 
 Wilcoxon signed rank tests were carried out on the data to compare subjects 
before and after treatment for most analytes. However, paired t-tests were performed 
on DMG, taurine, and S-adenosyl-homocysteine (SAH), because they fitted the 
criteria for normal distribution.  
 
Results 
Wilcoxon signed rank tests (or paired t-tests) showed that betaine and DMG 
were significantly elevated (p < 0.001) in the urine after treatment with fenofibrate for 
6 weeks compared to baseline (Fig. 4.12). Urine betaine increased with varying 
degrees in all subjects after treatment. Ten subjects (38.5%) were excreting betaine 
amounts higher than the normal range (>32.5 mmol/mol creatinine) when on 
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fenofibrate. Whereas, all subjects had normal betaine concentrations at baseline 
(range = 1.7 to 17.4 mmol/mol creatinine). A Wilcoxon signed rank test showed a 
significant increase (p = 0.011) in urine choline with fenofibrate treatment. TMAO 
was not significantly different before and after treatment (p = 0.648). Carnitine was 
not significantly different in the urine with fenofibrate treatment (p = 0.525), but 
acetylcarnitine was significantly lowered in the urine (p < 0.001) (Fig. 4.12). Taurine 
(p = 0.065) and myo-inositol (p = 0.213) concentrations were not significantly 








Fig. 4.12. Boxplots showing urine betaine, DMG, choline, TMAO, carnitine, 
acetylcarnitine, taurine, and myo-inositol concentrations in healthy subjects before and 
after treatment with fenofibrate. p-Values shown are from Wilcoxon signed rank tests, 





Fig. 4.13. Plots showing baseline versus 6 weeks of treatment with fenofibrate for 
urine betaine, dimethylglycine (DMG), choline, and acetylcarnitine. Regressions were 
performed on log-transformed data for betaine and acetylcarnitine to meet the 
requirement for the data to be normally distributed. 
 
 
There were strong correlations between the individuals at baseline and at 6 
weeks of fenofibrate treatment for betaine, DMG, and choline (Fig. 4.13). Betaine 
showed a logarithmic relationship between the time points. Acetylcarnitine showed a 
weaker correlation (r
2






Fig. 4.14. Boxplots showing baseline (pre) and 6 weeks on fenofibrate treatment 
(post) for homocysteine and metabolites in plasma. p-Values show the results of 
Wilcoxon signed rank tests, or paired t-test (for SAH). Abbreviations: S-adenosyl-




 Homocysteine and its metabolites S-adenosyl-methionine (SAM), cysteine, and 
methionine went up significantly (p < 0.05) on fenofibrate treatment (Fig. 4.14). 
Spearman’s rank correlations showed that urine betaine did not correlate with 
homocysteine at baseline (p = 0.738) or 6 weeks (p = 0.428). 
 
Discussion 
 This study has shown strong evidence that the drug fenofibrate causes an 
increase in the urinary excretion of betaine and DMG in healthy individuals. This is 
the first time a fibrate drug other than bezafibrate, namely fenofibrate, has been 
associated with increased urinary betaine excretion. The only previously published 
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betaine data for people on fibrates were from cardiovascular patients
15
 and people 
with type 2 diabetes who were placed on fibrate treatment by their doctors due to high 
blood lipids (see Section 4.2).
161
 It was previously unproven whether fibrates caused 
elevated betaine in the urine, or whether this effect was simply a consequence of the 
people who are prescribed fibrates having a high blood lipid profile. The strong 
correlations before and after treatment with fenofibrate for betaine, DMG, and choline 
confirm the high individuality for these metabolites in urine. There was an 
exponential relationship between the time points for betaine, showing that the higher 
the initial concentration of betaine, the larger the percentage increase observed after 
treatment with fenofibrate. This is particularly concerning when patients with 
diabetes, who are already likely to have high betaine excretion, are placed on fibrates. 
While betaine increased in the urine of healthy subjects on fenofibrate, the other 
osmolytes, taurine and myo-inositol did not significantly change. This suggests that 
the mechanism for urinary betaine loss with fibrate therapy is unlikely to be related to 
the role of betaine as an osmolyte, and is not the same mechanism that causes elevated 
urinary excretion of betaine and other osmolytes in diabetes. Whether or not fibrates 
affect the function of betaine transporters requires further investigation. 
While fibrate therapy may provide significant benefits to patients by lowering 
their blood lipids, they may also be doing damage by removing betaine from the body 
and placing it under greater osmotic stress. Low plasma betaine has been shown to be 
a strong predictor of developing diabetes.
61b
 However, the causality of betaine 
concentrations in developing the disease needs to be established to determine whether 
it is a risk factor or risk marker. The replacement of betaine by supplementation in 
patients who are on fibrate patients may help to counteract these effects. 
Plasma homocysteine was seen to increase significantly in healthy people given 
fenofibrate over a six week period. However, there was no correlation observed 
between plasma homocysteine and urine betaine, and the urinary betaine loss cannot 
be proven to be the cause of the increased plasma homocysteine with fibrate therapy. 
It is unclear why the SAM, cysteine, and methionine were increased in the plasma 
with fenofibrate therapy. Methionine is produced from homocysteine via betaine 
homocysteine methyltransferase (BHMT) activity,
167
 and there is likely to be more 
methionine produced due to the higher levels of homocysteine present, and the body’s 
attempt to metabolize it. 
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The decrease in urine acetylcarnitine after fenofibrate treatment is consistent 
with what was observed in the DEWL study data, where people on bezafibrate had 
lower urine acetylcarnitine. This fenofibrate data shows that fibrates are causal in 
lowering the acetylcarnitine, and that fibrates affect carnitine metabolism. It is likely 
that the plasma carnitine was elevated after subjects were placed on fenofibrate, which 
would also be consistent with the cross-sectional baseline DEWL study data. 
However, it was not possible to investigate metabolites in the fenofibrate study 
plasma as these samples were not available for analysis. The effects of fibrates on 
carnitine metabolism are likely to be related to the role of fibrates as lipid lowering 
drugs, considering that carnitine transports fatty acids across the mitochondrial 
membrane. The fact that betaine excretion changed significantly after administration 
of fenofibrate to healthy people provides strong evidence that fibrates cause the body 
to shed betaine. The mechanism remains unknown, and does not appear to be related 
to the function of betaine as an osmolyte. 
 
 
4.4. Chapter summary 
The studies described in this chapter show that important information about the 
metabolism of osmolytes can be obtained using the LC-MS/MS methods that have 
been developed in this project. The greater number of osmolytes that can be 
measured, and the improved sample throughput, allows for much more information to 
be gained when analyzing study samples. 
These studies have shown that the concentrations of many osmolytes are 
different in diabetes compared to other populations, and that many osmolytes 
correlate with known risk factors of disease such as LDL cholesterol, creatinine, and 
homocysteine. However, these studies are mostly cross sectional, and much more 













5.    Chapter Five - The Distribution of Betaine, 
Other Osmolytes, and Related Metabolites in 







The liquid chromatography – mass spectrometry methods that have been 
developed were used to investigate the distribution of betaine and related metabolites 
in the different components of blood. The concentrations of osmolytes in blood cells 
may better represent the concentrations in tissues than plasma or whole blood. A 
study on rats has shown that betaine concentrations in organs such as the liver and 
kidneys are in the millimolar range, whereas plasma betaine is in the micromolar 
range.
168
 Betaine concentrations in tissues are not necessarily reflected in the plasma 
concentrations.
168
 Betaine concentrations in whole blood have been reported to be 
nearly six times greater than in the plasma.
169
 Blood cells actively uptake betaine for 
osmo-regulation and for methylation. For example, blood platelets have been reported 
to express the betaine and γ-aminobutyric acid transporter BGT-1.
170
 Macrophages 
have also been shown to use the BGT-1 transporter in the mouse.
171
 Red cells, 
platelets, white cells, and plasma will be analyzed for betaine and related compounds 
to investigate the distribution. There is little published data on the distribution of 
betaine and other osmolytes in the different cell types found in blood. Measuring 
betaine and related metabolites and osmolytes in blood components such as: platelets, 
red cells, or white cells may give a better representation of the osmolyte status in the 
tissues than plasma betaine which has been traditionally measured. While there are 
several other types of white blood cells (including neutrophils, eosinophils, basophils, 
lymphocytes, and monocytes), they are not differentiated here. It would be difficult to 
separate and isolate them without using a buffer that would most likely alter the 




Thirteen baseline EDTA blood samples from men with the metabolic syndrome 
were collected during the betaine and body composition (BBC) study. Blood samples 
were centrifuged at 3000 rpm (1800 × g) for 10 minutes. Plasma was collected from 
the top layer, and red cells were collected from the bottom layer after the white cells 
were removed. White cells were enriched by collecting the buffy coat from four tubes 
with a pipette, re-centrifuging, and collecting the buffy coat again. After separation, 




 Fifty µL of each of the sample fractions (including: whole blood, plasma, red 
blood cells, and white blood cells) were extracted into 1.0 mL of extraction solvent 
containing 10 µmol/L of each of the deuterated internal standards, and placed on a 
vortex mixer for 10 minutes before centrifugation (13,000 g, 5 minutes). Samples 
were analyzed by single quadrupole mass spectrometry for the osmolytes: betaine; 
taurine; and myo-inositol, as well as: choline; DMG; carnitine; acetylcarnitine; and 
TMAO as described in Chapters 2 and 3. myo-Inositol was measured directly with an 
APCI source. 
 The concentrations of osmolytes and other methylamines were compared in the 
different blood components by Kruskal-Wallis analysis of variance on ranks using 
SigmaPlot (v13).   
 
Results and discussion 
 There were significant differences in osmolyte concentrations in the various 
blood components (Fig. 5.1). Median values and interquartile ranges of osmolytes and 
related methylamines are shown in Table 5.1. Kruskal-Wallis analysis of variance on 
ranks indicated that betaine was significantly higher in the white blood cell fractions 
compared to the plasma (p < 0.01). However red cell betaine was not significantly 
elevated compared to plasma betaine (p = 0.29). Taurine concentrations were 
considerably higher in the white cell fractions than in the plasma and whole blood (p 
< 0.001), but were not significantly elevated in the red cells. myo-Inositol was 
significantly elevated in the white blood cells compared to all other blood fractions (p 
< 0.001), and was also not significantly different in the red cells compared to the 
plasma. 
The observation that taurine and myo-inositol concentrations were higher in the 
white blood cell enriched fractions compared to the other blood components, indicates 
that these osmolytes are accumulated by white cells for osmo-regulation, even more 
so than betaine. 
The red cells contained significantly lower carnitine than all of the other blood 





Fig. 5.1. Data (mean ± standard error) showing the distribution of the osmolytes: 
betaine (A); myo-inositol (B), and taurine (C) in blood. Abbreviations: whole blood 
(WB); red cells (RC); white blood cells (WBC).  
 
DMG, TMAO, and carnitine concentrations were not significantly higher in the 
cells than in the plasma. The betaine results in whole blood were considerably lower 
(median = 48.7 µmol/L) in this study compared to those reported by Awward et al. 
(median = 165 µmol/L).
169
 Choline was higher in the cell fractions, which may be 
related to the presence of phosphatidylcholine in cell membranes. Awward et al. 
reported that the median choline concentration in whole blood was 66.6 (10 – 90 
percentile 43.2–154.8) µmol/L which was higher than what was observed in the 
present study (median = 29.7 µmol/L). Awward et al.
169
 also reported higher DMG 
concentrations in whole blood compared to plasma, but this was not observed here 
either. The study by Awward et al. was conducted on elderly people without 
metabolic syndrome.
169
 However, this is unlikely to explain the large differences in 
metabolite concentrations observed here. Awward et al. may have over-estimated the 
metabolite concentrations in whole blood due to an analytical error. 
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Table 5.1. The distribution of osmolytes and related methylamines in blood.  
 
      Plasma  Whole blood White blood cells      Red cells 
     Betaine (µmol/L) 37.2 (28.8 - 41.6) 48.7 (39.0 - 52.4) 59.8 (41.4 - 67.6) 43.6 (26.7 - 66.4) 
     Taurine (µmol/L) 45.0 (41.1 - 50.6) 143.1 (117.7 - 190.9) 1868 (763 - 2324) 36.9 (30.3 - 49.8) 
     myo-Inositol (µmol/L) 25.5 (23.3 - 30.1) 27.6 (22.6 - 33.2) 70.5 (52.3 - 99.2) 25.2 (21.2 - 29.9) 
     Choline (µmol/L) 10.7 (8.8 - 13.3) 29.7 (23.9 - 62.0) 65.2 (30.9 - 123.2) 67.5 (20.0 - 111) 
     DMG (µmol/L) 2.74 (2.25 - 3.09) 2.18 (1.88 - 2.24) 1.87 (1.33 - 2.27) 0.87 (0.72 - 1.52) 
     Carnitine (µmol/L) 42.7 (40.6 - 45.4) 33.9 (28.9 - 40.7) 36.9 (29.1 - 46.7) 13.9 (9.68 - 22.0) 
     Acetylcarnitine (µmol/L) 6.79 (6.26 - 8.75) 9.74 (5.72 - 15.3) 10.4 (2.57 - 37.6) 9.10 (3.15 - 13.4) 
     TMAO (µmol/L) 5.19 (2.61 - 10.6) 4.91 (2.0 - 8.0) 2.94 (0.48 - 4.57) 2.26 (1.20 - 3.81) 
          
 
Note: Median values and interquartile ranges are shown.  
 
The accumulation of betaine, taurine, and myo-inositol by the white cells 
suggests that they may be useful as a representation of tissue osmolyte concentrations. 
A limitation of this approach is that the white cells collected in this study were not 
pure, and were merely enriched with white cells compared to the whole blood. 
Therefore the error associated with these measurements is quite high. The types of 
white cells that accumulate osmolytes are also yet to be identified. Methods used for 
obtaining pure white cells involve the use of buffers which were be expected to 
change the osmotic status of the cells, and therefore the osmolyte concentrations 
would not be accurate either. There were no significant differences in metabolite 
concentrations in the platelet rich plasma compared to the platelet poor plasma (data 
not shown). To obtain a useful estimate of metabolite concentrations in platelets 
would require them to be purified and isolated, and such methods involve the use of 























6.1.  The synthesis of N,N-dimethylglycine-N-oxide and identification in plasma 
and urine using LC-MS/MS  
 
Introduction 
The advancement of mass spectrometry in recent years has led to improved 
sensitivity, which allows for the detection of metabolites that are present in very low 
concentrations, and may not have been previously discovered. The aim was to 
investigate if N,N-dimethylglycine (DMG) may be oxidized in the body to form the 
expected metabolite, N,N-dimethylglycine-N-oxide (DMGO) (Fig. 6.1). Both the 
carboxyl group and the N-oxygen require protonation to ionize the molecule for 
measurement by LC-MS/MS in positive ion mode. 
 
Fig. 6.1. Structure of DMGO. 
 
 To investigate if DMGO may be present in human samples, plasma and urine 
samples were initially analyzed by single quadrupole LC-MS using the methylamine 
chromatography system described in Section 2.2. The m/z = 120 signal was monitored 
in positive ion mode and several peaks were observed with this mass to charge ratio 
that could potentially be DMGO. In order to determine if any of these peaks were 
from the presence of DMGO, an analytical standard was synthesized and validated, 
and two different chromatography systems were developed to separate and measure it 
using tandem mass spectrometry. Mass transitions that correspond to the structure of 





Reagents and chemicals 
 N,N-Dimethylglycine free base, peracetic acid (32% wt in dilute acetic acid), 
formic acid, ammonium formate, and Dowex 50WX8 (200 – 400 mesh) strong cation 
exchange resin were purchased from Sigma. Acetonitrile and ammonia (25% v/v) 
were purchased from Merck. D3-N,N-Dimethylglycine (HCl) was purchased from 
CDN Isotopes. 
 
Synthesis of DMGO 
 N,N-Dimethylglycine (4.00 g, Sigma, free base) was dissolved in 25 mL of 
peracetic acid (32% wt in dilute acetic acid, Sigma). The reaction mixture was 
refluxed in a round bottom flask over a heating mantle for 2.5 hours. The excess 
peracetic acid was removed on a rotary evaporator at 40°C, and the reaction mixture 
was acidified with sulfuric acid and then added to a column containing acidified 
Dowex 50 strong cation exchange resin. The impurities were removed by washing 
approximately three column volumes of water. When the eluent no longer tested 
positive for peroxides using the potassium iodide starch test, the DMGO product was 
eluted off the column with aqueous ammonia solution (8% v/v). The ammonia and 
water were removed on a rotary evaporator at 40°C and DMGO crystallized as a 
white powder. 
 The purity of the DMGO was tested by LCMS, NMR spectroscopy, and 
elemental analysis. Elemental analysis was performed by the Campbell 
Microanalytical Laboratory at the Chemistry Department, University of Otago, New 
Zealand. 
For NMR analysis, approximately 10-20 mg of DMG or DMGO was added to 1 
mL of D2O, and approximately 10 mg of 3-(trimethylsilyl)propionic-2,2,3,3-D4 acid 
sodium salt (TSP, Sigma) was added as a reference standard. The TSP 
1
H signal was 
set to 0 ppm. A proton NMR spectrum was obtained in 5 mm NMR tubes using a 
Varian INOVA 500 MHz NMR spectrometer with 8 scans. 
Deuterated N,N-dimethylglycine-N-oxide (D3-DMGO) was made for use as an 
internal standard by reacting 0.0142 g of D3-N,N-dimethylglycine HCl (CDN 
Isotopes, Quebec, Canada) with 178 µL of peracetic acid (32 wt%, Sigma) at 60°C for 
2.5 hours in a sealed reaction tube. The reaction mixture was added to acidified 
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Dowex 50 cation exchange resin and the peroxide washed out with distilled water 
before elution with ammonia (8% v/v). The excess water and ammonia were dried 
down to a small volume in a rotary evaporator, and the contents made up to 10 mL in 
a volumetric flask to form a solution containing approximately 10 mmol/L D3-
DMGO. 
An initial attempt was made to synthesize DMGO by reaction with hydrogen 
peroxide in the presence of excess acetic acid as described by Ikutani and 
Matsumura.
172
 However, oxidation of DMG by this method resulted in low reaction 
yields and around half the DMG starting material left in the reaction mixture. The 
excess hydrogen peroxide was difficult to remove from the product. It was presumed 
that the most effective oxidizing agent in the reaction mixture was peracetic acid. 
Commercially available peracetic acid was found to oxidize much more efficiently 
than hydrogen peroxide, with complete reaction at 2.5 hours. DMGO was found to be 
difficult to crystallize in organic solvents such as 2-propanol or acetone. Drying down 
the reaction mixture produced an impure sticky white solid which gave an extra 
singlet peak at 2.712 ppm on the NMR. However, by placing the reaction mixture 
onto acidified strong cation exchange resin, the impurities such as peroxides could be 
washed off with water, then the purified DMGO was eluted with ammonia and the 
eluent dried down. 
 
Sample preparation 
 When measuring DMGO in urine an extraction solvent was used containing 10 
µmol/L D3-N,N-dimethylglycine-N-oxide (internal standard) in 20% methanol and 
80% acetonitrile. When measuring plasma DMGO, the internal standard was diluted 
to 100 nmol/L in the extraction solvent. Fifty µL of plasma, urine, or aqueous 
standards were pipetted into 1 mL of extraction solvent. Samples were vortexed and 




 In order to show that DMGO is present in plasma and urine, two different 
chromatography systems were used. The first system used a Cogent diamond hydride 
silica column (100 × 2.1 mm, 4 µm, Microsolv Technologies, NJ, USA), and the 
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second system used an Epic strong cation exchange column (SCX, 125 × 3 mm, 3 µm, 
ES Industries, NJ, USA). 
  The chromatography system for the Cogent diamond hydride silica column was 
as follows: Mobile phase solvent A contained 10 mmol/L formic acid, and 10 mmol/L 
ammonium formate in 50% distilled water and 50% acetonitrile (v/v). Solvent B 
contained 7.5 mmol/L trifluoroacetic acid (TFA) and 15 mmol/L formic acid in 
acetonitrile. A gradient was used starting with 5% A and 95% B, then to 25% A and 
75% B at 3 minutes, and 100% A at 7.5 to 8.5 minutes, and then back to starting 
conditions at 9 minutes. The run time was 12 minutes, the flow rate was 0.3 mL/min, 
the injection volume was 10 µL, and the column temperature was 40°C. 
The chromatography system used for the Epic SCX column was as follows: 
Solvent A contained 10 mmol/L formic acid and 10 mmol/L ammonium formate in 
50% distilled water and 50% acetonitrile. Solvent B contained 7.5 mmol/L TFA and 
15 mmol/L acetic acid in acetonitrile. The gradient started at 3% A and 97% B, going 
to 30% A and 70% B at 4 minutes, then to 100% A from 7.5 to 8.5 minutes, and back 
to 3% A and 97% B at 9 minutes. The run time was 12 minutes. The injection volume 
was 10 µL, the flow rate was 0.3 mL/min, and the oven temperature was 40°C. 
DMGO was initially detected on an AB Sciex API4000 (Applied Biosystems) 
triple quadrupole mass spectrometer with an electrospray ion source (ESI) in positive 
ion mode using the mass transitions m/z = 120.1 → 58.1 and 120.1 → 103.1. A third 
mass transition for DMGO, 120.1 → 102.1, was also monitored in urine, but was 
below the detection limits in plasma. The decoupling potential was 41 V, the collision 
energy was 27 V for the m/z =  120.1 → 58.1 mass transition (and 17 V for 103 and 
102 fragments), and the collision cell exit potential was 6 V. Samples were quantified 
using external aqueous standards of DMGO with D3-N,N-dimethylglycine-N-oxide 
(D3-DMGO) used as an internal standard. The mass transition for D3-DMGO was 123 
→ 61, the decoupling potential was 46 V, the collision energy was 29 V, and the 
collision cell exit potential was 4 V. 
As sensitivity was found to be a problem with detecting DMGO in plasma, a 
more sensitive tandem mass spectrometer, an Agilent 6490 (Mulgrave, VIC, 
Australia) with an ESI source was also used. A fourth mass transition for DMGO (120 
→ 42) was identified during compound optimization on the Agilent 6490 instrument. 
The collision energy was 32 V for the 120 → 58 mass transition, 56 V for the 120 → 
42 mass transition, and 10 V for the  120 → 103 and 120 → 102 mass transitions. The 
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collision energy used for the internal standard mass transition (123 → 61) was 32 V. 
The gas temperature was 220°C, the gas flow rate was 12 L/min, the sheath gas 
temperature was 350°C, the sheath gas flow rate was 11 L/min, the capillary voltage 
was 3000 V, and the cell accelerator voltage was 5 V. 
 
Method performance 
 To test the linearity of the urine method, 25, 50, and 100 µmol/L of DMGO was 
added to urine, and 3 replicates of each level of were measured by tandem mass 
spectrometry. To test the precision and accuracy of the method, six replicates of a 
urine sample, and the same urine sample with 25 µmol/L DMGO added, were 
analyzed for DMGO using tandem mass spectrometry.  
 To estimate the precision and accuracy of the plasma DMGO method, 6 
replicates of a plasma sample and the same plasma sample were analyzed for DMGO 
using tandem mass spectrometry. To investigate the linearity of the method in plasma, 
three replicates of plasma containing different spike levels (0, 0.1, 0.25, 0.5, 1, 5, and 
10 µmol/L) were analyzed for DMGO. 
 DMGO was measured in 62 plasma and urine samples from males with 
metabolic syndrome, and 16 plasma and urine samples from healthy males, using the 
two chromatography systems and various mass transitions. 
 
Results and discussion 
 
Synthesis of DMGO 
 
The yield of DMGO was 4.13 g (89%). The elemental analysis results for 
DMGO were: %C 40.31, %H 7.83, %N 11.79. This is consistent with the DMGO 
crystallizing as the free base with a molecular weight of 119.12 g/mol. The expected 
composition for this was: %C 40.33, %H 7.62, %N 11.76, %O 40.29. The pH of 
DMGO dissolved in distilled water was 3.98. 
There was no detectable unreacted DMG present in the product by LC-MS, or 
NMR spectroscopy. The 
1
H NMR spectrum of DMGO (Fig. 6.2) showed the product 
to be pure. The methyl group resonance shifted from 2.931 ppm to 3.485 ppm, and the 
CH2 resonance shifted from 3.731 ppm to 4.157 ppm with the addition of the oxygen 
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to the nitrogen. The peak area ratio of the CH3 peak to the CH2 peak was 3:1 as 
expected. 
The yield of D3-DMGO was estimated to be approximately 93%, considering 
there was still a small D3-DMG peak present by LC-MS/MS with approximately 7% 
the peak height of the product. The incomplete reaction of D3-DMG with peracetic 
acid may be because D3-DMG was purchased as the hydrochloride. It may be 









Fig. 6.2.  
1
H NMR spectrum of DMG (A), and 
1




H NMR (500 MHz, D2O) H 2.931 (3 H, s, CH3), 3.731 (2 H, s, CH2) 
DMGO: 
1




LC-MS/MS of DMGO  
The mass transitions 120 → 103 and 120 → 102 required a low collision energy 
(10 V), because the fragment ions correspond to the removal of a hydroxyl group and 
a water molecule from the nitrogen of DMGO, which are relatively weak bonds. The 
m/z 120 → 58 corresponds to the formation of a trimethylamine fragment ion, which 
is also observed when TMAO fragments in the mass spectrometer. The fragment ion 
that was most likely observed at m/z = 42 is [CH2NCH2]
+




Fig. 6.3. Mass transitions of DMGO in the Agilent 6490 observed in the triple 
quadrupole mass spectrometer. m/z 120 → 102 (A), m/z 120 → 103 (B), m/z  120 → 








Detection of DMGO in plasma 
DMGO eluted before 5 minutes on the Cogent Diamond Hydride silica column 
(Fig. 6.4). DMGO was retained longer on the strong cation exchange (SCX) column, 
eluting around 7.5 minutes (Fig. 6.5). The optimal chromatography for DMGO was 
achieved using the Cogent diamond hydride silica column. The baseline noise was 
greater when using the SCX column. 
DMGO initially gave poor chromatography with a broad tailing peak on the 
diamond hydride column, and peak splitting on the SCX column, which was likely to 
be caused by incomplete protonation of DMGO in the mobile phase. However, the 
addition of TFA to the mobile phase improved the peak shape of DMGO. As both the 
N-oxygen and the carboxyl group need to be protonated in order to make DMGO 
cationic, a low pH is required in the mobile phase. Sensitivity can be affected by the 
addition of TFA in the mobile phase, which has been reported to cause ion 
suppression.
48
 With the addition of TFA only to mobile phase B, then eluting with 
mobile phase A after sample injection, the concentration of TFA is lower when the 
DMGO peak elutes into the mass spectrometer. Adding a higher concentration of a 
weaker acid such as acetic acid or formic acid to the mobile phase can also reduce the 
ion suppression effects of TFA. 
 DMGO was observed in plasma at all four mass transitions using the more 
sensitive Agilent 6490 mass spectrometer. However, DMGO was only observed with 
the m/z 120 → 58, and 120 → 103 mass transitions on the AB Sciex API4000. There 
were peaks other than DMGO present in plasma for all mass transitions. Plasma 
components with the same mass as DMGO, such as threonine, may be showing up in 
the chromatograms. 
The intensity of the DMGO peak was different using the various mass 
transitions. Peak heights were in the following order of intensity: (m/z 120 → 102) < 
(m/z 120 → 103) < (m/z 120 → 42) < (m/z 120 → 58). However, there was slightly 
greater baseline noise in the m/z 120 → 58 transition, so overall sensitivity was not 
greatly different to the m/z 120 → 42 and m/z 120 → 103 mass transitions. Using the 
AB Sciex API4000 mass spectrometer, the limit of detection (S/N = 3) for DMGO in 
plasma and urine was 0.1 µmol/L for the m/z 120 → 58 mass transition, and 0.3 
µmol/L for the m/z 120 → 103 mass transition, and 1 µmol/L for the m/z  120 → 102 
mass transition on the SCX column. Detection limits were at approximately ten times 
lower when using the Agilent 6490 tandem mass spectrometer. 
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Initial attempts to quantify DMGO in plasma and urine using commercially 
available deuterated N,N-dimethylglycine (D3-DMG) produced poor precision and 
accuracy. To overcome this problem, D3-DMGO was synthesized on a small scale for 





Fig. 6.4. Chromatograms obtained for plasma separated on a Cogent diamond hydride 
silica column and detected using an Agilent 6490 tandem mass spectrometer. A 
plasma sample is shown (red) and the same plasma with the added concentrations of 
DMGO: 1, 2.5, and 5 µmol/L are overlaid. The chromatograms are as follows: m/z 












Fig. 6.5. Chromatograms obtained for plasma separated on an ES Industries SCX 
column. Samples were detected using an Agilent 6490 tandem mass spectrometer. A 
plasma sample is shown (blue), and the same plasma with an added concentration of 1 
µmol/L DMGO is overlaid in red. The chromatograms are as follows: m/z 120 → 58 












Fig. 6.6. Linear regression comparison of LC-MS/MS results for DMGO in plasma 
using the 120 → 58 mass transition versus the 120 → 42 mass transition (A), and the 
m/z 120 → 58 mass transition versus the m/z 120 → 103 mass transition (B). Results 
were obtained using the Cogent silica hydride column on the Agilent 6490. 
 
 
The plasma results obtained using the different mass transitions were in 
agreement (r
2
 > 0.992) (Fig. 6.6). This shows that almost identical results can be 
obtained using the mass transitions 120 → 58, 120 → 42, and 120 → 103. The m/z 







Fig. 6.7. Linear regression results for plasma obtained using the Agilent 6490 for the 
Cogent diamond hydride silica column (DH ) compared to the ES Industries strong 
cation exchange column (SCX). m/z 120 → 58 (A), m/z 120 → 42 (B), and m/z 120 
→ 103 (C). 
 
Results for the two chromatography systems were in agreement with r
2
 > 0.966 
for the three most intense mass transitions (Fig. 6.7). The slopes were greater than 
0.83. However, there were significant positive intercepts showing some interference 
was likely to be present when using the SCX chromatography system. The m/z 120 → 







Detection of DMGO in urine 
 
 DMGO was observed in urine on both the diamond hydride silica column (Fig. 
6.8) and the SCX column (Fig. 6.9). There was more DMGO observed in the urine 
samples than in the plasma, and interference from other components was less 
problematic. While there were some peaks other than DMGO observed in the urine 
chromatograms with both chromatography systems, the DMGO peak was well 





Fig. 6.8. Chromatograms showing the separation of DMGO in urine separated on a 
Cogent diamond hydride silica column. A urine sample (blue), and the same urine 
sample with 25 mol/L DMGO added (red) are shown. The mass transitions shown 
are: m/z 120 → 58 (A), m/z 120 → 42 (B), m/z 120 → 103 (C), and m/z 120 → 102 





Fig. 6.9. Chromatograms showing the separation of DMGO in urine separated on an 
ES Industries SCX column. A urine sample (blue), and the same urine sample with 25 
mol/L DMGO added (red) are shown. The mass transitions shown are: m/z 120 → 
58 (A), m/z 120 → 42 (B), m/z 120 → 103 (C), and m/z 120 → 102 (D). Samples 






Fig. 6.10. Linear regression analyses showing the comparison of LC-MS/MS results 
for DMGO in urine using: the m/z 120 → 58 mass transition versus the m/z 120 → 42 
mass transition (A); the m/z 120 → 58 mass transition versus the m/z 120 → 103 mass 
transition (B); the m/z 120 → 58 mass transition versus the m/z 120 → 102 mass 
transition (C); and the m/z 120 → 103 mass transition versus the m/z 120 → 102 mass 
transition (D). Results were obtained using the Cogent silica hydride column on the 
Agilent 6490 LC-MS/MS system. 
 
 Similar results were obtained in urine using all mass transitions (r
2
 > 0.995) 
(Fig. 6.10), which indicates that there is no significant interference affecting the 





Fig. 6.11. Urine DMGO results obtained using a Cogent silica diamond hydride (DH) 
column compared with results obtained with an ES Industries SCX column. Samples 
were measured for DMGO using the Agilent 6490 instrument. Results were obtained 
using D3-DMGO as the internal standard. 
 
 The urine results obtained using the two different chromatography systems 
agreed well (r
2
 = 0.982 to 0.996) for all four mass transitions (Fig. 6.11). This 
provides a high degree of confidence that DMGO is present in the samples and that 
the peak is not a product of interference from the sample matrix. It is unlikely that an 
interfering compound would chromatograph in the same place as DMGO on two 






Method performance for DMGO in plasma 
The use of deuterated DMGO (D3-DMGO) and the internal standard was found 
to be necessary to produce satisfactory precision and accuracy.   
The m/z 120 → 58 mass transition produced the largest peaks for DMGO. 
However, the baseline noise was greater, and the sensitivity was similar for the 42 and 
103 fragment ions. The imprecision for plasma was indicated by coefficients of 
variation ranging from 4.9% to 18% for a low concentration of 0.03 µmol/L, and CVs 
6% and lower at a concentration of 1 micromolar (Table 6.1). The DMGO 
concentration in some plasma samples were close to the detection limits, and may be 
below the theoretical limit of quantitation. Therefore, imprecision is higher at the 
lower concentrations. The limit of detection can also vary depending on how clean the 
mass spectrometer is on any particular day. Recoveries were over 83%. However, the 
slope of the curves in Fig. 6.12 indicates that the recoveries over the different 
concentration levels were between 100 and 106% for plasma. Greater method 
performance for plasma DMGO was possible when using the diamond hydride silica 
column. The SCX chromatography system had more background interference and co-
eluting peaks. Therefore the imprecision was greater, and the limits of detection were 
approximately twice as high. 
 
 
Table 6.1. Method performance results for DMGO in plasma. The diamond hydride 
silica column method was used to obtain these results. 
 
 
  m/z  
120 → 58 
    m/z  
120 → 42 
       m/z  
       120 → 103 
Plasma, mean 0.030 0.028 0.039 
Plasma, SD 0.005 0.003 0.002 
Plasma CV% 17.3 8.8 4.9 
    Plasma + 1 mol/L, mean 0.895 0.864 0.947 
Plasma + 1 mol/L, SD 0.054 0.038 0.030 
Plasma + 1 mol/L, CV% 6.0 4.4 3.2 
    Recovery% 87 84 91 






Fig. 6.12. Plasma with added DMGO concentrations detected using different mass 
transition. Means ± SE are shown. DMGO was separated using a diamond hydride 












Method performance for DMGO in Urine  
 The imprecision for urine DMGO was indicated by coefficients of variation 
(CVs) below 4.03% when using the diamond hydride silica column, and below 5.08% 
using the SCX column. The recovery of DMGO added to urine was over 95% for both 
columns (Table 6.2). The r
2
 value for DMGO added to urine was > 0.997 for the mass 
transitions: 120 → 103; 120 → 58; and 120 → 42 (Fig. 6.13). 
 
 
Table 6.2. Method performance results for DMGO in urine. 
 
Diamond hydride silica 
  m/z  
120 → 58 
  m/z  
120 → 42 
     m/z  
120 → 103 
Urine, mean 12.26 12.30 12.63 
Urine, standard deviation 0.49 0.45 0.46 
Urine CV% 4.02 3.64 3.61 
    Urine + 25 mol/L, mean 36.56 37.17 37.08 
Urine + 25 mol/L, SD 0.82 0.72 1.37 
Urine + 25 mol/L, CV% 2.26 1.93 3.70 
    Recovery% 97 99 98 
    
SCX column 
      m/z  
 120 → 58 
        m/z  
   120 → 42 
           m/z 
     120 → 103 
Urine, mean 11.98 12.03 11.94 
Urine, standard deviation 0.61 0.55 0.19 
Urine CV% 5.07 4.55 1.59 
    Urine + 25 mol/L, mean 37.39 35.87 37.00 
Urine + 25 mol/L, SD 1.45 0.55 0.93 
Urine + 25 mol/L, CV% 3.88 1.53 2.52 







Fig. 6.13. Urine with added DMGO concentrations detected with three mass 
transitions. Means ± SE are shown. DMGO was separated using a diamond hydride 















Is N-hydroxy-N-methylglycine a metabolite of DMGO? 
 
Introduction 
It is not known how DMGO may be further metabolized in the body. It is 
possible that DMGO may lose a methyl group to form N-hydroxy-N-methylglycine 
(HMG). It is hypothesized that if DMGO is demethylated by either dimethylglycine 
dehydrogenase (DMGDH) or betaine-homocysteine methyltransferase (BHMT), then 
HMG will also be present in human plasma and urine. The aim was to synthesize 




Synthesis of N-hydroxy-N-methylglycine 
 1.00 g (0.012 mol) of N-methylhydroxylamine hydrochloride, 10 g of sodium 
bicarbonate, and 50 mL of dichloromethane were added to a 100 mL conical flask and 
stirred for 3 hours. The reaction mixture was filtered, and 1.67 g (0.012 mol) 
bromoacetic acid dissolved in dichloromethane was added. This mixture was stirred 
for 3 hours at room temperature and then left to sit for 7 days. An oily substance 
developed at the bottom of the reaction mixture. Mass spectrometry confirmed that 
this substance had a mass of 106 corresponding to the expected mass of N-
methylhydroxyglycine (HMG). 50 mL of distilled water was added and the mixture 
was well shaken in a separation funnel. The aqueous layer was collected and dried 
under vacuum. The N-methylhydroxyglycine hydrobromide did not crystallize in 2-
propanol, and dried down to a yellow syrup.  
 
LC-MS/MS 
 A compound optimization of HMG produced fragments at m/z 42.1, and 60.2. 
HMG was separated using the SCX chromatography system that was described for 
separating DMGO. HMG was detected using the 106 → 42, and 106 → 60 mass 






Results and discussion 
There was no detectable HMG peak in the plasma samples. However, there was 
a small peak in the urine samples in the region of HMG (Fig. 6.14). It was not 
possible to reliably quantify this peak in the urine, but it suggests that HMG is likely 
to be present in sub-micromolar concentrations. The observation that no HMG was 
detected in plasma and only a small amount of HMG was observed in the urine shows 
that DMGO is likely to be only a minor substrate for DMGDH or BHMT, if it 
interacts at all. Another possible fate for DMGO is that it is readily excreted into the 




Fig. 6.14. Chromatograms showing the HMG peak in two urine samples and a 















 The results indicate that DMGO is present in plasma and urine samples. While 
the best chromatography was observed using a diamond hydride silica column, 
DMGO was also seen on an SCX column, although with more interference in the 
plasma. The high agreement for DMGO results obtained using different mass 
transitions corresponding to the structure of DMGO, along with the high agreement 
between two different chromatography systems, provides strong evidence that DMGO 
was observed in the samples.  
The co-eluting peaks observed in the chromatograms are likely to be 
compounds that are structurally similar to DMGO, as they are derived from the same 
mass transitions. Identification of these peaks may be useful for future studies.  
D3-DMG made a poor internal standard for the measurement of DMGO by mass 
spectrometry. More accurate and precise results were obtained after D3-DMGO was 
synthesized and used in the method. Measuring the low concentrations of DMGO that 
were observed in plasma requires the use of a highly sensitive tandem mass 
spectrometer. 
The fact that there was no HMG peak observed in plasma, and only a small peak 
(<1 µmol/L) in urine that may be attributable to HMG, shows that demethylation is an 
unlikely fate for DMGO in the body.  
The measurement of the low concentrations of DMGO present in plasma is 
dependent on using a highly sensitive mass spectrometer. While proton NMR would 
struggle to detect DMGO in many of the urine samples, NMR was useful for 
validating the DMGO that was synthesized for use as a quantitative standard. 
The presence of DMGO has not previously been reported in human samples, 
and its identification in plasma and urine paves the way for more research 















6.2. N,N-Dimethylglycine-N-oxide concentrations in subjects with metabolic 
syndrome, type 2 diabetes, and healthy controls 
 
Introduction 
N,N-Dimethylglycine-N-oxide (DMGO) has been identified in plasma and urine 
samples. In this section, DMGO was measured in samples from different populations 
including people with metabolic syndrome, people with type 2 diabetes, and a healthy 
population. Differences in DMGO concentrations between these groups, and how 
DMGO correlates with other metabolites in plasma and urine were investigated. This 





 Plasma and urine from 62 baseline samples from the betaine and body 
composition (BBC) study were analyzed for DMGO, betaine, DMG, choline, TMAO, 
creatinine, and myo-inositol. These subjects were selected because they had features 
of the metabolic syndrome, i.e. were overweight, had high lipids, and elevated blood 
pressure.
63
 A group with type 2 diabetes (n = 64) from the DEWL study
146
 were also 
analyzed for plasma and urine DMGO. Plasma and urine from a control group were 
analyzed from a control group consisting of 16 healthy male subjects obtained from a 
previous diet study
174
 which had been stored at -40°C. This control group contained 
only baseline samples when no treatment had been given. Correlations between the 
metabolites were observed using Spearman’s rank order tests. The groups were 
compared using Kruskal-Wallis analysis of variance on ranks with SigmaPlot (v13). 
Fractional clearances were calculated as: ((urine metabolite concentration / plasma 
metabolite concentration) / (urine creatinine concentration/ plasma creatinine 
concentration)) x 100. 
 Fifty microliters of urine was extracted into 1 mL of extraction solvent (80% 
acetonitrile, 20% methanol containing 10 µmol/L of D3-N,N-dimethylglycine-N-oxide 
(D3-DMGO) as an internal standard). Fifty microliters of plasma sample was 
extracted into1 mL of extraction solvent (80% acetonitrile, 20% methanol containing 
0.1 µmol/L of D3-DMGO as an internal standard). Samples were analyzed for DMGO 
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using an Agilent 6490 LC-MS/MS system with a Cogent diamond hydride silica 
column (100 × 2.1 mm, 4 µm, Microsolv Technologies, NJ, USA). Mobile phase 
solvent A contained 10 mmol/L formic acid, and 10 mmol/L ammonium formate in 
50% distilled water and 50% acetonitrile (v/v). Solvent B contained 7.5 mmol/L TFA 
and 15 mmol/L formic acid in acetonitrile. A gradient was used starting with 5% A 
and 95% B, then to 25% A and 75% B at 3 minutes, and 100% A at 7.5 to 8.5 
minutes, and then back to starting conditions at 9 minutes. The run time was 12 
minutes, the flow rate was 0.3 mL/min, the injection volume was 10 µL, and the 
column temperature was 40°C. The results reported in this Section were obtained 
using the most intense mass transition for DMGO, m/z 120 → 58, on an Agilent 6490 
tandem mass spectrometer after separation on a Cogent diamond hydride silica 
column. Further mass spectrometry details were provided in Section 6.1. 
  
Results and discussion 
 
Comparison of DMGO concentrations in the different groups 
Descriptive statistics are shown for plasma and urine DMGO, DMG, and 
betaine concentrations in people with the metabolic syndrome and the control group 
in Table 6.3. The median DMGO concentration in the plasma for the group with the 
metabolic syndrome was 0.13 µmol/L, the median plasma DMGO in the subset with 
diabetes was 0.19 µmol/L (Fig. 6.15), and the median DMGO concentration for the 
healthy control group was 0.57 µmol/L. The range was much narrower for plasma 





Fig. 6.15. Concentrations of: betaine (A), DMG (B), and DMGO (C) in plasma for 




Table 6.3. Descriptive statistics for DMGO, DMG, and betaine in metabolic syndrome 
subjects, people with type 2 diabetes, and the control group. 
 
Metabolic syndrome             Max Min Median  25%      75% 
Plasma Betaine (µmol/L) 68.7 15.0 32.6 27.4 42.8 
Plasma DMG (µmol/L) 12.9 1.64 2.82 2.25 3.33 
Plasma DMGO (µmol/L) 0.583 0.022 0.133 0.087 0.198 
Urine Betaine (mmol/mol creatinine) 106.0 1.98 6.32 4.58 10.40 
Urine DMG (mmol/mol creatinine) 10.37 0.51 2.69 1.97 3.87 
Urine DMGO (mmol/mol creatinine) 3.91 0.40 1.19 0.94 1.63 
Fractional clearance Betaine % 51.3 0.39 1.56 1.06 2.40 
Fractional clearance DMG % 20.4 1.94 7.23 4.97 9.88 
Fractional clearance DMGO% 229 38.5 75.4 60.8  91.7 
      Type 2 Diabetes             Max Min Median 25%      75% 
Plasma Betaine (µmol/L) 67.3 13.4 28.8 22.8 36.3 
Plasma DMG (µmol/L) 7.73 1.19 2.16 1.79 2.79 
Plasma DMGO (µmol/L) 0.390 0.124 0.193 0.161 0.24 
Urine Betaine (mmol/mol creatinine) 271.2 2.29 27.8 12.3 58.9 
Urine DMG (mmol/mol creatinine) 24.0 0.81 6.95 5.29 11.3 
Urine DMGO (mmol/mol creatinine) 13.3 0.44 1.96 1.43 3.17 
Fractional clearance Betaine % 40.9 0.91 6.56 3.43 20.4 
Fractional clearance DMG % 24.0 0.81 6.95 5.29 11.3 
Fractional clearance DMGO% 312 21.6 73.5 59.7 103 
 
Healthy controls           Max Min Median  25%      75% 
Plasma Betaine (µmol/L) 88.1 26.9 43.1 36.5 53.6 
Plasma DMG (µmol/L) 5.79 1.78 2.51 2.24 3.21 
Plasma DMGO (µmol/L) 2.708 0.159 0.568 0.377 1.02 
Urine Betaine (mmol/mol creatinine) 8.13 1.94 4.56 3.58 7.21 
Urine DMG (mmol/mol creatinine) 8.41 0.77 2.11 1.56 3.25 
Urine DMGO (mmol/mol creatinine) 21.2 0.40 1.12 0.89 1.65 
Fractional clearance Betaine % 1.84 0.38 0.74 0.57 1.31 
Fractional clearance DMG % 12.6 2.17 4.22 3.02 5.91 
Fractional clearance DMGO% 30.3 4.69 15.0 6.88 22.6 
 
 
Kruskal-Wallis one way analysis of variance on ranks showed that plasma 
DMGO was significantly lower in the subjects with diabetes and the subjects with 
metabolic syndrome compared to the healthy controls (p < 0.001). Plasma DMGO 
concentrations in the subjects with type 2 diabetes were also significantly different to 
the subjects with the metabolic syndrome (p < 0.001). Urine DMGO was significantly 
higher (p < 0.001) in the subjects with type 2 diabetes compared to the metabolic 
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syndrome samples and the healthy controls. Urine DMGO was not significantly 
different in the metabolic syndrome subjects compared to the healthy controls. 
Kruskal-Wallis tests showed that plasma betaine was significantly lower in the 
subjects with type 2 diabetes compared to the healthy controls (p < 0.001). However, 
plasma betaine in the metabolic syndrome subjects was not significantly different to 
the controls or the DEWL subjects (p > 0.05). Betaine was significantly higher (p < 
0.001) in the urine of the subjects with type 2 diabetes compared to the people with 
the metabolic syndrome and the healthy controls. However, urine betaine was not 
significantly different in the people with the metabolic syndrome compared to the 
healthy controls (p = 0.167). 
Plasma DMG concentrations were significantly higher in the group with the 
metabolic syndrome compared to the group with type 2 diabetes (p = 0.008). Neither 
group had significantly different plasma DMG than the healthy controls. 
 Kruskal-Wallis one way analysis of variance on ranks showed that the fractional 
clearance of DMGO in healthy subjects and people with metabolic syndrome were 
significantly different from each other (p < 0.001) (Fig. 6.16). However, people with 
diabetes and metabolic syndrome did not have significantly different fractional 
clearances of DMGO. The fractional clearance was higher in the groups with 
metabolic syndrome and diabetes because the plasma DMGO was lower in these 
groups compared to the healthy subjects. The urine concentrations of DMGO were not 
significantly different between the groups with metabolic syndrome and healthy 
controls. However, the group with diabetes had significantly higher DMGO in the 
urine compared to the other two groups (p < 0.001). The moderately low fractional 
clearance of DMGO in the healthy subjects (median = 15%) suggests that it is 
retained by the kidneys for a metabolic purpose. The subjects with metabolic 
syndrome and diabetes had median fractional clearances for DMGO of 75% and 73%. 
This shows that their kidneys are less able to retain it, most likely due to their 
impaired health and poorer metabolic function. The fractional clearance of DMGO 
may be a more sensitive marker of disease and possibly a predictor of health 
outcomes. Being an important osmolyte, and one-carbon metabolite, betaine is 






Fig. 6.16. The fractional clearance of N,N-dimethylglycine-N-oxide (DMGO) in 
metabolic syndrome subjects, people with type 2 diabetes, and the healthy controls. 
 
 
DMGO in subjects with metabolic syndrome 
 Spearman’s rank order correlation analysis (Table 6.4) showed that in the 
subjects with metabolic syndrome, plasma DMGO correlated strongly with plasma 
DMG (p < 0.001) and plasma betaine (p = 0.001). Plasma DMGO also correlated 
significantly (p < 0.05) with plasma choline and myo-inositol (p = 0.015). Urine 
DMGO correlated strongly (p < 0.001) with plasma DMGO, plasma DMG, and 
plasma betaine. Urine DMGO correlated negatively with urine betaine (p = 0.049), 
but did not correlate with urine DMG or urine choline. Some significant correlations 










Table 6.4. Spearman’s rank order correlations for DMGO in plasma and urine 
calculated from people with metabolic syndrome. 
 
                             Plasma DMGO               Urine DMGO 
Plasma DMGO 
 
r =  0.860 
  
p < 0.001 
Plasma betaine r = 0.407 r = 0.421 
 
p = 0.001 p < 0.001 
Plasma DMG r = 0.673 r = 0.657 
 
p < 0.001 p < 0.001 
Plasma choline r = 0.263 r = 0.149 
 
p = 0.039 p = 0.248 
Plasma TMAO r = 0.182 r = 0.058 
 
p = 0.064 p = 0.656 
Plasma creatinine r = 0.620 r = 0.029 
 
p = 0.187 p = 0.821 
Plasma myo-inositol r = 0.309 r = 0.235 
 p = 0.015  p = 0.067 
Urine betaine  r = -0.218 r = -0.203 
 
p = 0.088 p = 0.114 
Urine DMG r = 0.157 r = 0.290 
 
p = 0.222 p = 0.022 
Urine choline r = -0.028 r = -0.018 
 
p = 0.826 p = 0.888 
Urine TMAO r = 0.124 r = 0.090 










Fig. 6.17. Some significant correlations between plasma DMGO with: plasma DMG 
(A), plasma betaine (B), plasma choline (C), and urine DMGO (D). Linear regressions 




DMGO in subjects with the type 2 diabetes 
Spearman’s rank order correlations showed that plasma DMGO in the subjects 
with type 2 diabetes correlated with plasma DMG (p < 0.001), but the correlation with 
plasma betaine did not quite reach significance in this group (p = 0.051). Plasma 
DMGO correlated strongly with urine DMGO (p < 0.001). Plasma DMGO correlated 
negatively with total cholesterol (p = 0.018) and low density lipoprotein (LDL) 
cholesterol (p = 0.007), but did not correlate significantly with plasma homocysteine, 
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glucose, HbA1c, creatinine, or BMI (p > 0.05) (data supplied by DEWL study 
researchers). 
Urine DMGO correlated significantly (p < 0.001) with plasma DMGO and 
plasma DMG. Urine DMGO also correlated with urine DMG, urine choline, and urine 
TMAO (Table 6.5). 
 
Table 6.5. Spearman’s rank order correlations for DMGO in plasma and urine 
calculated from people with type 2 diabetes. 
 
                             Plasma DMGO               Urine DMGO 
Plasma DMGO 
 
r =  0.591 
  
p < 0.001  
Plasma betaine r = 0.120 r = 0.120 
 
p = 0.349  p = 0.349 
Plasma DMG r = 0.410  r = 0.410 
 
p < 0.001 p < 0.001 
Plasma myo-inositol r = 0.199 r = 0.013 
 
p = 0.114 p = 0.918 
Plasma TMAO r = 0.049 r = 0.049 
 
p = 0.701 p = 0.701 
Plasma taurine  r = -0.005 r = 0.019 
 
p = 0.968 p = 0.880 
Plasma creatinine r = 0.137 r = -0.202 
 
p = 0.280 p = 0.112 
Urine betaine  r = -0.086 r = 0.086 
 
p = 0.503 p = 0.503 
Urine DMG r = 0.128 r = 0.420 
 
p = 0.314 p < 0.001 
Urine choline r = 0.008 r = 0.293 
 
p = 0.947 p = 0.020 
Urine TMAO r = 0.157 r = 0.363 
  p = 0.214 p = 0.004 
 
 
DMGO in the healthy control group 
In the control group, urine DMGO correlated with plasma betaine (p = 0.002), 
and with plasma DMG (p < 0.001), but not with plasma DMGO (p = 0.153), nor 
plasma myo-inositol (p = 0.67), and plasma creatinine (p = 0.16). Urine DMGO did 
not correlate with urine betaine (p = 0.41) or urine DMG (p = 0.15) either. Plasma 
DMGO correlated with plasma betaine (p = 0.03), but not with plasma DMG (p = 
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0.14) in the control group. Further studies are required to investigate the normal range 
of DMGO using fresh samples collected on a greater number of healthy subjects. 
 
Summary 
The presence of DMGO in plasma and urine suggests that DMG is likely to be 
oxidized by an FMO enzyme in the same way that trimethylamine is converted to 
trimethylamine-N-oxide. FMO enzymes are found in the kidneys as well as the 
liver.
175
 If DMGO is formed by the oxidation of DMG, then it may play an important 
biological role in one-carbon metabolism. The proposed metabolic pathway for the 
formation of DMGO is shown in Fig. 6.18. There is still a question mark for the 
pathway from DMG to DMGO, and a question mark for the suggestion that an FMO 
enzyme may be responsible for the oxidation of DMG, because further studies will be 




Fig. 6.18. Proposed metabolic pathway showing the metabolism of betaine to DMG, 




It was previously thought that DMG was only metabolized by demethylation to 
sarcosine by dimethylglycine dehydrogenase.
4b
 However, the discovery of DMGO in 
human plasma and urine is likely to have important implications for one-carbon 
metabolism. Plasma concentrations of DMGO in the healthy subjects (median = 0.57) 
are lower, but comparable, to plasma concentrations that have been reported for 
sarcosine (range 0.60 to 2.67 μmol/L).
176
 The strong correlations observed for plasma 
and urine DMGO with plasma DMG and betaine, particularly in the group with 
metabolic syndrome, provide solid evidence that DMGO is a metabolite of DMG.  
The observation that DMGO is significantly lower in the plasma of people with 
the metabolic syndrome and people with type 2 diabetes compared to healthy controls 
suggests that it may be an important risk marker in disease. The negative correlation 
observed for plasma DMGO with LDL cholesterol may indicate that DMGO could be 
a useful risk marker, in the same way that betaine and choline have been reported to 
be for metabolic syndrome and diabetes.
73, 84
 A long term study relating DMGO 
concentrations to health outcomes, such as cardiovascular events and death, would 
help to determine the value of DMGO concentrations as a diagnostic marker. The 
proposed metabolism of DMG to DMGO in vivo needs to be confirmed. Whether or 
not DMGO is metabolized further in the body, and how it might be metabolized, also 
requires further investigation. The high fractional clearances observed in the groups 
with metabolic syndrome and diabetes suggests that DMGO is poorly retained by the 
kidneys, and if DMGO plays a role in modulating one-carbon metabolism, it is less 
likely to be effective in people with these health conditions. The strong correlation 
observed between plasma DMGO and urine DMGO in metabolic syndrome (r
2
 = 
0.74) also indicates that DMGO is readily excreted, or not resorbed by the kidneys. It 
may also be possible that DMG is converted to DMGO in order to remove it from the 
body, therefore increasing the ability for BHMT to lower homocysteine. DMG is a 
feedback inhibitor for BHMT pathway.
177
 However, DMG can also be removed by 




































7.1.  Thesis Summary 
At the start of this project, LC-MS/MS instruments were not found in most New 
Zealand clinical laboratories. However, in recent years the technology has become 
more affordable, and many clinical laboratories now have several instruments. This 
project has shown that liquid chromatography mass spectrometry (LC-MS and LC-
MS/MS) methods are not perfect, but provide many advantages over previous 
methods for the measurement of betaine, other osmolytes, and other one-carbon 
metabolites. Mass spectrometry has increased the number of osmolytes (and related 
metabolites) that can be reliably measured in order to provide more information about 
their metabolism and potential use as risk markers in disease. 
 
 
Re-addressing the research hypotheses 
 
 
 Hypothesis: Tandem mass spectrometry (LC-MS/MS) can be used to measure 
betaine, other osmolytes, and other one-carbon metabolites in plasma and 
urine with greater efficiency and improved performance than conventional 
HPLC-UV methods.  
 
Mass spectrometry improves efficiency for the analysis of methylamines in 
plasma and urine by decreasing sample preparation time and sample run times, 
therefore improving sample throughput compared with previous HPLC-UV methods. 
While the precision and accuracy was not significantly improved for many analytes 
using mass spectrometry compared to traditional HPLC-UV methods, the accuracy for 
the measurement of some analytes was greatly improved using mass spectrometry due 
to superior selectivity. Like other methods, the quality of results obtained by mass 
spectrometry is limited by sources of error such as: sample treatment; sample 
stability; and accuracy of pipetting, particularly when preparing calibration standards. 
Other problems encountered using mass spectrometry include: a narrow linear range; 
variable accuracy and precision when suitable isotopic standards could not be used; 
interference from closely related structural isomers; and insufficient sensitivity for 
some analytes. The advantages of mass spectrometry techniques over traditional 
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HPLC techniques are: simple and efficient sample preparation; a greater number of 
analytes can be measured within a shorter sample run time; isotopic internal standards 
help to correct for extraction and ionization differences between the samples and 
calibration standards; and there is a high degree of assurance that interfering 
compounds do not affect the accuracy of the results. Mass spectrometry methods also 
have the advantage that they save time and money compared to previous HPLC-UV 
methods. Sample preparation, and run times were reduced. Solvent flow rates were 
also reduced, leading to much lower consumption of acetonitrile in the mobile phase. 
 
 
 Hypothesis: Polyols (including sorbitol and myo-inositol) can be measured 
using derivatization or complexation with boronic acids or transition metals in 
combination with techniques such as HPLC, mass spectrometry, or NMR 
spectroscopy.  
 
The measurement of polyols was found to be challenging. Attempts to 
derivatize sorbitol and inositol with isocyanates or N-methylisotoic anhydride 
produced many chromatographic peaks for each compound which were difficult to 
distinguish in complex sample matrices. Complexing polyols with boronic acids was 
not successful either. These complexes are most stable under alkaline conditions 
which are not compatible with silica based columns. myo-Inositol as well scyllo-
inositol and chiro-inositol could be measured by LC-MS after separation on an amide 
column, either directly with APCI, or by detection as an iodide adduct using 
electrospray ionization. Unfortunately, a suitable method to quantify sorbitol was not 
developed in time to measure inositols in the DEWL study samples. The detection 
limits for inositols using LC-MS techniques were around 1 to 2 µmol/L. This is 
approximately the expected concentration range reported for plasma sorbitol in 
healthy people.
61a
 If sorbitol could be detected without significant interference, then 
these methods would most likely lack the required sensitivity. However, the elevated 






 Hypothesis: The analytical methods developed in this thesis can be used to 
investigate concentrations of betaine, other osmolytes, and other one-carbon 
metabolites in order to provide new information on their metabolism, and the 
usefulness of these metabolites as risk markers in disease. 
 
The methods developed in this thesis were used to investigate the metabolism of 
betaine, other osmolytes, and other one-carbon metabolites in an overweight 
population with type 2 diabetes. Important information was obtained about: how 
concentrations of these metabolites are different to other populations; the biological 
variability of these metabolites; how these metabolites correlate with markers of 
glycemic control and renal function; and the effect of diet treatment and drug 
treatment on concentrations of these metabolites. 
The concentrations of many osmolytes and related compounds were shown to 
be higher in the urine of people with diabetes compared to a group of overweight men 
without diabetes (with metabolic syndrome). The high individuality of betaine (and 
other one-carbon metabolites) in the group with diabetes show that single 
measurements are a useful representation of a person’s status, and do not vary greatly 
with time. The observation that plasma and urine TMAO measurements have a high 
intra-individual variation in diabetes is useful information, especially considering the 
current focus on using TMAO as a risk marker in disease. Despite the low reliability 
of single measurements of TMAO, it has still shown to be a strong predictor of health 
outcomes in disease, including diabetes.
98
 Urine betaine and urine myo-inositol 
correlated strongly with plasma glucose and HbA1c, showing that glycemic control 
has an effect on the urinary excretion of these osmolytes. Plasma myo-inositol was 
found to correlate strongly with markers of renal function, and homocysteine, a risk 
factor for cardiovascular disease. To determine whether osmolyte concentrations are 
predictive of outcomes, such as cardiovascular events or kidney failure in diabetes, 
would require the DEWL study participants to be identified and their medical records 
examined. However, ethics approval was not able to be obtained to do this. Proving 
the usefulness of osmolytes as diagnostic markers is beyond the scope of this project, 
and would require further research studies to relate osmolyte concentrations to health 
outcomes. 
Betaine metabolism has previously been shown to be affected by fibrate 
therapy.
15
 However, it has been shown here that only betaine and its metabolite, 
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DMG, were found to be elevated in the urine of people on fibrate therapy. The other 
osmolytes, myo-inositol, GPC, and taurine were not significantly elevated. This 
suggests that the mechanism causing betaine to be increased in the urine of people 
taking fibrates in unlikely to be related to the role of betaine as an osmolyte.  
The observation that betaine concentrations in the urine were significantly 
higher in healthy people after they began treatment on fenofibrate is strong evidence 
that the relationship with fibrate is causative. It was previously unknown whether 
people who were on fibrates had elevated urine betaine because fibrates affect betaine 
metabolism, or simply that the people were prescribed fibrates because they had high 
blood lipids and less healthy. However, the observation that healthy people had a 
significant increase in urine betaine after starting on the drug fenofibrate is strong 
evidence that fibrates cause the loss of betaine from the body. The reason why fibrates 
cause people to lose betaine remains unknown, but it is possible that fibrates may 
affect the ability of betaine transporters such as BGT1 to function normally. This is 
the first study to show an association between a fibrate other than bezafibrate and 
increased urine betaine. Betaine was the only osmolyte that was significantly affected 
in the urine by fenofibrate, confirming the findings from the group from the DEWL 
study that were on bezafibrate. 
No differences in osmolyte (or other metabolite) concentrations were observed 
between the two diets prescribed in the DEWL study. This may be because many of 
the DEWL study participants were not thought by the DEWL researchers to have 
followed dietary advice properly over the two years of the study.
146
 
The presence of DMGO in plasma and urine was a novel finding that was 
confirmed by using 2 different chromatography systems, and 4 different mass 
transitions. These mass transitions were based on mass fragments that are expected 
from the structure of DMGO. 
DMGO was found to be lower in the plasma of people with the metabolic 
syndrome and people with type 2 diabetes compared to healthy controls. Fractional 
clearances of DMGO, DMG, and betaine were significantly higher in the subjects 
with the metabolic syndrome due to their low plasma concentrations. The observation 
that DMGO has a moderately low fractional clearance (median = 15%) in healthy 
subjects suggests that it may be retained for further metabolism or has a specific 
purpose. Despite plasma DMGO concentrations being low (typically < 1 µmol/L), the 
correlations with DMG and betaine were highly significant. This is suggestive that 
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DMGO is a one-carbon metabolite that is formed from the oxidation of DMG. This 
will be confirmed by future studies. 
These osmolytes and other metabolites were found to be significantly different 
in various blood components. White cells in particular appear to accumulate high 
concentrations of betaine, taurine, and myo-inositol. Blood enriched with white cells 
were considerably higher in myo-inositol and taurine compared to whole blood and 
plasma. Further investigation is required to identify what blood samples are best for 
indicating the tissue status for osmolyte and other metabolite concentrations. The 
measurement of osmolytes in blood cells is problematic because traditional techniques 
for isolating blood cells require the use of buffers that are likely to change the osmotic 




Most osmolytes and related metabolites could be reliably measured by LC-MS 
techniques. However, further work is required to measure sorbitol using LC-MS 
techniques. Separation of sorbitol from mannitol and galactitol is challenging, but 
may be possible using interactions with reagents such as boronic acids if practical 
problems can be over-come and the right analytical conditions can be achieved. The 
analysis of GPC would be more reliable if an isotopic standard was available. The 
detection of TMA in plasma was also challenging. Derivatization of TMA with alkyl 
halides was useful. However, the cross reaction of TMAO with alkyl halides to form 
the same derivative as TMA was problematic, especially considering the much lower 
concentrations of TMA present in plasma. If a reliable LC-MS method for TMA can 
be developed, it would allow for further research on how TMA relates to its 
metabolite, TMAO as risk marker in disease.
87b
 A reliable method for TMA in plasma 
is required to determine whether or not it also has value as a risk marker. 
There are still unresolved questions regarding the role that osmolytes play in 
health and disease. The accelerated loss of the osmolytes: betaine; myo-inositol; and 
GPC in people with type 2 diabetes of concern considering the importance of 
osmolytes in maintaining osmotic control for cells. However, the long term health 
effects of a chronic deficiency of these osmolytes are still poorly understood. 
Supplementing people who have diabetes with these osmolytes may prove to be a 
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useful therapy, and could potentially help to reduce the incidence of secondary 
complications associated with diabetes, such as circulation problems, eye problems, 
and renal and cardiovascular disease. 
Two fibrate drugs (bezafibrate and fenofibrate) have been associated with 
increased urinary betaine excretion. However, it is not known if other fibrate drugs, 
such as gemfibrozil, have the same effect. If other fibrates do not increase betaine loss 
from the body, then they might be a better treatment option, particularly for people 
who have type 2 diabetes and are already at risk of betaine depletion. 
The identification of N,N-dimethylglycine-N-oxide (DMGO) in plasma and 
urine raises a number of unanswered questions. It is likely, but not yet proven, that 
DMGO is formed by the oxidation of DMG. This could be shown experimentally 
using deuterium labelled isotopes in an animal model. This could also help to identify 
how DMGO is further metabolized. DMGO may be cleaved to form TMAO, it may 
be demethylated by either BHMT or DMGDH, or it may be converted back to DMG. 
The quaternary amine structure of DMGO suggests that it is more likely to be a 
substrate for BHMT than for DMGDH. However, the observation that N-hydroxy-N-
methylglycine was undetectable in the plasma (and very low in the urine) suggests 
that demethylation is not a major fate for DMGO in the body. Once the metabolism of 
DMG to DMGO is confirmed in vivo, the enzyme responsible for the oxidation will 
need to be identified. Further work involving the measurement of DMGO in cohorts 
with metabolic syndrome, diabetes, and cardiovascular disease would help to identify 
its usefulness as a risk marker by monitoring the outcomes (such as cardiovascular 
events) for these people over time. While DMGO could not be measured in all of the 
DEWL study samples due to a time limit on the ethics approval, the biological 
variation of DMGO in people with diabetes and other populations still needs to be 
investigated. When measuring DMGO in future samples, it may be useful to also 
measure sarcosine, as they are both likely to be metabolites of DMG. A reliable 
method for the measurement of sarcosine still needs to be developed. The 
measurement of sarcosine is important as it is related to choline and betaine 
metabolism, and has been shown to also be a risk marker of diabetes.
61b
 However, 
sarcosine lacks the sensitivity to be measured in the same run as betaine and the other 
methylamines, and there was not time to measure sarcosine by another method in this 
project. Ueland et al.
178
 measured sarcosine by a GC-MS/MS method after 
derivatization, and it was measured along with a number of amino acids. They also 
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measured betaine, choline, and DMG and related metabolites on a different platform 
by LC-MS/MS.  
Blood plasma may not be the best sample type for indicating the status of 
osmolytes in the tissues. For example, betaine is known to be higher in tissues than in 
the plasma,
168
 and the kidneys have been shown to contain millimolar concentrations 
of betaine and other osmolytes.
32
 Blood enriched with white cells has been shown 
here to contain betaine, myo-inositol, and taurine at significantly higher 
concentrations than in the plasma. Therefore osmolyte concentrations in white cells 
may prove to be a more useful indicator of tissue osmolyte concentrations. Purifying 
white cells without changing the osmolyte concentrations is likely to be difficult. 
However, it should be possible to relate the concentrations to cell counts in the 
samples to obtain an estimate of the concentrations within the individual cell types.  
 
Conclusions 
Liquid chromatography - mass spectrometry techniques have been shown to be 
suitable for the measurement of most osmolytes and related metabolites. The ability to 
measure the more analytically challenging osmolytes, such as myo-inositol, taurine, 
and TMAO, is considerably improved when using LC-MS/MS compared to 
traditional methods that involve derivatization followed by HPLC with UV or 
fluorescence detection. However, there are still unresolved problems that make the 
reliable measurement of some osmolytes difficult. These include finding suitable 
chromatography and mass spectrometry conditions to reliably measure sorbitol, and 
obtaining a more appropriate isotopic internal standard for GPC.  
Betaine, other osmolytes, and other one-carbon metabolites were found to be 
affected by a range of factors in overweight people with type 2 diabetes, including 
glycemic control, renal function, and drug treatment. For example, the observed 
correlations of myo-inositol with other biological variables in diabetes suggest that it 
is a potentially useful risk marker. However, the longnitudinal studies that are 
required to relate myo-inositol concentrations to health outcomes are beyond the scope 
of this project. 
This project has shown that betaine and the other one-carbon metabolite 
concentrations were consistent in people with type 2 diabetes over a 2 year period. 
The low intra-individual variability of betaine, DMG, and choline in people with type 
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2 diabetes adds credence as to the usefulness of single measurements of these 
metabolites as risk markers for health outcomes. Despite TMAO being reported to be 
an important risk marker for cardiovascular disease,
87b
 the high intra-individual 
variability suggests that caution should be taken when considering the value of single 
TMAO measurements for a particular patient. TMAO concentrations can vary widely 
according to diet, and it is not retained by the kidneys. The relatively high intra-
individual variation observed for the osmolytes GPC and taurine could be related to 
factors such as glycemic control, and indicates that caution should be taken when 
considering the diagnostic value of single measurements. 
Because people who have type 2 diabetes and are taking fibrates lose excessive 
amounts of betaine in the urine, they are particularly likely to benefit from betaine 
supplementation, or by increasing the betaine content of their diet. Excessively high 
urinary betaine loss is likely to lead to a deficiency in tissue betaine concentrations, 
placing pressure on metabolic pathways to produce more betaine, and placing 
pressure on the body’s choline reserves. Choline deficiency is in itself harmful and 
has been associated with liver disease.
179
 Because the fenofibrate study has shown 
strong evidence that fibrates cause betaine to be lost from the body, the negative 
health consequences resulting from a potential betaine deficiency should be 
considered by clinicians before placing patients on these drugs to lower their blood 
lipids. 
Because they accumulate osmolytes, white blood cells are likely to be more 
useful than plasma for representing the osmolyte status in tissues. However, obtaining 
pure white cells without changing the osmotic environment remains a challenge. 
The use of LC-MS/MS has enabled the discovery of the previously unknown 
metabolite, DMGO, in human plasma and urine. This is a novel finding that, 
depending on the outcomes of future studies, may alter the currently accepted 
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